Multi-Drug Rapid Test Cassette with/without Adulteration (Urine)

Package Insert

Instruction Sheet for testing of any combination of the following drugs: ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/KET/OXY/C OT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL/MEP/ALC/MDPV/DIA/ZOP/MCAT/7-ACL/CF YL/CAF/CAT/TRO/ALP/PGB/COD/ZAL/MPRD/CNB/GAB/TZD/CAR/ABP/QTP/FLX/UR-144/KRA/TLD/

Including Specimen Validity Tests (S.V.T.) for:

Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde, Creatinine and Bleach

A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine. For healthcare professionals including professionals at point of care sites. Immunoassay for in vitro

[INTENDED USE]

The Multi-Drug Rapid Test Cassette is a rapid chromatographic immunoassay for the gualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations:

Test	Calibrator	Cut-off (ng/mL)
Acetaminophen (ACE 5,000)	Acetaminophen	5,000
Amphetamine (AMP 1,000)	d-Amphetamine	1,000
Amphetamine (AMP 500)	d-Amphetamine	500
Amphetamine (AMP 300)	d-Amphetamine	300
arbiturates (BAR 300)	Secobarbital Secobarbital	300 200
Barbiturates (BAR 200)		500
Senzodiazepines (BZO 500)	Oxazepam	
Benzodiazepines (BZO 300) Benzodiazepines (BZO 200) Benzodiazepines (BZO 100)	Oxazepam	300
senzodiazepines (BZO 200)	Oxazepam	200
enzodiazepines (BZO 100)	Oxazepam	100
Suprenorphine (BUP 10)	Buprenorphine	10
uprenorphine (BUP 5)	Buprenorphine	5
Cocaine (COC 300)	Benzoylecgonine	300
Cocaine (COC 200)	Benzoylecgonine	200
Cocaine (COC 150)	Benzoylecgonine	150
Cocaine (COC 100)	Benzoylecgonine	100
larijuana (THC 300)	11-nor-Δ ⁹ -THC-9 COOH 11-nor-Δ ⁹ -THC-9 COOH 11-nor-Δ ⁹ -THC-9 COOH	300
larijuana (THC 200)	11-nor-Δ ⁹ -THC-9 COOH	200
1arijuana (THC 150)	11-nor-Δ ⁹ -THC-9 COOH	150
larijuana (THC 50)	11-nor-Δ ⁹ -THC-9 COOH	50
larijuana (THC 30)	11-nor-Δ ⁹ -THC-9 COOH 11-nor-Δ ⁹ -THC-9 COOH 11-nor-Δ ⁹ -THC-9 COOH 11-nor-Δ ⁹ -THC-9 COOH 11-nor-Δ ⁹ -THC-9 COOH	30
larijuana (THC 25)	11-nor-Δ ⁹ -THC-9 COOH	25
larijuana (THC 200) larijuana (THC 150) larijuana (THC 150) larijuana (THC 30) larijuana (THC 30) larijuana (THC 25) larijuana (THC 20)	11-nor-Δ ⁹ -THC-9 COOH	20
Althadone (MTD 300)	Methadone	300
Methadone (MTD 200)	Methadone	200
ethamphetamine (MET 1,000)	d-Methamphetamine	1,000
ethamphetamine (MET 500)	d-Methamphetamine	500
Anthemphetamine (MET 300)	d-Methamphetamine	300
Methylenedioxymethamphetamine		
MDMA 300) Itethylenedioxymethamphetamine	d,I-Methylenedioxymethamphetamine	300
MDMA 500)	d,I-Methylenedioxymethamphetamine	500
Methylenedioxymethamphetamine MDMA 1,000)	d,I-Methylenedioxymethamphetamine	1,000
Norphine/Opiate (MOP/OPI 300)	Morphine	300
Norphine/Opiate (MOP/OPI 200)	Morphine	200
forphine/Opiate (MOP/OPI 100)	Morphine	100
fethaqualone(MQL)	Methaqualone	300
leperidine (MPRD)	Normeperidine	100
Dpiate (OPI 2,000)	Morphine	2,000
Dpiate (OPI 1,000)	Morphine	1,000
hencyclidine (PCP 50)	Phencyclidine	50
Phencyclidine (PCP 25)	Phencyclidine	25
ropoxyphene (PPX)	Propoxyphene	300
ricyclic Antidepressants (TCA1000)	Nortriptyline	1,000
ricyclic Antidepressants (TCA500)	Nortriptyline	500
ricyclic Antidepressants (TCA300)	Nortriptyline	300
ramadol (TML 100)	Cis-Tramadol	100
ramadol (TML 200)	Cis-Tramadol	200
ramadol (TML 300)	Cis-Tramadol	300
Cetamine (KET 1,000)	Ketamine	1,000
etamine (KET 500)	Ketamine	500
		300
(etamine (KET 300)	Ketamine	
tetamine (KET100)	Ketamine	100
Oxycodone (OXY 300)	Oxycodone	300
Dxycodone (OXY 100)	Oxycodone	100
cotinine(COT300)	Cotinine	300
otinine(COT200)	Cotinine	200
Cotinine(COT100)	Cotinine	100
-ethylidene-1,5-dimethyl- ,3-diphenylpyrrolidine (EDDP300)	2-ethylidene-1,5-dimethyl- 3,3-diphenylpyrrolidine	300
3-diphenylpyrrolidine (EDDP300) -ethylidene-1,5-dimethyl- ,3-diphenylpyrrolidine (EDDP100)	2-ethylidene-1,5-dimethyl- 3,3-diphenylpyrrolidine	100
entanyl(FYL300)	Fentanyl	300
entanyi(FYL100)	Fentanyl	100
entanyl(FYI 20)	Norfentanyl	20
entanyl(FYL20) entanyl(FYL10)	Norfentanyl	10
Synthetic Marijuana (K2-50)	JWH-018、JWH-073	50
ynthetic Marijuana (K2-30)	JWH-018、JWH-073	30
Synthetic Marijuana (K2-25)	JWH-018、JWH-073	25
-Monoacetylmorphine(6-MAM10)	6-MAM	10
±) 3,4-Methylenedioxy-		

Amphetamine(MDA500)	Amphetamine	
Ethyl- β-D-Glucuronide(ETG1,000)	Ethyl- β -D-Glucuronide	1,000
Ethyl- β-D-Glucuronide(ETG500)	Ethyl- β -D-Glucuronide	500 300
Ethyl- β-D-Glucuronide(ETG300) Clonazepam(CLO 400)	Ethyl- β -D-Glucuronide Clonazepam	400
Clonazepam(CLO 150)	Clonazepam	150
Lysergic Acid Diethylamide (LSD 10)	Lysergic Acid Diethylamide	10
Lysergic Acid Diethylamide (LSD 20)	Lysergic Acid Diethylamide	20
_ysergic Acid Diethylamide (LSD 50)	Lysergic Acid Diethylamide	50
Vethylphenidate (MPD 300)	Methylphenidate	300
Methylphenidate (MPD 150)	Methylphenidate	150
Zolpidem(ZOL) Mephedrone(MEP 500)	Zolpidem Mephedrone	50 500
Mephedrone(MEP 100)	Mephedrone	100
	Mephedione	100
3, 4-methylenedioxypyrovalerone MDPV 1000)	3, 4-methylenedioxypyrovalerone	1000
3, 4-methylenedioxypyrovalerone (MDPV 500)	3, 4-methylenedioxypyrovalerone	500
Diazepam(DIA 300)	Diazepam	300
Diazepam(DIA 200)	Diazepam	200
Zopiclone (ZOP 50)	Zopiclone	50
Methcathinone (MCAT 500)	S(-)-Methcathinone	500
7-Aminoclonazepam(7-ACL300)	7-Aminoclonazepam	300
7-Aminoclonazepam(7-ACL200)	7-Aminoclonazepam	200
7-Aminoclonazepam(7-ACL100)	7-Aminoclonazepam	100
Carfentanyl(CFYL500)	Carfentanyl	500
Cannabinol(CNB 500)	Cannabinol	500
Caffeine(CAF)	Caffeine	1000
Cathine (CAT)	(+)-Norpseudoephedrine	150
Tropicamide(TRO)	Tropicamide	350
Alprazolam(ALP)	Alprazolam	100
Prégabaline (PGB50,000)	Prégabaline	50,000
Prégabaline (PGB500)	Prégabaline	500
Codeine(COD)	Codeine	200
Gabapentin(GAB)	Gabapentin	2000
Zaleplon(ZAL)	Zaleplon	100
Carisoprodol(CAR)	Carisoprodol	2000
AB-PINACA(ABP)	AB-PINACA	10
Quetiazepam(QTP)	Quetiazepam	1000
Fluoxetine(FLX)	Fluoxetine	500
UR-144	UR-144 5-Pentanoic acid	25
Kratom(KRA)	Mitragynine	300
Tilidine(TLD)	Nortilidine	50
Trazodone(TZD)	Trazodone	200
Alpha-Pyrrolidinovalerophenone (a -PVP 2000)	Alpha-Pyrrolidinovalerophenone	1000
Alpha-Pyrrolidinovalerophenone	Alpha-Pyrrolidinovalerophenone	1000
Alpha-Pyrrolidinovalerophenone	Alpha-Pyrrolidinovalerophenone	500
Alpha-Pyrrolidinovalerophenone	Alpha-Pyrrolidinovalerophenone	500

Test	Calibrator	Cut-off
Alcohol(ALC)	Alcohol	0.02%
Configurations of the Multi-Drug Rapid Test C	assette come with any combination of the	e above listed drug
analytee with or without S V/T. This accov prov	idea only a proliminary analytical test rea	ult A moro coocifi

analytes with or without S.V.T. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated

[SUMMARY]

The Multi-Drug Rapid Test Cassette is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in urine.

Acetaminophen (ACE)

Acetaminophen is one of the most commonly used drugs, yet it is also an important cause of serious liver injury. Acetaminophen is the generic name of a drug found in many common brand name over-the-counter (OTĆ) products, such as Tylenol, and Prescription (Rx) products, such as Vicodin and Percocet. Acetaminophen is an important drug, and its effectiveness in relieving pain and fever is widely known Unlike other commonly used drugs to reduce pain and fever (e.g., non steroidalant inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, and naproxen), at recommended doses acetaminophen does not cause adverse effects, such as stomach discomfort and bleeding, and acetaminophen is considered safe when used according to the directions on its OTC or Rx labeling. However, taking more than the recommended amount can cause liver damage, ranging from abnormalities in liver function blood tests, to acute liver failure, and even death. Many cases of overdose are caused by patients inadvertently taking more than the recommended dose (i.e., 4 grams a day) of a particular product, or by taking more than one product containing acetaminophen (e.g., an OTC product and an Rx drug containing acetaminophen). The mechanism of liver injury is not related to acetaminophen itself, but to the production of a toxic metabolite. The toxic metabolite binds with liver proteins, which cause cellular injury. The ability of the liver to remove this metabolite before it binds to liver protein influences the extent of liver injury.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Acetaminophen in

urine exceeds detective leve Amphetamine (AMP)

Amphetamine is a Schedule II controlled substance available by prescription (Dexedrine®) and is also available on the illicit market. Amphetamines are a class of potent sympathomimetic agents with therapeutic applications. They are chemically related to the human body's natural catecholamines: epinephrine and norepinephrine. Acute higher doses lead to enhanced stimulation of the central nervous system (CNS) and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to amphetamines include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 hours following use and the drug has a half-life of 4-24 hours in the body. About 30% of amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated and deaminated derivatives.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of amphetamines in urine exceeds detective level

Barbiturates (BAR)

Barbiturates are CNS depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence. Short-acting barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

Only a small amount (less than 5%) of most barbiturates are excreted unaltered in the urine The approximate detection time limits for barbiturates are:

Short acting (e.g. Secobarbital)	100 mg PO (oral)	4.5 days	
Long acting (e.g. Phenobarbital)	400 mg PO (oral)	7 days ²	
The Multi-Drug Rapid Test Cassette yields	a positive result when the concentrat	ion of barbiturates in urin	ie

exceeds detective level **Benzodiazepines (BZO)**

Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, benzodiazepines have replaced barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal

Risk of physical dependence increases if benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.

Only trace amounts (less than 1%) of most benzodiazepines are excreted unaltered in the urine; most of the concentration in urine is conjugated drug. The detection period for benzodiazepines in urine is 3-7

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of benzodiazepines in urine exceeds detective level Buprenorphine (BUP)

Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex[™], Burrenex[™], Temgesic[™] and Suboxone[™], which contain Buprenorphine HCI alone or in combination with Naloxone HCI. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy. Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. Concentrations of free Buprenorphine and Norbuprenorphine in urine may be less than 1 ng/ml after therapeutic administration, but can range up to 20 ng/ml in abuse situations. The plasma half -life of Buprenorphine is 2-4 hours.⁷While complete elimination of a single dose of the drug can take as long as 6 days, the window of detection for the parent drug in urine is thought to be approximately 3 days. Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has been diverted from legitimate channels through theft, doctor shopping, and fraudulent prescriptions, and been abused via intravenous, sublingual, intranasal and inhalation

The Multi-Drug Rapid Test Cassette yields a positive result when the Buprenorphine in urine exceeds detective leve

Cocaine(COC)

Cocaine is a potent central nervous system stimulant and a local anesthetic. Initially, it brings about extreme energy and restlessness while gradually resulting in tremors, over-sensitivity and spasms. In large amounts, cocaine causes fever, unresponsiveness, difficulty in breathing and unconsciousness.

Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base smoking. It is excreted in the urine in a short time primarily as benzoylecgonine.³⁴ Benzoylecgonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Cocaine in urine exceeds detective level

Marijuana (THC)

THC (Δ9-tetrahydrocannabinol) is the primary active ingredient in cannabis (marijuana). When smoked or orally administered, THC produces euphoric effects. Users have impaired short-term memory and slowed learning. They may also experience transient episodes of confusion and anxiety. Long-term, relatively heavy use may be associated with behavioral disorders. The peak effect of marijuana administered by smoking occurs in 20-30 minutes and the duration is 90-120 minutes after one cigarette. Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 3-10 days after smoking. The main metabolite excreted in the urine is 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH).

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of THC-COOH in urine exceeds detective level

Methadone (MTD)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine). The pharmacology of oral methadone is very different from IV methadone. Oral methadone is partially stored in the liver for later use. IV methadone acts more like heroin. In most states you must go to a pain clinic or a methadone maintenance clinic to be prescribed methadone.

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of methadone in urine exceeds detective level.

Methamphetamine (MET)

Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the brain Methamphetamine is closely related chemically to Amphetamine, but the central nervous system effects of

Methamphetamine are greater. Methamphetamine is made in illegal laboratories and has a high potential for abuse and dependence. The drug can be taken orally, injected, or inhaled. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to Methamphetamine include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, psychotic behavior, and eventually, depression and exhaustion.

The effects of Methamphetamine generally last 2-4 hours and the drug have a half-life of 9-24 hours in the body. Methamphetamine is excreted in the urine primarily as Amphetamine, and oxidized and deaminated derivatives. However, 10-20% of Methamphetamine is excreted unchanged. Thus, the presence of the parent compound in the urine indicates Methamphetamine use. Methamphetamine is generally detectable in the urine for 3-5 days, depending on urine pH level.

The Multi-Drug Rapid Test Cassette is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Methamphetamine in urine. The Multi-Drug Rapid Test Cassette yields a positive result when the Methamphetamine in urine exceeds detective level

Methylenedioxymethamphetamine (MDMA)

Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity.⁵ Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Methylenedioxymethamphetamine in urine exceeds detective level.

Morphine/Opiate (OPI)

Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor.

Opioid analgesics comprise a large group of substances which control pain by depressing the CNS. Large doses of morphine can produce higher tolerance levels, physiological dependency in users, and may lead to substance abuse. Morphine is excreted upmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of morphine/Opiate in urine exceeds detective level

Methagualone (MQL)

Methaqualone (Quaalude, Sopor) is a quinazoline derivative that was first synthesized in 1951 and found clinically effective as a sedative and hypnotic in 1956.¹⁰It soon gained popularity as a drug of abuse and in 1984 was removed from the US market due to extensive misuse. It is occasionally encountered in illicit form, and is also available in European countries in combination with diphenhydramine (Mandrax). Methaqualone is extensively metabolized in vivo principally by hydroxylation at every possible position on the molecule. At least 12 metabolites have been identified in the urine.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Methaqualone in urine exceeds detective level

Meperidine (MPRD)

Meperidine (also known as Pethidine, Pethidin, Meperidol and Dolantin) a phenylpiperidine derivative, is a synthetic opioid analgesic. Many of its pharmacologic properties and indications are similar to those of morphine. Meperidine is preferred to morphine for obstetric use because its rapid onset of action and shorter duration usually permit greater flexibility in maternal analgesia, possibly with less effect on neonatal respiration. Like other opioid drugs, pethidine has the potential to cause physical dependence or addiction. It may be more likely to be abused than other prescription opioids, perhaps because of its rapid onset of action. When compared with oxycodone, hydromorphone, and placebo, pethidine was consistently associated with more euphoria, difficulty concentrating, confusion, and impaired psychomotor and cognitive performance when administered to healthy volunteers. The especially severe side effects unique to pethidine among opioids-serotonin syndrome, seizures, delirium, dysphoria, tremor-are primarily or entirely due to the action of its metabolite, norpethidine

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Normeperidine in urine exceeds detective level.

Phencyclidine (PCP)

Phencyclidine, also known as PCP or Angel Dust, is a hallucinogen that was first marketed as a surgical anesthetic in the 1950's. It was removed from the market because patients receiving it became delirious and experienced hallucinations

PCP is used in powder, capsule, and tablet form. The powder is either snorted or smoked after mixing it with marijuana or vegetable matter. PCP is most commonly administered by inhalation but can be used intravenously, intra-nasally, and orally. After low doses, the user thinks and acts swiftly and experiences mood swings from euphoria to depression. Self-injurious behavior is one of the devastating effects of PCP. PCP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days, depending on factors such as metabolic rate, user's age, weight, activity, and diet.⁶ PCP is excreted in the urine as an unchanged drug (4% to 19%) and conjugated metabolites (25% to 30%).⁶

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Phencyclidine in urine exceeds detective level. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

Propoxyphene (PPX)

Proposyphene (PPX) is a narcotic analgesic compound bearing structural similarity to methadone. As an analgesic, propoxyphene can be from 50-75% as potent as oral codeine. Darvocet™, one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of propoxyphene are achieved from 1 to 2 hours post dose. In the case of overdose, proposyphene blood concentrations can reach significantly higher levels

In humans, proposyphene is metabolized by N-demethylation to yield norproposyphene. Norproposyphene has a longer half-life (30 to 36 hours) than parent propoxyphene (6 to 12 hours). The accumulation of norpropoxyphene seen with repeated doses may be largely responsible for resultant toxicity.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Propoxyphene in urine exceeds detective level. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for propoxyphene positive specimens Tricyclic Antidepressants (TCA)

TCA (Tricyclic Antidepressants) are commonly used for the treatment of depressive disorders. TCA overdoses can result in profound CNS depression, cardiotoxicity and anticholinergic effects. TCA overdose is the most common cause of death from prescription drugs. TCAs are taken orally or sometimes by injection. TCAs are metabolized in the liver. Both TCAs and their metabolites are excreted in urine mostly in the form of metabolites for up to ten days.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Tricyclic Antidepressants in urine exceeds detective level. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for tricyclic antidepressant positive specimens

Tramadol (TML)

Tramadol(TML) is a quasi-narcotic analgesic used in the treatment of moderate to severe pain. It is a

synthetic analog of codeine, but has a low binding affinity to the mu-opioid receptors. Large doses of tramadol can develop tolerance and physiological dependency and lead to its abuse. Tramadol is extensively metabolized after oral administration. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% is excreted as metabolites. The major pathways appear to be N- and Odemethylation, glucoronidation or sulfation in the liver.

The Multi-Drug Rapid Test Cassette is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Tramadol in urine. The Multi-Drug Rapid Test Cassette yields a positive result when Tramadol in urine exceed detective level

Ketamine(KET)

Ketamine is a dissociative anesthetic developed in 1963 to replace PCP (Phencyclidine). While Ketamine is still used in human anesthesia and veterinary medicine, it is becoming increasingly abused as a street drug. Ketamine is molecularly similar to PCP and thus creates similar effects including numbness, loss of coordination, sense of invulnerability, muscle rigidity, aggressive / violent behavior, slurred or blocked speech, exaggerated sense of strength, and a blank stare. There is depression of respiratory function but not of the central nervous system and cardiovascular function is maintained. The effects of Ketamine generally last 4-6 hours following use. Ketamine is excreted in the urine as unchanged drug (2.3%) and metabolites (96.8%)

The Multi-Drug Rapid Test Cassette is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Ketamine in urine. The Multi-Drug Rapid Test Cassette yields a positive result when Ketamine in urine exceeds detective level

Oxycodone (OXY)

Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying thebaine, an alkaloid found in the opium poppy. Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxyContin®, Tylox®, Percodan® and Percocet®. While Tylox®, Percodan® and Percocet® contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone hydrochloride in a time-release form. Oxycodone is known to metabolize by demethylation into oxymorphone and noroxycodone. In a 24-hour urine, 33-61% of a single, 5 mg oral dose is excreted with the primary constituents being unchanged drug (13-19%), conjugated drug (7-29%) and conjugated oxymorphone (13-14%). The window of detection for Oxycodone in urine is expected to be similar to that of other opioids such as morphine.

The Multi-Drug Rapid Test Cassette is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Oxycodone in urine. The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Oxycodone in urine exceeds detective level

Cotinine (COT)

Cotinine is the first-stage metabolite of nicotine, a toxic alkaloid that produces stimulation of the autonomic ganglia and central nervous system when in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. In addition to tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine gum, transdermal patches and nasal sprays.

In a 24-hour urine, approximately 5% of a nicotine dose is excreted as unchanged drug with 10% as cotinine and 35% as hydroxycotinine: the concentrations of other metabolites are believed to account for less than 5%.¹⁰While cotinine is thought to be an inactive metabolite, it's elimination profile is more stable than that of nicotine which is largely urine pH dependent. As a result, cotinine is considered a good biological marker for determining nicotine use. The plasma half-life of nicotine is approximately 60 minutes following inhalation or parenteral administration.¹Nicotine and cotinine are rapidly eliminated by the kidney; the window of detection for cotinine in urine at a cutoff level of 200 ng/mL is expected to be up to 2-3 days after nicotine use.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Cotinine in urine exceeds detective level.

2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)

Methadone is an unusual drug in that its primary urinary metabolites (EDDP and EMDP) are cyclic in structure, making them very difficult to detect using immunoassays targeted to the native compound.10 Exacerbating this problem, there is a subsection of the population classified as "extensive metabolizers" of methadone. In these individuals, a urine specimen may not contain enough parent methadone to yield a positive drug screen even if the individual is in compliance with their methadone maintenance. EDDP represents a better urine marker for methadone maintenance than unmetabolized methadone

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of EDDP in urine exceeds detective level.

Fentanyl (FYL)

Fentanyl, belongs to powerful narcotics analgesics, and is a µ special opiates receptor stimulant. Fentanyl is one of the varieties that been listed in management of United Nations "Single Convention of narcotic drug in 1961". Among the opiates agents that under international control, fentanyl is one of the most commonly used to cure moderate to severe pain¹. After continuous injection of fentanyl, the sufferer will have the performance of protracted opioid abstinence syndrome, such as ataxia and irritability etc^{2,3}, which presents the addiction after taking fentanyl in a long time. Compared with drug addicts of amphetamine, drug addicts who take fentanyl mainly have got the possibility of higher infection rate of HIV, more dangerous injection behavior and more lifelong medication overdose 4

The FYL Rapid Test Cup (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of FYL in urine. The FYL Rapid Test Cup (Urine) yields a positive result when FYL in urine exceeds detective level. Synthetic Marijuana (K2)

Synthetic Marijuana or K2 a psychoactive herbal and chemical product that, when consumed, mimics the effects of Marijuana. It is best known by the brand names K2 and Spice, both of which have largely become genericized trademarks used to refer to any synthetic Marijuana product. The studies suggest that synthetic marijuana intoxication is associated with acute psychosis, worsening of previously stable psychotic disorders, and also may have the ability to trigger a chronic (long-term) psychotic disorder among vulnerable individuals such as those with a family history of mental illness.

Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 72 hours after smoking (depending on usage/dosage). As of March 1, 2011, five cannabinoids, JWH -018, JWH- 073, CP- 47, JWH- 200and cannabicyclohexanol are now illegal in the US because these substances have the potential to be extremely harmful and, therefore, pose an imminent hazard to the public safety.

The Multi-Drug Rapid Test Cassette yields a positive result when the synthetic marijuana metabolite in urine exceeds detective level

6-Monoacetylmorphine (6-MAM)

6-Monoacetylmorphine (6-MAM) or 6-acetylmorphine (6-AM) is one of three active metabolites of heroin (diacetylmorphine), the others being morphine and the much less active 3-monoacetylmorphine (3-MAM). 6-MAM is rapidly created from heroin in the body, and then is either metabolized into morphine or excreted in the urine, 6-MAM remains in the urine for no more than 24 hours. So a urine specimen must be collected soon after the last heroin use, but the presence of 6-MAM guarantees that heroin was in fact used as recently as within the last day. 6-MAM is naturally found in the brain, but in such small quantities that detection of this compound in urine virtually guarantees that heroin has recently been consumed.

The 6-MAM Rapid Test Cup is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of 6-MAM in urine. The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of 6-Monoacetylmorphine in urine exceeds detective level. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA) (±) 3, 4-Methylenedioxyamphetamine (MDA)

3,4-Methylenedioxyamphetamine (MDA), also known as tenamfetamine (INN), or with the street name "Śally" or "Sass" or "Śass-a-frass^{*}, is a psychedelic and entactogenic drug of the phenethylamine and amphetamine chemical classes. It is mainly used as a recreational drug, an entheogen, and a tool in use to supplement various types of practices for transcendence, including in meditation, psychonautics, and as an agent in psychedelic psychotherapy. It was first synthesized by G. Mannish and W. Jacobson in 1910. There are about 20 different synthetic routes described in the literature for its preparation.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of 3.4-Methylenedioxyamphetamine in urine exceeds detective level.

Ethyl- 8-D-Glucuronide(ETG)

Ethyl Glucuronide (ETG) is a metabolite of ethyl alcohol which is formed in the body by glucuronidation following exposure to ethanol, such as by drinking alcoholic beverages. It is used as a biomarker to test for ethanol use and to monitor alcohol abstinence in situations where drinking is prohibited, such as in the military, in professional monitoring programs(health professionals, attorneys, airline pilots in recovery from addictions), in schools, in liver transplant clinics, or in recovering alcoholic patients. ETG can be measured in urine up to approximately 80 hours after ethanol is ingested. ETG is a more accurate indicator of the recent exposure to alcohol than measuring for the presence of ethanol itself.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Ethyl Glucuronide in urine exceeds detective level

Clonazepam(CLO)

Clonazepam is a benzodiazepine drug having anxiolytic, anticonvulsant, muscle relaxant, amnestic, sedative, and hypnotic properties. Clonazepam has an intermediate onset of action, with a peak blood level occurring one to four hours after oral administration. Long-term effects of benzodiazepines include tolerance, benzodiazepine dependence, and benzodiazepine withdrawal syndrome, which occurs in one third of patients treated with clonazepam for longer than four weeks. Benzodiazepines such as clonazepam have a fast onset of action, high effectivity rate, and low toxicity in overdose; however, as with most medications, it may have drawbacks due to adverse or paradoxical effects. The detection period for the Benzodiazepines in the urine is 3-7 days.

The Multi-Drug Rapid Test Cassette yields a positive result when the Clonazepam in urine exceeds detective level

Lysergic Acid Diethylamide (LSD)

Lysergic acid diethylamide (LSD) is a white powder or a clear, colorless liquid. LSD is manufactured from lysergic acid which occurs naturally in the ergot fungus that grows on wheat and rye. It is a Schedule I controlled substance, available in liquid, powder, tablet (microdots), and capsule form. LSD is recreationally used as a hallucinogen for its ability to alter human perception and mood. LSD is primarily used by oral administration, but can be inhaled, injected, and transdermally applied. LSD is a non-selective 5-HT agonist, may exert its hallucinogenic effect by interacting with 5-HT 2Areceptors as a partial agonist and modulating the NMDA receptor-mediated sensory, perceptual, affective and cognitive processes. LSD mimics 5-HT at 5-HT 1A receptors, producing a marked slowing of the firing rate of serotonergic neurons LSD has a plasma half-life of 2.5-4 hours. Metabolites of LSD include N-desmethyl-LSD, hydroxy-LSD. 2-oxo-LSD, and 2-oxo-3-hydroxy-LSD .These metabolites are all inactive. LSD use can typically be detected in urine for periods of 2-5 days.

The Multi-Drug Rapid Test Cassette vields a positive result when Lysergic Acid Diethylamide in urine exceeds detective level.

Methylphenidate (MPD)

Methylphenidate (Ritalin) is a psychostimulant drug approved for treatment of ADHD or attention-deficit hyperactivity disorder, postural orthostatic tachycardia syndrome and narcolepsy. Methylphenidate primarily acts as a norepinephrine-dopamine reuptake inhibitor. Methylphenidate is most active at modulating levels of dopamine and to a lesser extent norepinephrine. Similar to cocaine, methylphenidate binds to and blocks dopamine transporters and norepinephrine transporters. Methylphenidate has both dopamine transporter and norepinephrine transporter binding affinity, with the dextromethylphenidate enantiomers displaying a prominent affinity for the norepinephrine transporter. Methylphenidate may also exert a neuroprotective action against the neurotoxic effects of Parkinson's disease and methamphetamine abuse. Methylphenidate taken orally has a bioavailability of 11-52% with a duration of action around 1-4 hours forinstant release, 3-8 hours for sustained release, and 8-12 hours for extended release(Concerta). The half-life of methylphenidate is 2-3 hours, depending on the individual. The peak plasma time is achieved at about 2 hours

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Methylphenidate in urine exceeds detective level

Zolpidem(ZOL)

Zolpidem (brand names Ambien, Ambien CR, Intermezzo, Stilnox, Stilnoct, Sublinox, Hypnogen, Zonadin, Sanval and Zolsana) is a prescription medication used for the treatment of insomnia and some brain disorders.¹It is a short-acting nonbenzodiazepine hypnotic of the imidazopyridine class¹ that potentiates GABA, an inhibitory neurotransmitter, by binding to GABAA receptors at the same location as benzodiazepines.² It works quickly, usually within 15 minutes, and has a short half-life of two to three

Zolpidem may be detected in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest, or to assist in a medico-legal death investigation. Blood or plasma Zolpidem concentrations are usually in a range of 30-300 ug/l in persons receiving the drug therapeutically, 100-700 µg/l in those arrested for impaired driving, and 1000-7000 µg/l in victims of acute over dosage. Analytical techniques, in general, involve gas or liquid chromatography

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Zolpidem in urine exceeds detective level.

Mephedrone(MEP)

Mephedrone, also known as 4-methylmethcathinone (4-MMC) or 4-methylephedrone is a synthetic stimulant drug of the amphetamine and cathinone classes. Slang names include drone, ¹²M-CAT, ¹³ White Magic¹⁴ and meow meow. ¹⁵It is chemically similar to the cathinone compounds found in the khat plant of eastern Africa.

Mephedrone comes in the form of tablets or a powder, which users can swallow, snort or inject, producing similar effects to MDMA, amphetamines and cocaine. In addition to its stimulant effects, Mephedrone produces side effects, of which teeth grinding are the most common. A number of metabolites are possible, however the n-demethyl metabolite of Mephedrone will be 4-Methylcathinone. This metabolite appears to be nearly inactive as a Monoamine Oxydase Inhibitor .On further metabolism of this metabolite one of the possible metabolites is 4-Methylnorephedrine, caused by the reduction of the Keto A dose of 150mg-250mg is the average, giving a duration of around 2 hours. the duration will lengthen in larger 250mg+ dosages

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Mephedrone in urine exceeds detective level

3, 4-methylenedioxypyrovalerone(MDPV)

3, 4-methylenedioxypyrovalerone (MDPV) is a psychoactive recreational drug with stimulant properties which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was first developed in the 1960s by a team at Boehringer Ingelheim. MDPV remained an obscure stimulant until around 2004 when it was reportedly sold as a designer drug. Products labeled as bath salts containing MDPV were previously sold as recreational drugs in gas stations and convenience stores in the United States, similar to the marketing for Spice and K2 as incense.

MDPV is the 3.4-methylenedioxy ring-substituted analog of the compound pyrovalerone, developed in the 1960s, which has been used for the treatment of chronic fatigue and as an anorectic, but caused problems of abuse and dependence. However, despite its structural similarity, the effects of MDPV bear little resemblance to other methylenedioxy phenylalkylamine derivatives such as 3.4-methylenedioxy-N-methylamphetamine (MDMA), instead producing primarily stimulant effects with only mild entactogenic qualities.

MDPV undergoes CYP450 2D6, 2C19, 1A2, and COMT phase 1 metabolism (liver) into methylcatechol and pyrrolidine, which in turn are glucuronated (uridine 5'-diphospho-glucuronosyl-transferase) allowing it to be excreted by the kidneys, with only a small fraction of the metabolites being excreted into the stools. No free pyrrolidine will be detected in the urine.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of 3, 4-methylenedioxypyrovalerone in urine exceeds detective level.

Diazepam (DIA)

Diazepam is a medication of the benzodiazepine family that typically produces a calming effect. It has anticonvulsant properties. Diazepam has no effect on GABA levels and no effect on glutamate decarboxylase activity, but has a slight effect on garma-amino butyric acid transaminase activity. Diazepam can be administered orally, intravenously intramuscularly (IM), or as a suppository. When administered orally, it is rapidly absorbed and has a fast onset of action. The onset of action is one to five minutes for IV administration and 15–30 minutes for IM administration. The duration of diazepam's peak pharmacological effects is 15 minutes to one hour for both routes of administration of diazepam's peak pharmacological effects is 15 minutes to one hour for both routes of administration. The bioavailability after oral administration is 100% and 90% after rectal administration. Peak plasma levels occur between 30 and 90 minutes after oral administration, peak plasma levels occur between 30 and 60 minutes after intramuscular administration; after rectal administration, beak plasma levels occur after durate protein-bound, with 96 to 99% of the absorbed drug being protein-bound. The distribution half-life of diazepam is 2 to 13 minutes. When diazepam is administered IM, absorption is slow, erratic, and incomplete.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Diazepam in urine exceeds detective level.

Zopiclone (ZOP)

Zopicione is a nonbenzodiazepine hypotoic agent used in the treatment of insomnia. It is a cyclopyrrolone, which increases the normal transmission of the neurotransmitter gamma-aminobutyric acid in the central nervous system, as benzodiazepines do, but in a different way. Zopicione is indicated for the short-term treatment of insomnia where sleep initiation or sleep maintenance are prominent symptoms. Long-term use is not recommended, as tolerance, dependence, and addiction can occur with prolonged use. Zopiclone is partly extensively metabolized in the liver to form an active N-demethylated derivative (N-desmethylzopiclone) and an inactive zopiclone-N-xoide.

In urine, the N-demethyl and N-oxide metabolites account for 30% of the initial dose. Between 7 and 10% of zopicione is recovered from the urine, indicating extensive metabolism of the drug before excretion. The terminal elimination half-life of zopicione ranges from 3.5 to 6.5 hours (5 hours on average).¹⁶ Time to peak plasma concentration is 1 - 2 h, the absorption rate constant is 1.3 h-1 and maximum plasma concentration after administration of 7.5 mg is 131µg/l.

Zopiclone may be measured in blood, plasma, or urine by chromatographic methods. Plasma concentrations are typically less than 100µg/l during therapeutic use, but frequently exceed 100µg/l in automotive vehicle operators arrested for impaired driving ability and may exceed 1000µg/l in acutely poisoned patients. Post mortem blood concentrations are usually in a range of 0.4-3.9 mg/l in victims of fatal acute overdose. ^{17,16,19}

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Zopiclone in urine exceeds detective level.

Methcathinone(MCAT)

Methicathinone, is a 'monoamine alkaloid and psychoactive stimulant, a substituted cathinone. Methicathinone is a highly addictive drug, primarily psychologically addicting and most of the signs of addiction to the drug are emotional or psychological. It has been popularized and continues to be sold under misleading names such as 'bath salts', 'plant fertilizers' or 'research chemicals', but it is actually a powerful psycho-stimulant used as a recreational drug. Effects of this drug typically last from 4 to 6 hours. It is used as a recreational drug due to its potent stimulant and euphoric effects and is considered to be addictive, with both physical and psychological withdrawal occurring if its use is discontinued after prolonged or high-dosage administration ²⁰. It is usually snorted, but can be smoked, injected, or taken orally. Methicathinone is listed as a Schedule I controlled substance by the Convention on Psychotropic Substances and the United States' Controlled Substances Act, and as such it is not considered to be addictive, with so the svery strong affinities for the dopamine transporter and the norepinephrine (noradrenaline) transporter. Its affinity for the serotonin transporter is less than that of methamphetamine²¹.

Effects of short term intoxication are similar to those produced by crack cocaine or methamphetamine: stimulation of heart rate and respiration; feeling of euphoria; loss of appetite; increased alertness; pupils may be dilated; body temperature may be slightly elevated. Acute intoxication at higher doses may also result in: insomnia, tremors and muscle twitching, fever, headaches, convulsions, irregular heart rate and respirations, anxiety, restlessness, paranoia, hallucinations and delusions.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Methcathinone in urine exceeds detective level.

7-aminoclonazepam (7-ACL)

7-aminocionazepam is the major metabolite of clonazepam. Clonazepam sold under the brandname Klonopin among others, is a medication used to prevent and treat seizures, panic disorder, and for the movement disorder known as akathisal. It is a type of benzodiazepine. As a major metabolite, 7-aminocionazepam may be used to monitor use of the parent drug, clonazepam. Clonazepam, marketed as Klonopin and Rivotril, is a long-acting benzodiazepine with anxiolytic, anticonvulsant, muscle relaxant, and hypnotic properties.

The Multi-Drug Rapid Test Cassette (Urine) is a rapid urine-screening test that can be performed without the use of an instrument. The test utilizes the antibody to selectively detect elevated levels of 7-aminoclonazepam in urine. The Multi-Drug Rapid Test Cassette (Urine) yields a positive result when the 7-aminoclonazepam in urine exceed the cut-off level.

Carfentanyl(CFYL)

Carfentanyl is an analog of the synthetic opioid analgesic fentanyl. It is 10,000 times more potent than morphine, making it among the most potent commercially used opioids. Carfentanil was first synthesized in 1974. It is marketed under the trade name Wildnil as a general anaesthetic agent for large animals. Side effects of carfentanil are similar to those of fentanyl, which include itching, nausea and respiratory depression, which can be life-threatening. Carfentanil is classified as Schedule II under the Controlled Substances Act in the United States with a DEA ACSCN of 9743.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Carfentanyl in urine exceeds detective level.

Tropicamide(TRO)

Tropicamide is an antimuscarinic drug usually prescribed as an ophthalmic solution to induce short-term mydriasis and cycloplegia. Tropicamide is currently abused (injected intravenously) as an inexpensive recreational deliriant drug²⁷. Misuse of tropicamide typically occurs through IV injection; its effects last from 30 min to 6 h, and It is usually mixed with heroin, methadone, and other opioid drugs to potentiate the " rush" when injected intravenously.Medical effects of tropicamide misuse include slurred speech, persistent mydriasis, unconsciousness/unresponsiveness, hallucinations, kidney pain, dysphoria, "open eye dreams," hyperthermia, tremors, suicidal feelings, convulsions, psychomotor agitation, tachycardia and headache. The TRO Rapid Test Cup (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of tropicamide in urine. The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Tropicamide in urine exceeds detective level.

Caffeine(CAF)

Caffeine is a central nervous system (CNS) stimulant of the methylxanthine class. It is the world's most widely consumed psychoactive drug. It is found in the seeds, nuts, or leaves of a number of plants native to South America and East Asia and confers on them several survival and reproductive benefits.

Caffeine can produce a mild form of drug dependence – associated with withdrawal symptoms such as steepiness, headache, and irritability – when an individual stops using caffeine after repeated daily intake.

each of the first 4 hourly specimens. Blood samples taken 10 and 70 minutes after injection of the drug were analyzed and showed 0.29 and 0.28mg, per 100 cc., espectively. There are to be contrasted with the 1st hour urine which contained 0.73mg.per 100 cc., espectively. There are to be contrasted with the 1st hour urine which contained 0.73mg.per 100 cc., espectively. There are to be contrasted with the 1st hour urine which contained 0.73mg.per 100 cc., espectively. There are to be contrasted with the 1st hour urine which contained 0.73mg.per 100 cc., espectively. There are to be contrasted with the 1st hours, remained relatively constant through the 8th hours. At 48 hours, a urine specimen contained approximately 0.17mg, per 100 cc. of caffeine. In addition, flu-like symptoms, nausea/vomiting, and muscle pain/stiffness were judged likely to represent valid symptom categories. In experimental studies, the incidence of headache was 50% and the incidence of clinically significant distress or functional impairment was 13%. Typically, onset of symptoms occurred 12–24 h after abstinence, with peak intensity at 20–51 h, and for a duration of 2–9 days. ¹¹% to 3% of caffeine is excerted unchanged in the urine. The rate of caffeine metabolism is variable, with a half-life of 4 to 6h. ^{16, 17}

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Caffeine in urine exceeds detective level.

Cathine (CAT)

Cathinone, also known as benzoylethanamine, or β-keto-amphetamine is a monamine alkaloid found in the shrub Catha edulis (CAT) and is chemically similar to ephedrine, Cathinone, methCathinone and other amphetamines. It with amphetamine, ephedrine, methamphetamine and mephedrone belongs to excitatory amphetamines psychiatric drugs, has the strong central excitement and suppress appetite, has been widely appled in the depression, fatigue, obesity, gastric ulcer, etc. The earliest found in Arab tea, because of its structure and pharmacological activities are similar to amphetamines. ²³ thas approximately 10-14% the potency of amphetamine. ²³

S-(-)-Cathinone (S-(-)-alpha-aminopropiophenone) is the major active principle of that leaves (Catha edulis), which are widely used in East Africa and the Arab peninsula as an amphetamine-like stimulant. After oral administration of synthesized cathinone (isomers, racemate), 22-52% was recovered in 24 h urine samples mainly as aminoalcohol metabolites. With GC/MS, HPLC and CD, the main metabolite of S-(-)-cathinone was identified as R/S-(-)-orophedrine and the main metabolite of R-(+)-cathinone as R/R-(-)-norpseudoephedrine. Both aminoalcohols are formed by a stereospecific keto reduction.²⁴

Use too much Cathinone can cause loss of appetite, anxiety, irritability, insomnia, illusion and panic attacks. Abusers have for a long time for the development of personality disorder and continuing the risk of myocardial infarction. The World Anti-Doping Agency's list of prohibited substances (used for the Olympic Games among other athletic events) bars cathine in concentrations of over 5 micrograms per milliliter in urine.Cathine is a Schedule III drug under the Convention on Psychotropic Substances.²⁵

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Cathinone in urine exceeds detective level.

Alprazolam (ALP)

Alprazolam, available under the trade name Xanax among others, is a short-acting anxiolytic of the benzodiazepine class. It is commonly used for the treatment of panic disorder, and anxiety disorders, such as generalized anxiety disorder (GAD) or social anxiety disorder (SAD). ²⁷²⁰Alprazolam, like other benzodiazepines, binds to specific sites on the GABAA receptor. It possesses anxiolytic, sedative, hvonotic. skeletal muscle relaxant. anticonvulsant. and amnestic properties.

A mean half-life of alprazolam of 16.3 hours has been observed in healthy elderly subjects (range: 9.0-26.9 hours, n=16) compared to 11.0 hours (range: 6.3-15.8 hours, n=16) in healthy adult subjects. Alprazolam and its metabolites are excreted primarily in the urine. The pharmacokinetics of alprazolam and two of its major active metabolites (4-hydroxyalprazolam and d-hydroxyalprazolam) are linear, and concentrations are proportional up to the recommended maximum daily dose of 10 mg given once daily. Peak concentrations in the plasma occur in one to two hours following administration. Plasma levels are proportionate to the dose given; over the dose range of 0.5 to 3.0 mg, peak levels of 8.0 to 37ng/ml were observed.²⁸

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Alprazolam in urine exceeds detective level.

Pregabalin(PGB)

Pregabalin, also known as B-isobutyl-y-amino butyric acid (beta-isobutyl-GABA), is a medication used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder.³⁴Common side effects include: sleepiness, confusion, trouble with memory, poor coordination, dry mouth, problem with vision, and weight gain. Potentially serious side effects include angioedema, drug misuse, and an increased suicide risk.³⁵

Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. The Pregabalin is predominantly excreted unchanged in urine (\geq 98%)³⁶. Pregabalin mean elimination half-life is 6.3 hours.³⁷ 50% would be expected to have negative urine specimens within 3 days and a total of 5 days would be needed to achieve negative urine specimens in the subject with the maximum urinary concentration measured.³⁶

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Pregabalin in urine exceeds detective level.

Codeine(COD)

Codeine is an opiate used to treat pain, as a cough medicine, and for diarrhea. It is typically used to treat mild to moderate degrees of pain. Codeine is not itself centrally active, and must first be converted via first pass metabolism into morphine by the cytochrome P450 enzyme CYP2D6. Codeine is also metabolised into the inactive norcodeine via the CYP3A4 enzyme system.

Zaleplon(ZAL)

Zalepion is a sedative-hypnotic, almost entirely used for the management/treatment of insomnia. It is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class.

Zaleplon has a pharmacological profile similar to benzodiazepines, characterized by an increase in slow wave deep sleep (SWDS) with rapid onset of hypnotic action. Zaleplon is a full agonist for the benzodiazepine of receptor located on the GABAA receptor complex in the body, with lower affinity for the a d a subsites. It selectively enhances the action of GABA similar to, but more selectively than benzodiazepines. Zaleplon, although not a benzodiazepine, maintains a very similar chemical structure nonetheless, known for inducing hypnotic effects by of subreceptor sites, anxiolytic and muscle relaxant effects via c2 and o3 subsites, with negligible anticonvulsant properties (via c5 subsite), as zaleplon action is modulateapeine receptor sites. The elimination hall-life of zaleplon is about 1–1.5 hours. The absorption rate of zaleplon is rapid and the onset of therapeutic effects is typically breached within 5– 15 minutes following ingestion. Zaleplon is primarily metabolised by aldehyde oxidase, and its hall-life can be affected by substances which inhibit or induce aldehyde oxidase. Taken orally, zaleplon reaches full concentration in about one hour. It is extensively metabolised into 5-oxozaleplon and 5-oxodesethylzaleplon (the latter via desethylzaleplon), with less than 1% of it excreted intact in urine. Cannabinol (CNB)

Cannabinol (CNB) is a non-psychoactive cannabinoid found only in trace amounts in Cannabis.⁴⁰ and is mostly found in aged Cannabis.⁴⁰ Pharmacologically relevant quantities are formed as a metabolite of tetrahydrocannabinol (THC).⁴¹CNB acts as a partial agonistat the CB1 receptors, but has a higher affinity to CB2 receptors; however, it has lower affinities relative to THC.^{42, 43} Degraded or oxidized cannabis products, such as low-quality baled cannabis and traditionally produced hashish, are high in CNB, but modern production processes minimize the formation of CNB.

Unlike other cannabinoids, CNB does not stem from cannabigerol (CBG). There is no clinical evidence that THC breaks down naturally into CNB once the THC has become decarboxylated and forms delta-9 THC. CNB is formed by decarboxylation of cannabinolic acid.

Gabapentin(GAB)

Gabapentin, sold under the brand name Neurontin among others, is a medication which is used to treat epilepsy (specifically partial seizures), neuropathic pain, hot flashes, and restless legs syndrome. ^{44,65} Common side effects of gabapentin include sleepiness and dizziness. Serious side effects of sicicide an increased risk of suicide, aggressive behavior, and drug reaction with eosinophilia and systemic symptoms. In 2009 the U.S. Food and Drug Administration issued a warning of an increased risk of suicidal thoughts and behaviors in patients taking some anticonvulsant drugs, including gabapentin, ⁶⁶ modifying

the packaging inserts to reflect this.47

The oral bioavailability of gabapentin enacarbil (as gabapentin) is greater than or equal to 68%, across all doses assessed (up to 2,800 mg), with a mean of approximately 75%. ^{4,84} Gabapentin undergoes little or no metabolism.⁴⁵⁵The T-max of the instant-release (IR) formulation of gabapentin enacarbil (as active gabapentin) is about 2.1 to 2.6 hours across all doses (350–2,800 mg) with single administration and 1.6 to 1.9 hours across all doses (350–2,100 mg) with repeated administration.⁵⁵

Trazodone is a triazolopyridine derivative which is used to treat major depressive disorder. It possesses antidepressant, and also some anxiolytic and hypnotic activity.

Trazodone(TZD)

The primary use of trazodone is the treatment of major depression. Data from open and double-blind trials suggest the antidepressant efficacy of trazodone is comparable to that of amitriptyline, doxepin, and mianserin. Also, trazodone showed anxiolytic properties, low cardiotoxicity, and relatively mild side effects.⁵³ The half-life of trazodone in the initial phase is about 3–6 h and the half-life in the terminal phase is about 5–9 h. TZD is extensively metabolized with only about 1% of the dose excreted unchanged in urine after 24 hr.⁵⁵ Around 70 to 75% of 14C-labelled trazodone was found to be excreted in the urine within 72 hours.⁵⁴

Carisoprodo(CAR)

Carisoprodol, marketed under the brand name Soma among others, is a medication used for musculoskeletal pain. Use is only approved for up to three weeks. Effects generally begin within half an hour and last for up to six hours. It is taken by mouth.

Common side effects include headaché, dizziness, and skepiness. Serious side effect may include addiction, allergic reactions, and seizures. In people with a sulfa allergy certain formulations may result in problems. Safety during pregnancy and breastfeeding is not clear. Meprobamate and other muscle-relaxing drugs often were subjects of misuse in the 1950s and 60s. Overdose cases were reported as early as 1957, and have been reported on several occasions since then.

Carisoprodol is metabolized by the liver and excreted by the kidneys so this drug must be used with caution with patients that have impaired hepatic or renal function. Because of potential for more severe side effects, this drug is on the list to avoid for elderly people.

The Carisoprodol Rapid Test is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Carisoprodol in urine. The Carisoprodol Rapid Test (Urine) yields a positive result when Carisoprodol in urine exceeds 2000ng/mL.

AB-PINACA(ABP)

AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication. AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, ECS0 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, ECS0 = 2.5 nM) and fully substitutes for A9-THC in rat discrimination studies, while being 1.5x more potent. The ABP Rapid Test (Unine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of AB-PINACA in urine.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Alprazolam in urine exceeds detective level.

Quetiapine(QTP)

Quetiapine, sold under the trade name Seroquel among others, is an atypical antigsvchotic used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. It is also used as a sleep aid due to its sedating effect, but this use is not recommended. It is taken by mouth.

Common side effects include sleepiness, constipation, weight gain, and dry mouth. Other side effects include low blood pressure with standing, seizures, a prolonged erection, high blood sugar, tardive dyskinesia, and neuroleptic malignant syndrome. In older people with dementia, its use increases the risk of death Use in the later part of pregnancy may result in a movement disorder in the baby for some time after birth. Quetiapine is believed to work by blocking a number of receptors including serotonin and dopamine.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Alprazolam in urine exceeds detective level.

Fluoxetine (FLX)

Fluoxetine, also known by trade names Prozac and Sarafem, among others, is an antidepressant of the selective serotonin reuptake inhibitor(SSRI)class. It is used for the treatment of major depressive disorder, obsessive-compulsive disorder(OCD), bulimia nervosa, panic disorder and premenstrual dysphoric disorder. It may decrease the risk of suicide in those over the age of 65. It has also been used to treat premature elaculation. Fluoxetine is taken by mouth.

Common side effects include trouble sleeping, sexual dysfunction, loss of appetite, dry mouth, rash and abnormal dreams. Serious side effects include serotonin syndrome, mania, seizures, an increased risk of suicidal behavior in people under 25 years old and an increased risk of bleeding. If stopped suddenly, a withdrawal syndromemay occur with anxiety, dizzinessand changes in sensation. It is unclear if it is safe in pregnancy. If already on the medication, it may be reasonable to continue during breastfeeding. Its machanism of action is not entirely clear but believed to be related to increasing serotonin activity in the brain.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Alprazolam in urine exceeds detective level.

UR-144

UR-144 is a synthetic cannabinoid receptor agonist (SCRA) and has affinity for CB1 and CB2 receptors. It has a high selectivity for the CB2-receptors.

UR-144 is a psychoactive substance and has effects similar to delta-9-tetrahydrocannabinol (THC), though slightly less potent than THC. UR-144 has been detected in herbal products marketed under a variety of names.

In mice, UR-144 is moderately potent in reducing in a time- and dose-dependent manner the locomotor activity (ID50-value 7.8 mg/kg), induces an anti-nociceptive effect, and decreases rectal temperature and ring immobility with potencies several-fold greater than THC. In mice, UR-144 substituted for THC in a THC discrimination study (ED50-value 7.1 to 7.4 µmol/kg intra-peritoneal), an effect antagonized by rimonabant. The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Alprazolam in urine exceeds detective level.

Kratom(KRA)

Mitragynine (MG) and its major metabolites 7-hydroxymitragynine (7-OH-MG) are two of the major components of the plant extract Kratom, which is a tree planted in Southeast Asia. Kratom has long been used by opioid-dependent individuals as an alternative to their unavailable opioid of choice and chronic pain medication, as a stealth-to-urine drug screening opiate substitute while in opioid recovery treatment and recreationally, alone or as a booster. In this study, a direct infusion method was utilized and electrospray ionization triple quadrupole mass spectrometer was used as the detector for data acquisition. Pharmacokinetic study was conducted to investigate the effect of mitragynine and 7-hydroxymitragynine and major fragments of both compounds were proposed.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Alprazolam in urine exceeds detective level.

Tilidine(TLD)

Tilidine, or tilidate (brand names: Tilidin, Valoron and Valtran) is a synthetic opioid painkiller, used mainly in Germany, Switzerland, South Africa and Belgium for treatment of moderate to severe pain, both acute and chronic. Its onset of pain relief after oral administration is about 10-15 minutes and peak relief from pain occurs about 25-50 minutes after oral administration.

It usually comes in its hydrochloride hemihydrate salt form; in this form it is highly soluble in water, ethanol and dichloromethane and appears as a white/almost white crystalline powder. Its storage is restricted by its sensitivity to degradation by light and oxygen, hence necessitating its storage in amber bottles and at temperatures below 30 degrees Celsius, respectively.

Tilidine is a prodrug from which the active metabolite nortilidine is formed by demethylation. The pharmacokinetics of tilidine (T), nortilidine (NT) and bisnortilidine (BNT) were studied in nine healthy subjects following single intravenous (10 min infusion) and oral 50 mg T-HCl dose as well as following multiple 50 mg T-HCl oral doses. Systemic availability of the parent substance was 6% and of the active metabolite NT 99%. The terminal half-life of NT was 3.3 h following single oral administration, 4.9 h following intravenous administration and 3.6 h following multiple dosing. Following intravenous infusion, concentrations of unchanged substance were found which were 30 times higher than following oral administration. BNT was eliminated with half-lives of 5 h after oral administration and 6.9 h after intravenous administration. Renal elimination of unchanged substance was 1.6% of the dose following intravenous administration and less than 0.1% of the dose following oral administration. Approximately 3% were recovered in urine as NT and 5% as BNT following both routes of administration.

The Tilidine Rapid Test (Urine) is a rapid urine-screening test that can be performed without the use of an instrument. The test utilizes the antibody to selectively detect elevated levels of Nortilidine in urine. The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Alprazolam in urine exceeds detective level.

Alpha-Pyrrolidinovalerophenone(a -PVP)

alpha-Pyrrolidinovalerophenone (also known as α -PVP, A-PVP, alpha-PVP, and Flakka) is a synthetic stimulant substance of the cathinone and pyrrolidine chemical classes.10-PVP may be quantified in blood, plasma or urine to confirm a diagnosis of poisoning in hospitalized patients or to provide evidence in a medicolegal death investigation.2 It generally comes in the form of either a crystalline powder or crystallized shards which users can ingest to produce powerful but short-lived euphoric stimulant effects which are comparable to those of methamphetamine and cocaine when insufflated or vaporized. a PVP has been reported to be the cause, or a significant contributory cause of death in suicides and overdoses caused by combinations of drugs.3, 4 It has also been linked to at least one death where it was combined with pentedrone and caused heart failure.

The α-PVP Rapid Test Dipstick (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of alpha-Pyrrolidinovalerophenone in urine. The α-PVP Rapid Test Dipstick (Urine) yields a positive result when alpha-Pyrrolidinovalerophenone in urine exceeds 500ng/mL Alcohol(ALC)

Alcohol intoxication can lead to loss of alertness, coma, death and birth defects. Determination of ethyl alcohol in blood, saliva and urine is commonly used for measuring legal impairment, alcohol poisoning, etc. The BAC (Blood Alcohol Content) at which a person becomes impaired is variable. The United States Department of Transportation (DOT) has established a BAC of 0.02% (0.02g/dL) as the cut-off level at which an individual is considered positive for the presence of alcohol.

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of Alcohol in urine exceeds 0.02%

WHAT IS ADULTERATION

Adulteration is the tampering of a urine specimen with the intention of altering the test results. The use of adulterants can cause false negative results in drug tests by either interfering with the screening test and/or destroying the drugs present in the urine. Dilution may also be employed in an attempt to produce false negative drug test results.

One of the best ways to test for adulteration or dilution is to determine certain urinary characteristics such as pH, specific gravity and creatinine and to detect the presence of oxidants/PCC, nitrites or glutaraldehvde in urine

Oxidants/PCC (Pyridiniumchlorochromate) tests for the presence of oxidizing agents such as bleach and hydrogen peroxide. Pyridiniumchlorochromate (sold under the brand name Urine Luck) is a commonly used adulterant.8 Normal human urine should not contain oxidants of PCC.

Specific gravity tests for sample dilution. The normal range is from 1.003 to 1.030. Values outside this range may be the result of specimen dilution or adulteration.

pH tests for the presence of acidic or alkaline adulterants in urine. Normal pH levels should be in the range of 4.0 to 9.0. Values outside of this range may indicate the sample has been altered.

Nitrite tests for commonly used commercial adulterants such as Klear and Whizzies. They work by oxidizing the major cannabinoid metabolite THC-COOH.9 Normal urine should contain no trace of nitrite. Positive results generally indicate the presence of an adulterant.

Glutaraldehyde tests for the presence of an aldehyde. Adulterants such as Urin Aid and Clear Choice contain glutaraldehyde which may cause false negative results by disrupting the enzyme used in some immunoassay tests.⁹ Glutaraldehyde is not normally found in urine; therefore, detection of glutaraldehyde in a urine specimen is generally an indicator of adulteration.

Creatinine is a waste product of creatine; an amino-acid contained in muscle tissue and found in urine.² A person may attempt to foil a test by drinking excessive amounts of water or diuretics such as herbal teas to flush" the system. Creatinine and specific gravity are two ways to check for dilution and flushing, which are the most common mechanisms used in an attempt to circumvent drug testing. Low Creatinine and specific gravity levels may indicate dilute urine. The absence of Creatinine (<5 mg/dl) is indicative of a specimen not consistent with human urine.

Bleach tests for the presence of bleach bleach refers to a number of chemicals which remove color, whiten or disinfect, often by oxidation. Bleaches are used as household chemicals to whiten clothes and remove stains and as disinfectants. Normal human urine should not contain bleach

[PRINCIPLE (FOR DOA TESTS EXCLUDING ALCOHOL)]

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test region of the specific drug dipstick. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test region.

A drug-positive urine specimen will not generate a colored line in the specific test region of the dipstick because of drug competition, while a drug-negative urine specimen will generate a line in the test region

because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

[PRINCIPLE (FOR ALCOHOL)]

The urine Alcohol Rapid Test consists of a plastic strip with a reaction pad attached at the tip. On contact with alcohol, the reaction pad will change colors depending on the concentration of alcohol present. This is based on the high specificity of alcohol oxidase for ethyl alcohol in the presence of peroxidase and enzyme substrate such as TMB

[REAGENTS(FOR DOA TESTS EXCLUDING ALCOHOL)]

Each test line contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates. The control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG. [REAGENTS (FOR ALCOHOL)]

ename	suiyiberizi
Alcohol	Oxidase

Peroxidase [S.V.T REAGENTS]

Adulteration Pad	Reactive indicator	Buffers and non-reactive ingredients
Creatinine	0.04%	99.96%
Nitrite	0.07%	99.93%
Bleach	0.39%	99.71%
Glutaraldehyde	0.02%	99.98%
pH	0.06%	99.94%
Specific Gravity	0.25%	99.75%
Oxidants / PCC	0.36%	99.64%

[PRECAUTIONS]

- · For healthcare professionals including professionals at point of care sites.
- · Immunoassay for in vitro diagnostic use only. The Test Cup should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.

The used Test Cup should be discarded according to local regulations.

[STORAGE AND STABILITY]

Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The Test Cup must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date

[SPECIMEN COLLECTION AND PREPARATION]

Urine Assay The urine specimen should be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing. When testing cards with S.V.T. or Alcohol storage of urine specimens should not exceed 2 hours at room temperature or 4 hours refrigerated prior to testing. [MATERIALS]

Materials Provided


- Test Cassettes Droppers Package insert
- · Adulteration Color Chart (when applicable)

Materials Required But Not Provided

Timer [DIRECTIONS FOR USE]

Allow the test, urine specimen, and/or controls to reach room temperature (15-30°C) prior to testina.

- 1. Bring the pouch to room temperature before opening it. Remove the cup from the sealed pouch and use it within one hour
- 2. Place the test cassette on a clean and level surface. Hold the dropper vertically and transfer 3 full drops of urine (approx. 120 µL) to the specimen well (S) of the test cassette, and then start the timer. Avoid trapping air bubbles in the specimen well (S). See the illustration below.
- 3. Read the adulteration strips and Alcohol strip between 3-5 minutes according to color chart provided separately/on foil pouch. Refer to your Drug Free Policy for guidelines on adulterated specimens. We recommend not to interpret the drug test results and either retest the urine or collect another specimen in case of any positive result for any adulteration test
- 4. The drug strip result should be read at 5 minutes. Do not interpret the result after 10 minutes



[INTERPRETATION OF RESULTS]

(Please refer to the illustration above)

NEGATIVE:* A colored line appears in the Control region (C) and colored lines appear in the Test region (T). This negative result means that the concentrations in the urine sample are below the designated cut-off levels for a particular drug tested.

*NOTE: The shade of the colored lines(s) in the Test region (T) may vary. The result should be considered negative whenever there is even a faint line.

POSITIVE: A colored line appears in the Control region (C) and NO line appears in the Test region (T). The positive result means that the drug concentration in the urine sample is greater than the designated cut-off for a specific drug.

INVĂLID: No line appears in the Control region (C). Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for Control line failure. Read the directions again and repeat the test with a new test card. If the result is still invalid, contact your manufacturer.

[INTERPRETATION OF RESULTS (S.V.T/ ADULTERATION)]

(Please refer to the color chart)

Semi Quantitative results are obtained by visually comparing the reacted color blocks on the strip to the printed color blocks on the color chart.

No instrumentation is required. [INTERPRETATION OF RESULTS (ALCOHOL STRIP)]

Negative: Almost no color change by comparing with the background. The negative result indicates that the urine alcohol level is less than 0.02% Positive: A distinct color developed all over the pad. The positive result indicates that the urine alcohol

concentration is 0.02% or higher.

Invalid: The test should be considered invalid If only the edge of the reactive pad turned color that might be ascribed to insufficient sampling. The subject should be re-tested. Besides, if the color pad has a blue color before applying urine sample, do not use the test.

[QUALITY CONTROL]

A procedural control is included in the test. A line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance

[LIMITATIONS]

- 1. The Multi-Drug Rapid Test Cassette provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography /mass spectrometry (GC/MS) is the preferred confirmatory method.^{1,10}
- 2. There is a possibility that technical or procedural errors, as well as interfering substances in the urine specimen may cause erroneous results.
- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- A positive result does not indicate level or intoxication, administration route or concentration in urine.
- 5 A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- This test does not distinguish between drugs of abuse and certain medications.
- 7. A positive test result may be obtained from certain foods or food supplements. Alcohol in the atmosphere, such as spray from perfumes, deodorizers, glass cleaners etc. can affect the Alcohol Rapid Tests. Therefore, adequate measures should be taken to avoid undue interference from such atmospheric agents in the testing area.
- 8. The test is only for detection of presence/ absence of alcohol in the urine, which may result from habitual drinking or medications and does not discriminate the two.

[S.V.T/ ADULTERATION LIMITATIONS]

- 1 The adulteration tests included with the product are meant to aid in the determination of abnormal specimens. While comprehensive, these tests are not meant to be an "all-inclusive" representation of possible adulterants.
- 2. Oxidants/PCC: Normal human urine should not contain oxidants or PCC. The presence of high levels of antioxidants in the specimen, such as ascorbic acid, may result in false negative results for the oxidants/PCC pad.
- 3. Specific Gravity: Elevated levels of protein in urine may cause abnormally high specific gravity values.
- 4. Nitrite: Nitrite is not a normal component of human urine. However, nitrite found in urine may indicate urinary tract infections or bacterial infections. Nitrite levels of > 20 mg/dL may produce false positive glutaraldehyde results.
- 5. Glutaraldehyde: is not normally found in urine. However certain metabolic abnormalities such as ketoacidosis (fasting, uncontrolled diabetes or high protein diets) may interfere with the test results.
- 6. Creatinine: Normal Creatinine levels are between 20 and 350 mg/dL. Under rare conditions, certain kidney diseases may show dilute urine.
- 7. Bleach: Normal human urine should not contain bleach. The presence of high levels of bleach in the specimen may result in false negative results for the bleach pad. [EXPECTED VALUES]

The negative result indicates that the drug concentration is below the detectable level. Positive result means the concentration of drug is above the detectable level. [PERFORMANCE CHARACTERISTICS]

Accuracy

A side-by-side comparison was conducted using the Multi-Drug Rapid Test Cassette and commercially available drug rapid tests. Testing was performed on approximately hundred specimens per drug type previously collected from subjects presenting for Drug Screen Testing. Presumptive positive results were confirmed by GC/MS

nfirmed by GC/M		0.0/	10			
Met		GC/I		% agreement with GC/M		
Multi-Drug Rapi		Positive	Negative	0		
ACE	Positive	29	1	93.5%		
5,000	Negative	2	68	98.6%		
AMP	Positive	103	3	98.1%		
1,000	Negative	2	142	97.9%		
AMP	Positive	110	2	99.1%		
500	Negative	1	137	98.6%		
AMP	Positive	116	2	99.1%		
300	Negative	1	131	98.5%		
BAR	Positive	98	2	96.1%		
300	Negative	4	146	98.6%		
BAR	Positive	101	3	95.3%		
200	Negative	5	141	97.9%		
BZO	Positive	112	3	98.2%		
500	Negative	2	133	97.8%		
BZO	Positive	121	1	98.4%		
300	Negative	2	126	99.2%		
BZO	Positive	127	2	99.2%		
200	Negative	1	120	98.4%		
BZO	Positive	128	3	99.2%		
100	Negative	1	118	97.5%		
BUP	Positive	105	0	99.1%		
10	Negative	1	144	>99.9%		

ilti-Drud Rani	hod d Test Cassette	GC/I Positive	Negative	% agreement with GC/MS
BUP	Positive	105	0	99.1%
5	Negative	1	144	>99.9%
COC	Positive	111	3	98.2%
300	Negative	2	134	97.8%
COC	Positive	40	0	>99.9%
200	Negative	0	60	>99.9%
COC	Positive	116 2	4	98.3% 97.0%
150 COC	Negative Positive	117	4	99.2%
100	Negative	1	128	97.0%
THC	Positive	85	3	95.5%
300	Negative	4	158	98.1%
THC	Positive	85	4	93.4%
200	Negative	6	155	97.5%
THC	Positive	86	4	94.5%
150	Negative	5	155	97.5%
THC	Positive	92	3	97.9%
50	Negative	2	153	98.1%
THC	Positive	94	3	97.9%
30	Negative	2	151	98.1%
THC	Positive	95	4	96.9%
25	Negative	3	148	97.4%
THC	Positive	92	1	94.8%
20	Negative	5	152	99.3%
MTD 300	Positive	89 1	2 158	98.9%
MTD	Negative Positive	91	2	98.8%
200	Positive	91	∠ 156	98.9% 98.7%
MET	Negative Positive	76	5	
1,000	Positive Negative	3	166	96.2% 97.1%
MET	Positive	83	5	97.6%
500	Negative	2	160	97.0%
MET	Positive	88	4	97.8%
300	Negative	2	156	97.5%
MDMA	Positive	99	1	98.0%
1,000	Negative	2	148	99.3%
MDMA	Positive	102	1	98.1%
500	Negative	2	145	99.3%
MDMA	Positive	103	1	98.1%
300	Negative	2	144	99.3%
MOP/OPI	Positive	95	7	99.3%
300 X00				
	Negative	5	143	95.3%
MOP/OPI	Positive	95	6	95.0%
200	Negative	5	144	96.0%
MOP/OPI	Positive	98	5	97.0%
100	Negative	3	144	96.6%
MPRD	Positive	19	1	95.0%
	Negative	1	49	98.0%
MQL	Positive	79	11	89.8%
	Negative	9	151	93.2%
OPI	Positive	117	8	96.7%
2000	Negative	4	121	93.8%
OPI	Positive	116	8	95.9%
1000	Negative	5	121	93.8%
PCP	Positive	84	5	92.3%
50		7	154	92.3%
PCP	Negative			
25	Positive	85	5	92.4%
20	Negative	7	153	96.8%
PPX	Positive	97	9	96.0%
	Negative	4	140	94.0%
TCA	Positive	91	13	94.8%
TCA 1000	Positive Negative	5	141	91.6%
TCA 1000 TCA	Positive Negative Positive	5 93	141 12	91.6% 94.9%
TCA 1000	Positive Negative	5	141	91.6%
TCA 1000 TCA	Positive Negative Positive	5 93	141 12	91.6% 94.9%
TCA 1000 TCA 500	Positive Negative Positive Negative	5 93 5	141 12 140	91.6% 94.9% 92.1%
TCA 1000 TCA 500 TCA 300	Positive Negative Positive Negative Positive	5 93 5 94	141 12 140 12	91.6% 94.9% 92.1% 94.9%
TCA 1000 TCA 500 TCA 300 TML	Positive Negative Positive Negative Positive Negative Positive	5 93 5 94 5 82	141 12 140 12 139 12	91.6% 94.9% 92.1% 94.9% 92.1% 88.2%
TCA 1000 TCA 500 TCA 300 TML 100	Positive Negative Positive Positive Negative Positive Negative Negative	5 93 5 94 5 82 11	141 12 140 12 139 12 145	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4%
TCA 1000 TCA 500 TCA 300 TML 100 TML	Positive Negative Positive Positive Negative Positive Negative Positive	5 93 5 94 5 82 11 82	141 12 140 12 139 12 145 6	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2%
TCA 1000 TCA 500 TCA 300 TML 100 TML 200	Positive Negative Negative Positive Negative Positive Negative Positive Negative	5 93 5 94 5 82 11 82 11 82 11	141 12 140 12 139 12 145 6 151	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2% 96.2%
TCA 1000 TCA 500 TCA 300 TML 100 TML 200 TML	Positive Negative Positive Negative Negative Positive Negative Positive Negative Positive	5 93 5 94 5 82 11 82 11 82 11 81	141 12 140 12 139 12 145 6 151 6	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2% 96.2% 88.0%
TCA 1000 TCA 500 TCA 300 TML 100 TML 200 TML 300	Positive Negative Positive Positive Negative Positive Negative Negative Negative Negative Negative Negative	5 93 5 94 5 82 11 82 11 81 11	141 12 140 12 139 12 145 6 151 6 152	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2% 96.2% 88.0% 96.2%
TCA 1000 TCA 500 TCA 300 TML 100 TML 200 TML 300 KET	Positive Negative Positive Negative Negative Positive Negative Positive Negative Positive	5 93 5 94 5 82 11 82 11 81 81 11 77	141 12 140 12 139 12 145 6 151 6 151 152 3	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2% 96.2% 88.0% 96.2% 97.5%
TCA 1000 TCA 500 TCA 300 TML 100 TML 200 TML 300	Positive Negative Positive Positive Negative Positive Negative Negative Negative Negative Negative Negative	5 93 5 94 5 82 11 82 11 81 81 11 77 2	141 12 140 12 139 12 145 6 6 151 6 151 6 152 3 3 168	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 92.4% 96.2% 96.2% 96.2% 97.5% 98.2%
TCA 1000 TCA 500 TCA 300 TML 100 TML 200 TML 300 KET	Positive Negative Positive Positive Negative Positive Negative Positive Negative Negative Negative Negative Negative	5 93 5 94 5 82 11 82 11 81 81 11 77	141 12 140 12 139 12 145 6 151 6 151 152 3	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2% 96.2% 88.0% 96.2% 97.5%
TCA 1000 TCA 500 TCA 300 TML 200 TML 200 TML 300 KET 1,000	Positive Negative Positive Negative Positive Positive Positive Negative Positive Negative Positive Negative Negative Positive Negative	5 93 5 94 5 82 11 82 11 81 81 11 77 2	141 12 140 12 139 12 145 6 6 151 6 151 6 152 3 3 168	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 92.4% 96.2% 96.2% 96.2% 97.5% 98.2%
TCA 1000 TCA 500 TCA 300 TML 200 TML 300 TML 200 TML 300 KET 1,000 KET 500	Positive Negative Positive Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Negative Negative Negative Negative	5 93 5 94 5 82 11 82 11 82 11 81 11 77 2 81 2	141 12 140 12 139 12 145 6 151 151 6 152 3 168 3 164	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2% 96.2% 88.0% 96.2% 96.2% 97.5% 98.2% 97.6% 98.2%
TCA 1000 TCA 500 TCA 300 TML 100 TML 300 TML 300 KET KET KET KET	Positive Negative Positive Negative Positive Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive	5 93 5 94 5 82 11 82 11 81 11 77 2 81 2 89	141 12 140 12 139 12 145 6 151 6 152 3 168 3 164 4	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 96.2% 96.2% 96.2% 97.5% 98.2% 97.5% 98.2% 97.6% 98.2% 96.7%
TCA 1000 TCA 500 TCA 300 TML 100 TML 200 TML 300 KET 500 KET 300	Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative	5 93 5 94 5 82 11 81 81 11 81 11 77 2 81 2 81 2 89 3	141 12 140 12 139 12 145 6 151 6 152 3 168 3 164 4	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2% 96.2% 96.2% 96.2% 97.5% 98.2% 96.7% 96.7%
TCA 1000 TCA 500 TCA 300 TML 100 TML 200 TML 300 KET 500 KET 500 KET 500 KET 500 KET	Positive Negative Positive Positive Positive Positive Negative Positive Negative Positive Negative Negative Positive Negative Positive Negative Positive Negative Positive Negative Negative Negative Negative	5 93 5 94 5 82 11 82 11 81 11 77 2 81 2 81 2 81 2 8	141 12 140 12 139 12 145 6 151 6 152 3 168 3 164 4	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2% 96.2% 96.2% 96.2% 97.5% 98.2% 97.6% 98.2% 97.6% 98.2% 96.7% 97.5%
TCA 1000 TCA 500 TCA 300 TML 100 TML 200 TML 300 KET 500 KET 300	Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative	5 93 5 94 5 82 11 81 81 11 81 11 77 2 81 2 81 2 89 3	141 12 140 12 139 12 145 6 151 6 152 3 168 3 164 4	91.6% 94.9% 92.1% 94.9% 92.1% 88.2% 92.4% 88.2% 96.2% 96.2% 96.2% 97.5% 98.2% 96.7% 96.7%

Meth Multi-Drug Rapid		GC/MS Positive	Negative	% agreement with GC/MS
OXY	Positive	84	1	97.7%
100	Negative	2	163	99.4%
	Positive	88	4	97.7%
COT 300		2	156	97.5%
	Negative			
COT	Positive	88	4	96.7%
200	Negative	3	155	97.5%
COT	Positive	93	3	97.9%
100	Negative	2	152	98.1%
EDDP	Positive	92	1	97.9%
300	Negative	2	155	99.4%
EDDP	Positive	95	5	96.9%
100	Negative	3	147	96.7%
FYL	Positive	32	2	97.0%
300	Negative	1	185	98.9%
FYL	Positive	65	2	95.6%
100	Negative	3	97	98.0%
FYL	Positive	79	1	98.8%
20	Negative	1	169	99.4%
		80	1	
FYL 10	Positive	1	168	98.8%
10	Negative			99.4%
K2-50	Positive	78	3	97.5%
-	Negative	2	167	98.2%
K2-30	Positive	82	2	97.6%
	Negative	2	164	98.8%
K2-25	Positive	82	3	97.6%
	Negative	2	163	98.2%
6-MAM	Positive	42	2	97.7%
10	Negative	1	105	98.1%
MDA	Positive	103	3	98.1%
500	Negative	2	142	97.9%
	Positive	79	1	98.8%
ETG 300		1		99.4%
	Negative		169	
ETG	Positive	83	1	97.6%
500	Negative	2	164	99.4%
ETG	Positive	81	1	95.3%
1,000	Negative	4	164	99.4%
CLO	Positive	101	1	97.1%
400	Negative	3	145	99.3%
CLO	Positive	103	2	99.0%
150	Negative	1	144	98.6%
LSD	Positive	33	1	94.3%
10	Negative	2	65	98.5%
LSD	Positive	33	1	94.3%
20		2	64	
	Negative			98.5%
LSD	Positive	32	1	94.1%
50	Negative	2	65	98.5%
MPD	Positive	35	1	94.6%
300	Negative	2	62	98.4%
MPD	Positive	34	1	91.9%
150	Negative	3	62	98.4%
ZOL	Positive	20	2	90.9%
201	Negative	2	66	97.1%
MEO	Positive	20	1	95.2%
500	Negative	1	65	98.5%
	Positive	19	2	90.5%
MEP 100		2		
	Negative		64	97.0%
MDPV	Positive	28	1	93.3%
1000	Negative	2	69	98.6%
MDPV	Positive	27	1	93.1%
500	Negative	2	59	98.3%
DIA	Positive	121	1	98.4%
300	Negative	2	126	99.2%
DIA	Positive	121	1	98.4%
200	Negative	2	126	99.2%
	-			
ZOP	Positive	19	2	86.4%
50	Negative	3	69	97.2%
MCAT	Positive	20	4	90.9%
500	Negative	2	76	95.0%
7-ACL	Positive	32	1	94.1%
300	Negative	2	43	97.7%
7-ACL	Positive	35	1	94.6%
7-ACL 200	Negative	2	40	94.6%
	-			
7 ACL	Positive	36	1	94.7%
7-ACL	NI			
100 CFYL	Negative Positive	2 36	39	97.5% 94.7%

			Meth							GC/M				0/	. 20	iroom	ont	with	GC/N	19
Μ	lulti-Dr 50		Rapid					Posi			1	Vegati	ve	70	ay	leen			GC/I	/13
_	CA				egativ ositiv			2			-	72						.6% .3%		
	100		ľ		gativ			2				66						.7%		
	CA			P	ositiv	е		1				2						.5%		
	15				gativ			2				73						.3%		
	TR 35				ositiv			2				2 64						.0% .0%		
	AL				egativ ositiv			2				2		_				.0%		
	10				gativ			2				74						.4%		
	PG			P	ositiv	е		2	0			2					90	.0%		
	50,0				gativ			2				73						.3%		
	PG 50				ositiv egativ			2				2 52		_				.2% .3%		
	CC				ositiv			5				5		-				.3 %		
	20				gativ			3				84						.4%		
	ZA				ositiv			2				1						.2%		
	10				gativ			1				38						.4%		
	CN 50				ositiv egativ			2				1 40		_				.8% .6%		
-	GA				ositiv			2				1						.3%		
	200				egativ			2	2			65						.5%		
	TZ				ositiv			2				3						.9%		
\vdash	20				gativ			2				73		+				.1% 5%		
	CA 200				ositiv egativ			1			<u> </u>	49		+				.2%		
	AB	BP			ositiv			2				2						2%		
	1(egativ			2				68						.1%		
	QT 100				ositiv			3				1 59						.1%		
	FL				egativ ositiv			3				2		_				.3% .1%		
	100				gativ			1				57						.6%		
	UR-	144			ositiv			3				1					97	.1%		
_	25				gativ			1				62						.4%		
	KR 30				ositiv egativ			2				1 59		_	95.7% 98.3%					
-	TL				ositiv			3			-	1					97			
	50				gativ			1				57						.3%		
	α-P				ositiv			3				2						.8%		
_	200				gativ			5				60						.8%		
	α-Ρ΄ 100				ositiv egativ			3				2 60		-				.1% .8%		
	α-P				ositiv			3				3						.9%		
	50				egativ			3				60					95	.2%		
	α-P				ositiv			3				2						.5%		
	30	0		Ne	egativ		Agree	4 emen		h Cor	nme	60 rcial I	Kit				96	.8%		
			ACE			AMP	AMF	P B	AR	BAF	۲ I	BZO	BZ	ZO		ZO	ΒZ		BUP	
Posit	ive		5,000			500	300		300	200		500		00		00	10		10	5
Agree	ement		*	>99.9	9%>!	99.9%	> 99.9	%>9	9.9%	>99.9	9%>9	99.9%	>99	9%	>99	9.9%	>99.	.9%>	99.99	* *
Nega Aaree	ative ement		*	>99.9	9%>	99.9%	> 99.9	%>9	9.9%	>99.9	9%>9	99.9%	>99	9.9%	>99	9.9%	>99.	9%>	99.99	* *
	Resul		*	>99.9	9%>	99.9%	>99.9	%>9	9.9%	>99.9	9%>9	99.9%	>99	9.9%	>99	9.9%	>99.	9%>	99.99	% *
													_		_				-	
			OC 300	COC 200	150	CO 100		HC 00	THC 30/30		HC 50	TH 50		TH 25		MT 30		MT 20		MET 1,000
Posit	tive ement	~0	9.9%	*	*	>99.9		9.9%	*		9.9%			>99.9		>99.		>99.		99.9%
Nega			9.9%	*	*		9%>99	a qo/	*	_		>99.						\00		
Agre Total		_								_										
Resu		>9	9.9%	*	*	>99.9	9% >99	9.9%	*	>9	9.9%	>99.	9%	>99.9	9%	>99.	9%	>99.	9%>	99.9%
		м	ET	MET	м	DMA	MDM	л Мг	DMA I	MOP	OPI	MOP/	OPI	1		OP	11.6	PCP	PC	P
			00	300		000	500		00	300/		20		M	JL	200		50	2	
Positi Agree		>99	9.9%	>99.99	%>9	9.9%	>99.99	%	*	>99.	9%	*		>99	.9%	ć *		*	>99	.9%
	ement			>99.99	%>9	9.9%	>99.99	%	*	>99.	9%	*		>99	.9%	<u>،</u> *	T	*	>99	.9%
Nega		>99	9.9%		Ξŕ Υ				*					-			+	*	-	
Nega Agree	ative ement			06.1	<u> </u>	0.000		w 1	~	>99.	9%	*		>99	.9%	o *	1	*	>99	.9%
Nega	ative ement			>99.99	%>9	9.9%	>99.99	/0		200.	• • •									
Nega Agree Total	ative ement	>99	9.9%						ТМ			KE.	r I	KEI	r I	KE.	r Id	сот	СОт	COT
Nega Agree Total Resu	ative ement Ilts	>99		>99.9° TCA 1000	TC/		A TML			IL K	ET 000	KE 500		KE1 300		KE 100		COT 300	COT 200	
Nega Agree Total Resu Positi	ative ement Ilts ive	>99 F	9.9%	TCA 1000	TC/	A TC	A TML	TM		IL K 0 1,	ET	500)))			COT 100 *
Nega Agree Total Resu Positi Agree	ive ement ive ement ative	>99 F	9.9% PPX	TCA 1000	TC/ 500	A TC/ 0 300	A TML 0 100	TM 200) 30	IL K 0 1, >9!	ET 000	500) 9%>	300) 9%:	100) 9%	300	200	100
Nega Agree Total Resu Positi Agree	ative ement its ive ement ative ement	>99 F >9 >9	9.9% PPX 99.9%	TCA 1000	TC/ 500	A TC/ 300	A TML 0 100 *	TM 200	30	IL K 0 1, >99	ET 000 9.9%	500 >99.9 >99.9) 9% > 9% >	300 99.9))%;)%;	100 >99.9) 9% 9%	300 *	200 *	100 *

	OXY 300/ 100	EDDF 300/1 0				YL 20	FYL 10	K2 5 30/2			/IDA 500		TG 000	ET 50		ETG 300
ositive	*	*	*					*	*		*		*	*		*
greement legative	*	*	*					*			*		*	*		*
greement	*	` *	*					*			*		*	•		*
otal Results	*	*	*					*	*		*	I	*	*		*
	CLO 400	CLO 150	LSD 20	LSD 50	MPD 300	Z	OL 8		MDPV 1000/ 500	DIA 300			ZOF 50		/CAT 500	LS 10
Positive Agreement	*	*	٠	*	*		*	*	٠	*	,	•	*		*	*
Negative Agreement	*	*	*	*	*		*	*	*	*	,	•	*		*	*
Total Results	*	*	٠	*	*		*	*	٠	*		•	*		*	*
	7-ACL		7-ACL	CFYL			CAT	TRO	ALP	OF		HC	MF		PGE	
ositive	300	200	100	500 *	100	0	150	350	*	100	0	20 *	15	,	500C	00 1
greement legative	-															
greement	*	*	*	*	*		*	*	*	*		*	*	'	*	,
otal Results	*	*	*	*	*		*	*	*	*		*	*	,	*	
	COD 200	PGB 500	CNB 500			ZAL 100		MPRE	QTF 1000			R-1 25	KRA 300		D 2	-PVF 2000/ 1000/ 00/300
Positive Agreement	*	*	*	*	*	*	*	*	*	*		*	٠			*
Negative Agreement	*	*	*	*	*	*	*	*	٠	*		*	٠		•	*
Total Results	*	*	*	*	*	*	*	*	*	*		*	*		•	*
	Based	on GC	C/MS d	lata ins	tead o		omme		it.					-		
each site. The	ugs at o e results	concen s are gi	tration					6 cut-c	ff leve	, was	labe		blind	ded	and	teste
each site. The	ugs at o e results PHEN Amp	concen s are gi (ACE 5 hetami c. (ng/n	tration iven be 5,000) ine	s of ±	50% a n p sit	and : er e	± 259	6 cut-c	ff leve	l, was Si -	labe te B	led,	blind -	ded Site	and e C +	teste
each site. The	ugs at o results PHEN Amp cond	concen s are gi (ACE 5 hetami c. (ng/n 0 2,500	tration iven be 5,000) ine	s of ±	50% a n p sit 10	er e)	± 259 - 10 10	Site A	+ 0 0	, was Si - 10 10	labe	-)	blind - 10	Site	and e C + 0	teste
ach site. The	ugs at o e results PHEN Amp cond	concen s are gi (ACE 5 hetami c. (ng/n 0	tration iven be 5,000) ine	s of ±	50% a n p sit	er e))	± 259 - 10	Site A	+ 0	l, was Si - 10	te B	- -)	blind - 10	Site	and e C + 0	testee
ach site. The	ugs at o results PHEN Amp cond	concen s are gi (ACE 5 hetamic: (ng/n 0 2,500 3,750 6,250 7,500	tration iven be 5,000) ine hL)	s of ±	50% a n p sit 10 10	er e))))	± 25%	Site A	+ 0 1	, was Si - 10 10 9	labe	- -))	blind - 10 8	Site	and + 0 0 2	
ach site. The	Amp conc NE (AM Amp	concen s are gi (ACE 5 hetamic: (ng/n 0 2,500 3,750 6,250 7,500 MP 1,00 hetami	tration iven be 5,000) ine hL) 00)	s of ±	50% a n p sit 10 10 10	er e D D D D D	± 25%	Site A	ff leve + 0 1 9 10	l, was Si - 10 10 9 1 0	te B	- -))	blind - 10 10 8 1 0	Site	and + 0 0 2 9 10	
ach site. The	Amp conc NE (AM Amp	concen s are gi (ACE 5 hetamic: (ng/n 0 2,500 3,750 6,250 7,500 MP 1,00 hetamic: (ng/n	tration iven be 5,000) ine hL) 00)	s of ±	50% a n p sit 1(1(1(1(1(1(1(1) sit	er e D D D D D C C C C C C C C C C C C C C	± 25%	Site A	+ 0 0 1 9 10 +	I, was Si - 10 10 9 1 0 Si -	labe	-)) 0	blind - 10 10 8 1 0	Site	and + 0 0 2 9 10 + + + + +	
ach site. The	Amp conc NE (AM Amp	concen s are g (ACE 5 hetamic: (ng/n 0 2,500 3,750 6,250 7,500 <i>I</i> P 1,00 hetamic: (ng/n 0	tration iven be 5,000) ine hL) 00)	s of ±	50% a n p sit 10 10 10 10 10 10 10 10 10 10	er e)))))) er e))	± 25%	Site A	+ 0 0 1 9 10 + 0	, was Si - 10 10 9 1 0 5 i - 10	labe	-)))))	blind - 10 10 8 1 0 -	Site	and	
CETAMINO	Amp conc NE (AM Amp	concen s are gi (ACE 5 hetamic: (ng/n 0 2,500 3,750 6,250 7,500 MP 1,00 hetamic: (ng/n	tration iven be 5,000) ine hL) 00)	s of ±	50% a n p sit 1(1(1(1(1(1(1(1) sit	er e))))) er e))	± 25%	Site A	+ 0 0 1 9 10 +	I, was Si - 10 10 9 1 0 Si -	labe	- -)) 0	blind - 10 10 8 1 0	Site	and + 0 0 2 9 10 + + + + +	
ach site. The	Amp conce NE (AM Amp conce NE (AM Amp conce	concen s are g (ACE 2 hetamic: (ng/n 0 2,500 3,750 6,250 7,500 MP 1,00 hetamic: (ng/n 0 500 7,50 1,250	tration iven be 5,000) ine hL) 00)	s of ±	50% a n p sit 1(1(1(1(1(1(1(1(1(1(1(1(1(er e 0) 0) 0) 0) 0) 0) 0) 0) 0) 0)	± 259	Site A	+ 0 0 1 9 10 + 0 0 0 1 0 0 1 9 9	l, was Si - 10 10 9 1 0 5i - 10 10 10 8 2	Iabe Image: Base of the second sec	- - - - - - - - - - - - - - - - - - -		Site	and	
MPHETAMI	Amp cond NE (AM Amp cond	concen s are g (ACE 5 hetamic: (ng/n 0 2,500 3,750 6,250 7,500 AP 1,00 hetamic: (ng/n 0 500 750 1,250 1,250	tration iven be 5,000) ine nL)	s of ±	50% a n p sit 1(1(1(1(1(1(1(1(1(1(er e 0) 0) 0) 0) 0) 0) 0) 0) 0) 0)	± 259	Site A	ff leve + 0 1 9 10 + 0 0 1	l, was Si 10 10 9 1 0 5i - 10 10 10 8 2 0	labe	- - - - - - - - - - - - - - - - - - -	- 100 100 88 11 00 - 100 100 99	Site	and	
MPHETAMI	NE (AM Amp	concen s are g (ACE 5 hetamic: (ng/n 0 2,500 3,750 6,250 7,500 AP 1,00 hetamic: (ng/n 0 500 750 1,250 1,250	tration iven bs ine inc) ine inc) ine inc) ine ine ine	s of ±	50% a n p sit 1(1(1(1(1(1(1(1(1(1(1(1(1(er e e)))))))))))))))))	± 259	Site A	+ 0 0 0 1 9 10 10 10 10 10 10 10 10 10 10 10 10 10	l, was Si 10 10 9 1 0 5i - 10 10 10 8 2 0	labe te B 4 ()		blind 100 100 8 11 00 100 100 100 9 9 2 0 0	Site	and	
MPHETAMI	NE (AM Amp	concen s are g (ACE 5 (ACE 5 (ng/m) 0 2,500 3,750 6,250 7,500 AP 1,00 (ng/m) 0 500 7,500 1,250 1	tration iven bs ine inc) ine inc) ine inc) ine ine ine	s of ±	n p p sit 10 10 10 10 10 10 10 10 10 10 10 10 10	er ee 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0)	± 259	Site A	+ 0 0 1 9 10 + 0 0 1 9 10 9 10	l, was Si 10 10 9 1 0 5i - 10 10 10 8 2 0	labe		blind 100 100 8 11 00 100 100 100 9 9 2 0 0	Site Site Site	and + + 0 0 2 9 9 10 	
MPHETAMI	NE (AM Amp	concent s are grading (ACE 5 hetam c. (ng/n 0 2,500 3,750 6,250 7,750 7,750 0 500 7,500 1,250 1,500 7,500 1,250 1,500 0 2,500 1,250	tration iven bs ine inc) ine inc) ine inc) ine ine ine	s of ±	n p siti 100 100 100 100 100 100 100 100 100 10	and :: er e 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0)	± 259 	Site A Site A Site A Site A Site A Site A	+ 0 0 1 9 1 10 - + 0 0 1 9 1 10 - + - 0 - 11 - 9 - 10 - + - 0 - + - 0 - 0 -	I, was Si - 10 10 9 1 0 5 10 10 10 8 2 0 5 i - 10 10 10 10	labe te B + ()		blind 	Site Site Site Site	and $\Rightarrow C$ + 0 0 2 9 9 10 2 2 0 1 0 0 0 1 1 8 10 0 0 0 0 0 0 0	
	NE (AM Amp	concent s are given thetamin c. (ng/m 0 2,500 3,750 3,750 1,250 1,250 1,250 1,250 1,250 1,250 1,250 3,75	tration iven bs ine inc) ine inc) ine inc) ine ine ine	s of ±	50% a site site 10(10(10(10(10(10(10(10(10(10(er e e)))))))))))))))))		Site A Site A Site A Site A Site A Site A	+ 0 0 1 9 1 1 9 1 10 0 1 9 1 10 1 9 1 1 9 1 1 9 1 1 9 1 1 9 1 1 9 1 1 9 1 10 1 9 1 0 0 1 1 9 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	I, was Si - 10 10 9 1 0 5 i - 10 8 2 0 5 i - 10	labe		blind 	Site Site Site Site	and $\Rightarrow C$ + 0 0 2 9 9 10 $\Rightarrow C$ + 0 0 0 2 2 3 0 0 2 2 3 0 0 2 2 0 0 0 0 0 0 0 0	
	ugs at L results Amp conc NE (AM Amp conc NE (AM	concents s are g hetamin 2,500 2,500 3,750 6,250 7,500 MP 1,00 1,250 1,250 1,250 1,250 1,250 1,250 1,250 1,250 3,750 6,257 7,50	tration iven bs ,000) nL) 00) ine nL)) ine nL)	s of ±	50% a site of the second secon	er e 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0)	± 259 	Site A	+ 0 0 0 1 1 9 9 10	I, was Si - 10 10 9 1 0 5 10 10 10 8 2 0 5 i - 10 10 10 10	labe		blind 	Site Site Site Site	and	
AMPHETAMI	ugs at tresultities of the second sec	concen s are g s are g (ACE 5 hetam) 0 2,500 3,750 6,250 7,500 1,500 AP 1,00 AP 1,00 AP 1,00 1,250 1,250 3,755 625 750 AP 300 hetam) 0 250 3,757 625 750 AP 300 hetam)	tration iven bk (s,000) ine nL)))))))))))))))))))	s of ±	n p siti 100 100 100 100 100 100 100 100 100 10	and : er e)))))))))))))))))	± 259	Site A	+ 0 0 1 1 9 10 - + 0 0 1 1 - 9 10 + 0 0 1 1 - 9 10 + 0 0 1 1 - 8 - 10 -	I, was Si - 10 10 9 1 0 Si - 10 10 10 8 2 0 5 10 10 10 9 1 10 0	labe		blind 	Site Site Site Site	and	
AMPHETAMI	ugs at tresultities of the second sec	concent s are g (ACE 5 hetam) 2, (ng/n 2,500 3,750 6,250 7,500 AP 1,00 hetam) 2, (ng/n 0 5 0 1,500 1,250 1,500 0 750 1,250 1,500 0 5 0 1,250 1,500 0 7 50 1,250 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 500 1,500 0 7 50 0 1,500 0 7 50 1,500 0 7 50 1,500 0 7 50 1,500 1,500 1,	tration iven bk (s,000) ine nL)))))))))))))))))))	s of ±	50% a n p siti 100 100 100 100 100 100 100 10	and : er e)))))))))))))))))	± 25% 	Site A	+ - 0 0 1 - 9 - 10 - - - 0 0 1 - 9 - 10 - + - 0 0 1 - 8 - 10 - + - 0 1 - - - - + -	I, was Si - 10 10 9 1 0 - 10 10 10 10 8 2 0 - 10 10 10 9 9 1 0 0 Si - - 10 5 - - - - - - - - - - - - - - - - - -	labe		blind 	Site Site Site	and	
	ugs at tresultities of the second sec	concen s are g s are g (ACE 5 hetam) 0 2,500 3,750 6,250 7,500 1,500 AP 1,00 AP 1,00 AP 1,00 1,250 1,250 3,755 625 750 AP 300 hetam) 0 250 3,757 625 750 AP 300 hetam)	tration iven bk (s,000) ine nL)))))))))))))))))))	s of ±	n p siti 100 100 100 100 100 100 100 100 100 10	and : er e)))))))))))))))))	± 259	Site A	+ 0 0 1 1 9 10 - + 0 0 1 9 10 + 0 0 1 10 - 10 -	I, was Si - 10 10 9 1 0 Si - 10 10 10 8 2 0 5 10 10 10 9 1 10 0	labe ie B iii iii iiii iiiiiiiiiiiiiiiiiiiiiiii		blind 	Site	and $\Rightarrow C$ + 0 0 2 9 9 10 $\Rightarrow C$ + 0 0 2 2 9 9 0 2 2 9 0 2 2 0 0 2 2 0 0 2 2 0 0 2 2 0 0 2 2 0 0 0 0 0 0 0 0	
	ugs at tresultities of the second sec	concen sare g (ACE 5 (ACE 5 (A	tration iven bk (s,000) ine nL)))))))))))))))))))	s of ±	n p sitti 100 100 100 100 100 100 100 100 100 100	and : er er er er er er er er er er	+ 25% 	Site A (1997)	+ 0 0 1 10 9 10 1 9 10 1 9 10 1 9 10 1 1 9 10 1 1 9 10 1 1 9 1 0 1 1 8 10 1 8 10 + 0 0 2	, was Si - 10 10 9 1 0 Si - 10 10 8 2 0 Si - 10 10 9 1 0 Si - 10 10 9 1 0 Si - 10 10 9 1 0 - 10 - 10 - - - - - - - - - - - - -	labe		blind 	Site	and 2 C + 0 0 2 2 9 9 9 10 2 2 2 2 2 2 2 2	
	ugs at tresultities of the second sec	concent sare gi (ACE 5 (ACE 5	tration iven bk (s,000) ine nL)))))))))))))))))))	s of ±	n p situit 100 100 100 100 100 100 100 100 100 10	and : er er er er er er er er er er	+ 25% 	Site A	+ 0 0 1 1 9 10 - + 0 0 1 1 9 10 - + 0 0 1 1 1 9 10 + 0 0 0 1 1 8 10 + 0 0 2 8 8	, was Si - 10 10 9 1 0 - 10 10 - 10 10 8 2 0 - 10 10 9 1 0 - - 10 10 9 1 0 - - - 10 0 9 - - - - - - - - - - - - -	labe te B 1 </td <td></td> <td>blind </td> <td>Site</td> <td>and and and and and and and and</td> <td></td>		blind 	Site	and and and and and and and and	
	ugs at t resulting PHEN Amprovention NE (AM Amprovention NE (AM Amprovention NE (AM	concent sare g (ACE 5 (ACE 5 (tration (ven be (000) (00) (00) (00) (00) (00) (00) (0	s of ±	n p sitti 100 100 100 100 100 100 100 100 100 100	and : er er er er er er er er er er	+ 25% 	Site A	+ 0 0 1 10 9 10 1 9 10 1 9 10 1 9 10 1 1 9 10 1 1 9 10 1 1 9 1 0 1 1 8 10 1 8 10 + 0 0 2	, was Si - 10 10 9 1 0 Si - 10 10 8 2 0 Si - 10 10 9 1 0 Si - 10 10 9 1 0 Si - 10 10 9 1 0 - 10 - 10 - - - - - - - - - - - - -	labe te B 1		blind 	Site	and	
	vigs at t e result: Ampresent NE (AN Ampresent NE (AN Ampresent Ampresent NE (AN Ampresent Conce NE (Ampresent Conce NE (Ampre	concent sare g (ACE 5 (ACE 5 (tration (iven ba (iven ba (ivenbaba (iven ba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba)) (ivenbaba (ivenbaba)) (iven	s of ±	n p sitt sit </td <td>and :: er e 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0)</td> <td>+ 25% </td> <td>Site A</td> <td>+ 0 0 1 10 9 10 1 9 10 10 1 9 10 10 1 9 10 11 9 10 1 8 10 + 0 0 2 8 10</td> <td>l, was Si - 10 10 9 1 0 - 10 10 10 8 2 0 Si - 10 10 9 1 0 Si - 10 10 9 1 0 - 10 10 9 10 10 10 9 10 10 10 9 10 10 10 10 9 10 10 10 10 10 10 10 10 10 10</td> <td>label te B te I te I</td> <td></td> <td>blind </td> <td>Site</td> <td>and and C + + 0 0 2 9 9 9 0 0 2 9 9 0 0 2 9 0 0 2 9 0 0 2 9 0 0 2 9 0 0 0 0 0 0 0 0 0 0 0 0 0</td> <td></td>	and :: er e 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0)	+ 25% 	Site A	+ 0 0 1 10 9 10 1 9 10 10 1 9 10 10 1 9 10 11 9 10 1 8 10 + 0 0 2 8 10	l, was Si - 10 10 9 1 0 - 10 10 10 8 2 0 Si - 10 10 9 1 0 Si - 10 10 9 1 0 - 10 10 9 10 10 10 9 10 10 10 9 10 10 10 10 9 10 10 10 10 10 10 10 10 10 10	label te B te I		blind 	Site	and and C + + 0 0 2 9 9 9 0 0 2 9 9 0 0 2 9 0 0 2 9 0 0 2 9 0 0 2 9 0 0 0 0 0 0 0 0 0 0 0 0 0	
	vigs at t e result: Ampresent NE (AN Ampresent NE (AN Ampresent Ampresent NE (AN Ampresent Conce NE (Ampresent Conce NE (Ampre	concent sare gi (ACE 5 hetam 2, (ng/n 0 2,500 AP 1,00 AP 1,00 hetam 1,250 750 1,250 750 1,250 750 1,250 375 625 625 625 625 625 625 625 625 625 62	tration (iven ba (iven ba (ivenbaba (iven ba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba)) (ivenbaba (ivenbaba)) (iven	s of ±	n p sitti 100 100 100 100 100 100 100 100 100 100	er e e e e e e e e e e e e e e e e e e	± 25% 	Site A	+ 0 0 0 1 19 10 1 + 0 0 1 10 1 + 0 0 1 + 0 0 1 + 0 0 1 + 0 0 2 8 10 + 0 0 2 8 10	I, was Si - 10 10 9 10 10 10 10 10 10 8 2 0 Si - 10 10 10 10 10 10 10 10 10 10	label te B 1 0 1		blind 	Site Site Site Site	and and	
	vigs at t e result: Ampresent NE (AN Ampresent NE (AN Ampresent Ampresent NE (AN Ampresent Conce NE (Ampresent Conce NE (Ampre	concent sare g (ACE 5 (ACE 5 (tration (iven ba (iven ba (ivenbaba (iven ba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba (ivenbaba)) (ivenbaba (ivenbaba)) (iven	s of ±	n p sitt sit </td <td>er ee e 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0)</td> <td>+ 25% </td> <td>Site A</td> <td>+ 0 0 1 10 9 10 1 9 10 10 1 9 10 10 1 9 10 11 9 10 1 8 10 + 0 0 2 8 10</td> <td>l, was Si - 10 10 9 1 0 - 10 10 10 8 2 0 Si - 10 10 9 1 0 Si - 10 10 9 1 0 - 10 10 9 10 10 10 9 10 10 10 9 10 10 10 10 9 10 10 10 10 10 10 10 10 10 10</td> <td>label te B te I te I</td> <td></td> <td>blind </td> <td>Site Site Site Site</td> <td>and and C + + 0 0 2 9 9 9 0 0 2 9 9 0 0 2 9 9 0 0 2 9 0 0 2 9 0 0 2 9 0 0 0 0 0 0 0 0 0 0 0 0 0</td> <td></td>	er ee e 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0) 0)	+ 25% 	Site A	+ 0 0 1 10 9 10 1 9 10 10 1 9 10 10 1 9 10 11 9 10 1 8 10 + 0 0 2 8 10	l, was Si - 10 10 9 1 0 - 10 10 10 8 2 0 Si - 10 10 9 1 0 Si - 10 10 9 1 0 - 10 10 9 10 10 10 9 10 10 10 9 10 10 10 10 9 10 10 10 10 10 10 10 10 10 10	label te B te I		blind 	Site Site Site Site	and and C + + 0 0 2 9 9 9 0 0 2 9 9 0 0 2 9 9 0 0 2 9 0 0 2 9 0 0 2 9 0 0 0 0 0 0 0 0 0 0 0 0 0	
	vigs at t e result: Ampresent NE (AN Ampresent NE (AN Ampresent Ampresent NE (AN Ampresent Conce NE (Ampresent Conce NE (Ampre	concent searce g (ACE 5 (ACE 5	tration (iven ba (iven ba (ivenbaba)) (iven ba (ivenbaba)) (ivenbab	s of ±	n p sitt 100	er e e 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	± 25% 	Site A Site A	# 0 0 1 0 1 10 1 10 1 10 1 11 9 10 1 11 9 10 1 11 1 12 1 13 1 14 1 15 1 16 1 17 1 18 1 10 1 10 1 10 1 10 1 10 1 10 1 10 1 10 1 10 1 10 1 10 1	I, was Si - 10 10 10 9 1 0 - 10 10 10 8 2 0 - 10 10 9 1 0 - - 10 10 9 1 0 - - - - - - - - - - - - - - - - - -	label te B + ()		blind 	Site Site Site Site	and	

BARBITURATES (BAR 200) Site A Site B Site C Secobarbital n per site conc. (ng/mL) + + -+ 1 9 0 10 **BENZODIAZEPINES (BZO 500)** Site A Site B Site C Oxazepam n per conc. (ng/mL) site + -+ - + 10 0 10 0 9 1 8 2 2 8 1 9 0 10 0 10 BENZODIAZEPINES (BZO 300) Site A Site B Site C Oxazepam n per conc. (ng/mL) site + + - + 10 0 10 0 10 0 10 0 q 0 10 0 10 0 10 BENZODIAZEPINES (BZO 200) Site A Site B Site C Oxazepam n per site conc. (ng/mL) -+ + -+ 2 8 0 10 **BENZODIAZEPINES (BZO 100)** Site B Site C Site A Oxazepam n per conc. (ng/mL) site + + - + --2 8 0 10 0 10 **BUPRENORPHINE (BUP 10)** Site C Site A Site B Buprenorphine n per conc. (ng/mL) site -+ -+ -+ 7.5 12.5 **BUPRENORPHINE (BUP 5)** Site A Site B Site C Buprenorphine conc. (ng/mL) n per site - + + + 10 0 10 0 2.5 3.75 6.25 7.5 0 10 0 10 COCAINE (COC 300) Site A Site B Site C Benzoylecgonine n per conc. (ng/mL) site + - + . -+ 10 0 10 0 10 0 10 0 0 10 0 10 COCAINE (COC 200) Site A Site B Site C Benzoylecgonine n per conc. (ng/mL) site + - + + 10 0 10 0 10 0 1 9 1 0 10 COCAINE (COC 150) Site A Site B Site C Benzoylecgonine n per conc. (ng/mL) site + - + - +

	0	10	10	0	10	0	10	0
	75	10	10	0	10	0	10	0
	112.5	10	9	1	9	1	9	1
	187.5	10	2	8	2	8	2	8
COCAINE (COC 10	225	10	0	10	0	10	0	10
	coylecgonine	n per	Sit	e A	Sit	eВ	Site	e C
	nc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	50	10	10	0	10	0	10	0
	75	10	9	1	9	1	9	1
	125	10	2	8	2	8	2	8
	150	10	0	10	0	10	0	10
MARIJUANA (THC	300) 9-THC-9 COOH		0.14	e A	Cit	еB	Site	
Concer	tration (ng/mL)	n per site	-	e A +	-	+	-	
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	8	2	9	1	9	1
	375	10	2	8	3	7	1	9
	450	10	0	10	0	10	0	10
MARIJUANA (THC								
	9-THC-9 COOH	n per	Sit	e A	Sit	eВ	Site	еC
COL	nc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	100	10	10	0	10	0	10	0
	150	10	9	1	9	1	9	1
	250	10	2	8	1	9	1	9
	300	10	0	10	0	10	0	10
MARIJUANA (THC			-	-			-	
	9-THC-9 COOH	n per	Sit	e A		e B	Site	e C
COL	nc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	75	10	10	0	10	0	10	0
	112.5	10	9	1	9	1	9	1
	187.5	10	2	8	1	9	1	9
MARIJUANA (THC	225	10	0	10	0	10	0	10
· · ·	1		0.4	e A	C:+	e B	C:+-	e C
	9-THC-9 COOH nc. (ng/mL)	n per site	-	е А +	-	е Б +	-	+
	0	10	- 10	+	- 10	+	- 10	+ 0
	25	10	10	0	10	0	10	0
	37.5	10	9	1	8	2	9	1
	62.5	10	9 1	9	1	9	2	8
	75	10	0	10	0	10	0	10
MARIJUANA (THC			. <u> </u>				~	
	THC-9 COOH conc.	n per		Site A		Site B		Site (
	(ng/mL)	site	-	+	-	-	+	
	0	10	10	0	10	0	10	0
	15	10	10	0	10	0	10	0
	22.5	10	9	1	9	1	9	1
	37.5	10	2	8	2	8	1	9
MARIJUANA (THC	45	10	0	10	0	10	0	10
	2-5) 9-THC-9 COOH	n per	Sit	e A	Sit	eВ	Site	еC
	nc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	12.5	10	10	0	10	0	10	0
	18.75	10	8	2	8	2	8	2
	31.25	10	1	9	1	9	2	8
	37.5	10	0	10	0	10	0	10
MARIJUANA (THC			<u> </u>		<u> </u>	<u> </u>		
	9-THC-9 COOH	n per	Sit	e A	Sit	e B	Site	еC
	nc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	10	10	10	0	10	0	10	0
	15	10	8	2	8	2	8	2
	25	10	1	9	1	9	2	8
		10	0	10	0	10	0	10
	30		5	.0	5	.0	5	
METHADONE (MT	30 D300)			۰ ۸	Sit	e B	Site	еC
	D300)	n per	Sit	eA				+
		n per site	Sit	е А +	-	+		
M	D300) ethadone			-		+	- 10	0
M	D300) ethadone nc. (ng/mL)	site	-	+	-			
M	D300) ethadone nc. (ng/mL) 0	site 10	- 10	+ 0	- 10	0	10	0
M	D300) ethadone nc. (ng/mL) 0 150	site 10 10	- 10 10	+ 0 0	- 10 10	0	10 10	0

METHADONE (MTD200)

						-		_		
Methadone	n p			ite A			e B		Site	
conc. (ng/mL)	sit		-	_	+	-	_	+	-	+
0	10		10	_	0	10	_	0	10	0
100	10	-	10 8		0 2	10 8	_	0 2	10 8	0
250	10	-	0		2	0	_	2	2	8
300	10	-	0	_	10	0	_	10	0	10
METHAMPHETAMINE (MET1,000)		•						0	•	10
Methamphetamine	n p		S	ite A		Sit	eВ		Site	еC
conc. (ng/mL)	sit		-	-	+	-	_	+	-	+
0	10		10 10	_	0	10 10		0	10 10	0
500 750	10		9		1	9		1	9	1
1,250	1(-	1	_	9	2	_	8	1	9
1,500	1(0	0	1	10	0	1	10	0	10
METHAMPHETAMINE (MET 500)				ite A		0.14	eВ		Site	
Methamphetamine conc. (ng/mL)	n p sit		-	-	+	-	<u> </u>	+	-	+
0	10	0	10	_	0	10	_	0	10	0
250	10		10	_	0	10	_	0	10	0
375	10	0	9		1	9		1	9	1
625	1(0	1		9	1		9	1	9
750	10	0	0	1	10	0	1	10	0	10
METHAMPHETAMINE (MET300)			- C	ite A		0:+	eВ	— T	Site	- C
Methamphetamine conc. (ng/mL)	n p sit	te	-	1	+	-		+	-	+
0	10	0	10		0	10		0	10	0
150	10	0	10	-	0	10	_	0	10	0
225	10		9	-	1	9	_	1	9	1
375	10		1	_	9	1	_	9	1	9
	10 INE (1	-	0		10 stasy	0	1	10	0	10
METHYLENEDIOXYMETHAMPHETAM Methylenedioxymethamphetami		n pe			te A		Site	B	Sit	te C
conc. (ng/mL)		site			+	-		+	-	+
0		10		10	0	10	_	0	10	0
500		10		10	0	10)	0	10	0
750		10 10		9	1	9	+	1	8	2
1,230		10		0	10		+	10	0	10
IETHYLENEDIOXYMETHAMPHETAM				Ecst	asy					
Methylenedioxymethamphetami	ine	n pe		Si	te A		Site		Sit	te C
conc. (ng/mL)		site		- 10	+	- 10	+	+	- 10	+
250		10 10		10	0	10	_	0	10	0
375		10		8	2	9	+	1	9	1
625		10		1	9	1		9	1	9
750		10		0	10	0 0	l	10	0	10
IETHYLENEDIOXYMETHAMPHETAM			- 1							
Methylenedioxymethamphetami conc. (ng/mL)	ine	n pe site	er	S				D	0.0	
0					te A		Site		Sit	te C +
			е	-	+	-	Ī	+	-	+
150		10 10	e)	- 10 10	1)			
150 225		10	e))	- 10	+	- 10)	+ 0	- 10	+ 0
225 375		10 10 10 10	e)))))	- 10 10 8 2	+ 0 0 2 8	- 10 10 9 1)	+ 0 0 1 9	- 10 10 7 1	+ 0 0 3 9
225 375 450		10 10 10	e)))))	- 10 10 8	+ 0 0 2	- 10 10 9 1)	+ 0 0 1	- 10 10 7	+ 0 0 3
225 375 450 AORPHINE (MOP/OPI 300)		10 10 10 10 10	e	- 10 10 8 2 0	+ 0 2 8 10	- 10 10 9 1 0 0)	+ 0 1 9 10	- 10 10 7 1 0	+ 0 3 9 10
225 375 450		10 10 10 10	e	- 10 10 8 2	+ 0 2 8 10	- 10 10 9 1 0 0)	+ 0 1 9 10	- 10 10 7 1 0	+ 0 0 3 9
225 375 450 MORPHINE (MOP/OPI 300) Morphine		10 10 10 10 10 10	e	- 10 10 8 2 0	+ 0 2 8 10 • A	- 10 10 9 1 0 0)	+ 0 1 9 10 B	- 10 10 7 1 0	+ 0 0 3 9 10
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL)		10 10 10 10 10 10 10	e /	- 10 10 8 2 0 Site	+ 0 2 8 10 • A +	- 10 9 1 0 0 5)	+ 0 1 9 10 B +	- 10 10 7 1 0 Sit	+ 0 3 9 10 te C +
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225		10 10 10 10 10 10 10 10	e /	- 10 10 8 2 0 Site - 10 10 9	+ 0 2 8 10 • A + 0 0 1	- 10 9 1 0 0 - - 10 10 9 9)	+ 0 1 9 10 B + 0 0 1	- 10 10 7 1 0 Sit 10 10 10 9	+ 0 3 9 10 te C + 0 0 1
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375		10 10 10 10 10 10 10 10 10	e / / / / / / / / / / / / / / / / / / /	- 10 10 8 2 0 Site - 10 10 9 1	+ 0 2 8 10 • A + 0 0 1 9	- 10 9 1 0 0 - - 10 10 9 10 9 11)	+ 0 1 9 10 B + 0 0 1 9	- 10 10 7 1 0 Sit - 10 10 10 9 1	+ 0 0 3 9 10 e C + 0 0 0 1 9
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375 450		10 10 10 10 10 10 10 10	e / / / / / / / / / / / / / / / / / / /	- 10 10 8 2 0 Site - 10 10 9	+ 0 2 8 10 • A + 0 0 1	- 10 9 1 0 0 - - 10 10 9 9)	+ 0 1 9 10 B + 0 0 1	- 10 10 7 1 0 Sit 10 10 10 9	+ 0 3 9 10 te C + 0 0 1
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375 450 MORPHINE (MOP/OPI 200)		10 10 10 10 10 10 10 10 10 10		- 10 8 2 0 Site - 10 10 9 1 0	+ 0 2 8 10 • • • • • • • • • • • • • • • • • •	- 10 10 9 1 0 0 5 - 10 10 10 9 9 1 1 0)) Site	+ 0 1 9 10 B + 0 0 1 9 9 10	- 10 10 7 1 0 Sit - 10 10 9 9 1 0	+ 0 3 9 10 te C + 0 0 1 9 10
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375 450		10 10 10 10 10 10 10 10 10		- 10 10 8 2 0 Site - 10 10 9 1	+ 0 2 8 10 • • • • • • • • • • • • • • • • • •	- 10 10 9 1 0 0 5 - 10 10 10 9 9 1 1 0)	+ 0 1 9 10 B + 0 0 1 9 9 10	- 10 10 7 1 0 Sit - 10 10 9 9 1 0	+ 0 0 3 9 10 e C + 0 0 0 1 9
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375 450 MORPHINE (MOP/OPI 200) Morphine		100 100 100 100 100 100 100 100 100 100		- 10 10 8 2 0 Site - 10 10 9 1 0 Site	+ 0 2 8 10 • A + 0 0 1 9 10 •	- 10 10 9 1 0 0 5 - 10 10 10 9 9 1 1 0)) Site	+ 0 1 9 10 B + 0 0 1 9 10 B	- 10 10 7 1 0 Sitt - 10 10 9 9 1 0 Sitt 0	+ 0 3 9 10 te C + 0 0 1 9 10
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375 450 MORPHINE (MOP/OPI 200) Morphine conc. (ng/mL)		100 100 100 100 100 100 100 100 100 100		- 10 10 8 2 0 Sitte - 10 10 9 1 0 Sitte -	+ 0 2 8 10 2 8 10 0 1 9 10 0 4 4 +	- 10 9 1 0 0 0 5 - 10 10 9 9 1 1 0 0)) Site	+ 0 1 9 10 B + 0 0 1 9 9 10 B +	- 10 10 7 1 0 Sitt - 10 10 10 9 9 1 0 Sitt - - - - - - - - - - - - -	+ 0 3 9 10 te C + 0 0 1 9 10 te C + + 0 0 0 1 1 9 10
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375 450 MORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0		10 10 10 10 10 10 10 10 10 10 10 10 10 1		- 10 10 8 2 0 Site - 10 10 9 1 0 0 Site - 10	+ + 0 0 2 8 10 2 8 10 0 0 1 1 9 0 10 0 0 4 + 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0)) Site	+ 0 0 1 9 10 8 + 0 0 1 9 10 10 8 + 0 0	- 10 10 7 1 0 Sitt - 10 10 9 1 0 Sitt - 10 10 10 10 - 10 10 - - 10 - - - - - - - - - - - - -	+ 0 3 9 10 e C + 0 0 10 e C + 10 e C + 0 0 0 10
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375 450 MORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0 100		100 100 100 100 100 100 100 100 100 100		- 10 10 8 2 0 Site - 10 10 0 Site - 10 10 10	+ + 0 0 2 8 10 0 0 1 1 9 0 0 1 0 0 0 0 0 0 0 0 0 0	- 10 10 9 1 0 0 - 10 10 10 9 1 10 - - 10 10 9 - - 10 10 10 10 - - - 10 10 - - - - - - - - - - - - -)) Site	+ 0 1 9 10 B + 0 0 1 9 10 10 B + 0 0	- 10 10 7 1 0 Sit - 10 10 9 1 0 Sit - 10 10 10 9 1 0 Sit 10 10 10 - - - - - - - - - - - - -	+ 0 0 3 9 10 te C + 0 0 10 10 te C + 10 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0
225 375 450 Morphine conc. (ng/mL) 0 150 225 375 450 IORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0 100 150		10 10 10 10 10 10 10 10 10 10 10 10 10 1		- 10 10 8 2 0 5 10 10 9 1 0 0 5 10 0 0 5 11 0 0 7	++ 0 0 2 8 8 10)) Site	+ 0 0 1 9 10 B + 0 0 1 9 9 10 B + 0 0 1 0 1	- 10 10 7 1 0 5 it - 10 10 9 1 0 5 it - 10 10 9 5 it - 10 10 9 5 it - - - - - - - - - - - - -	+ 0 0 3 9 10 te C + 0 0 1 1 9 10 te C + 10 te C + 0 10 te C 10 te C 10 t 10 t 10 t 10 t 10 t 10 t 10 t 10
225 375 450 MORPHINE (MOP/OPI 300) 0 150 225 375 450 MORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0 100 150 250 300		10 10 10 10 10 10 10 10 10 10 10 10 10 1		- 10 10 8 2 0 Site - 10 10 9 1 0 Site - 10 10 7 1 0 0	++ 0 2 8 10)) Site	+ 0 1 9 10 + 0 0 1 9 9 10 8 + 0 0 1 8 1 8 10	- 10 10 7 1 0 - 10 10 9 1 0 - 10 10 9 1 0 - - 10 10 9 1 0 - - - - - - - - - - - - -	+ 0 3 3 9 10 + 0 0 1 1 9 9 10 -
225 375 450 MoRPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375 450 MORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0 100 150 250 300 MORPHINE (MOP/OPI 100) Morphine		100 100 100 100 100 100 100 100 100 100		- 10 10 8 2 0 Sitte - 10 10 9 1 0 Sitte - 10 10 7 1 10 7 1	++000 2288 1000 248 1000 1000 26A +0000 339 1000 3000 10000 300000000000000)) Site	+ 0 1 9 10 + 0 0 1 9 10 8 + 0 0 1 10 8 10 8	- 10 10 7 1 0 - 10 10 9 1 0 - 10 10 9 1 0 - - 10 10 9 1 0 - - - - - - - - - - - - -	+ 0 3 9 10 e C + 0 10 10 e C + 0 10 e C + 9 10 0 10 e C 1 9 9 10 0 0 10 e C + 9 9 10 0 0 0 10 0 0 10 0 0 10 0 10 10 10 10
225 375 450 MORPHINE (MOP/OPI 300) Morphine conc. (ng/mL) 0 150 225 375 450 MORPHINE (MOP/OPI 200) Morphine conc. (ng/mL) 0 150 250 300 MORPHINE (MOP/OPI 100)		10 10 10 10 10 10 10 10 10 10 10 10 10 1		- 10 10 8 2 0 Site - 10 10 9 1 0 Site - 10 10 7 1 0 0	++ 0 2 8 10)) Site	+ 0 1 9 10 + 0 0 1 9 9 10 8 + 0 0 1 8 1 8 10	- 10 10 7 1 0 - 10 10 9 1 0 - 10 10 9 1 0 - - 10 10 9 1 0 - - - - - - - - - - - - -	+ 0 3 3 9 10 + 0 0 1 1 9 9 10 -

50	10	10	0	10	0	10	0
75	10	9	1	9	1	9	1
125	10	1	9	1	9	1	9
150 METHAQUALONE (MQL 300)	10	0	10	0	10	0	10
Methagualone	n per	Site	Α	Sit	e B	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	9	1	9	1	9	1
375	10	1	9	1	9	1	9
450	10	0	10	0	10	0	10
MORPHINE/OPIATE (OPI 2,000)	r	Site		Cit	e B	Site	
Morphine conc. (ng/mL)	n per site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
1,000	10	10	0	10	0	10	0
1,500	10	9	1	9	1	9	1
2,500	10	1	9	1	9	1	9
3,000	10	0	10	0	10	0	10
MORPHINE/OPIATE (OPI 1,000)							
Morphine	n per	Site		Sit	e B	Site	
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500 750	10 10	10 8	0	10 9	0	10 9	0
1,250	10	0	9	2	8	9	9
1,500	10	0	10	0	10	0	10
MEPERIDINE (MPRD100)							
Normeperidine	n per	Site	eΑ	Sit	e B	Site	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50 75	10 10	10 8	0	10 9	0	10 9	0
125	10	2	8	2	8	1	9
150	10	0	10	0	10	0	10
PHENCYCLIDINE (PCP 50)							
Phencyclidine	n per	Site	eΑ	Sit	e B	Sit	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
25	10	10	0	10	0	10	0
37.5	10	8	2	9	1	9	1
37.5 62.5	10 10	8 1	2 9	9 1	1 9	9 1	1 9
37.5 62.5 75	10	8	2	9	1	9	1
37.5 62.5 75 PHENCYCLIDINE (PCP 25)	10 10 10	8 1 0	2 9 10	9 1 0	1 9 10	9 1 0	1 9 10
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine	10 10 10 n per	8 1	2 9 10 e A	9 1 0	1 9 10 e B	9 1 0	1 9 10 e C
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL)	10 10 10 n per site	8 1 0 Site	2 9 10 e A +	9 1 0 Site	1 9 10 e B +	9 1 0 Site	1 9 10 e C +
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0	10 10 10 n per site 10	8 1 0 Site - 10	2 9 10 e A + 0	9 1 0 Site - 10	1 9 10 e B + 0	9 1 0 Site - 10	1 9 10 e C + 0
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL)	10 10 10 n per site	8 1 0 Site	2 9 10 e A +	9 1 0 Site	1 9 10 e B +	9 1 0 Site	1 9 10 e C +
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5	10 10 10 n per site 10 10	8 1 0 Site - 10 10	2 9 10 • A + 0 0	9 1 0 Situ - 10 10	1 9 10 e B + 0 0	9 1 0 Site - 10 10	1 9 10 e C + 0 0
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75	10 10 10 n per site 10 10 10	8 1 0 Site - 10 10 8	2 9 10 e A + 0 0 2	9 1 0 Situ - 10 10 9	1 9 10 e B + 0 0 1	9 1 0 Situ - 10 10 9	1 9 10 e C + 0 0 1
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5	10 10 10 10 10 10 10 10 10	8 1 0 Sitte - 10 10 8 1 0	2 9 10 → A + 0 0 2 9 9 10	9 1 0 Site - 10 10 9 1 0	1 9 10 • B + 0 0 1 9 10	9 1 0 Site - 10 10 9 1 0	1 9 10 e C + 0 0 1 9 10
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene	10 10 10 10 10 10 10 10 10 10 10 10	8 1 0 Site - 10 10 8 1	2 9 10 • A + 0 0 2 9 10 • A	9 1 0 Site - 10 10 9 1 0	1 9 10 e B + 0 1 9 10 e B	9 1 0 Sitt 10 10 9 1 0 Sitt	1 9 10 e C + 0 0 1 9 10 e C
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL)	10 10 10 10 10 10 10 10 10 10 10	8 1 0 - 10 10 8 1 0 Site	2 9 10 • A + 0 0 2 9 10 • A + • +	9 1 0 - 10 10 9 1 0 Situ	1 9 10 • B + 0 0 1 9 10 • B +	9 1 0 5itu - 10 10 9 1 0 5itu -	1 9 10 e C + 0 0 1 9 10 e C +
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 0	10 10 10 10 10 10 10 10 10 10 10 10 10	8 1 0 - 10 10 8 1 0 Sitte - 10	2 9 10 • A + 0 0 2 9 10 • A + 0 • A + 0	9 1 0 - 10 10 9 1 0 Site - 10	1 9 10 e B + 0 0 1 9 10 2 9 10 e B + 0	9 1 0 3 10 10 9 1 0 5 3 10 - 10	1 9 10 e C + 0 0 1 9 10 e C + 0
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150	10 10 10 10 10 10 10 10 10 10 10 10 10 1	8 1 0 - 10 10 8 1 0 Sitte - 10 10	2 9 10 • A + 0 0 2 9 10 • A + 0 0 0	9 1 0 - 10 10 9 1 0 - - 10 10 10	1 9 10 e B + 0 0 1 9 10 e B + 0 0	9 1 0 - 10 10 9 1 0 Situ - 10 10	1 9 10 e C + 0 0 1 9 10 e C + 0 0
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PX) Propoxyphene conc. (ng/mL) 0 150 225	10 10 10 10 10 10 10 10 10 10 10 10 10 1	8 1 0 5 10 10 8 1 0 5 5 10 10 8 8	2 9 10 • A + 0 0 2 9 10 • A + 0 0 2	9 1 0 - 10 10 9 1 0 - - - 10 10 9 9	1 9 10 e B + 0 1 9 10 e B + 0 0 1	9 1 0 - 10 10 9 1 0 Situ - 10 10 9 9	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375	10 10 10 10 10 10 10 10 10 10 10 10 10 1	8 1 0 - 10 10 8 1 0 Site - 10 10 8 1	2 9 10 • A • + 0 0 2 9 10 • A + 0 0 2 9 9 9 9 9	9 1 0 - 10 10 9 1 0 Site - 10 10 9 1	1 9 10 • B + 0 0 1 9 10 • B + 0 0 1 9 9	9 1 0 - 10 10 9 1 0 Site - 10 10 9 1	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 9
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450	10 10 10 10 10 10 10 10 10 10 10 10 10 1	8 1 0 5 10 10 8 1 0 5 5 10 10 8 8	2 9 10 • A + 0 0 2 9 10 • A + 0 0 2	9 1 0 - 10 10 9 1 0 - - - 10 10 9 9	1 9 10 e B + 0 1 9 10 e B + 0 0 1	9 1 0 - 10 10 9 1 0 Situ - 10 10 9 9	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450	10 10 10 10 10 10 10 10 10 10	8 1 0 - 10 10 8 1 0 Site - 10 10 8 1	2 9 10 • A • + 0 2 9 10 • A • + 0 0 2 9 10	9 1 0 - 10 9 1 0 5 itt - 10 10 10 9 1 0 0	1 9 10 • B + 0 0 1 9 10 • B + 0 0 1 9 9	9 1 0 Situ - 10 10 9 1 0 Situ - 10 10 9 1 0 9 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 9
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10	10 10 10 10 10 10 10 10 10 10 10 10 10 1	8 1 0 10 10 8 8 1 0 Site - 10 10 10 8 8 1 0	2 9 10 • A • + 0 2 9 10 • A • + 0 0 2 9 10	9 1 0 - 10 9 1 0 5 itt - 10 10 10 9 1 0 0	1 9 10 + 0 1 9 10 0 8 8 + 0 0 1 9 10	9 1 0 Situ - 10 10 9 1 0 Situ - 10 10 9 1 0 9 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 10
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Nortriptyline	10 10 10 10 10 10 10 10 10 10	8 1 0 Site - - 10 10 8 1 0 Site - 10 10 10 8 1 0 0 Site	2 9 10 + 0 0 2 9 10 2 9 10 0 2 9 10 0 2 9 10 0 0 2 9 9	9 1 0 5itt - 10 10 9 9 1 0 5itt - 10 10 10 9 9 5itt 5itt - 5it - 5itt - 5itt - 5itt - 5itt - 5itt - 5itt - 5itt - 5itt - 5itt - 5itt - 5itt - 5 - 5itt - 5itt - 5 - 5itt - 5itt - 5i - 5 - 5 - 5 - 5 - 5 - 5 - 5 - 5 -	1 9 10 e B + 0 1 9 10 e B + 0 0 1 0 1 9 10 e B e B e B e B e B e B e B e B e B e B	9 1 0 5itt - 10 10 9 9 1 0 5itt - 10 10 10 9 9 5itt 5itt 5itt 5itt - 9 5itt 5itt 5itt 5itt 5itt 5itt 5itt 5i	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 0 10 e C e C
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Notrriptyline conc. (ng/mL)	10 10 10 10 10 10 10 10 10 10	8 1 0 Sitte - 10 10 8 1 0 Sitte - 10 0 Sitte - - - - - - - - - - - - -	2 9 10 8 A + 0 0 2 9 10 8 A + 0 0 2 9 10 0 2 9 10 0 2 9 10	9 1 0 10 10 9 1 0 0 5 itt 10 10 9 1 0 0 5 itt 10 0 0 5 itt 10 0 0 5 5 itt 10 0 0 5 10 0 0 10 0 0 10 0 0 10 0 0 0	1 9 10 8 8 4 7 0 0 1 9 10 8 8 4 9 10 1 9 10 9 10 9 10 9 10 9 10 9 10	9 1 0 10 10 9 1 0 5 itt - 10 10 9 1 0 5 itt - 5 5 itt - 5 5 5 5 10 - 10 - 10 - 10 - 10 - 10 -	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 1 9 10 e C + + 0 0 1 1 9 10 -
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Nortriptyline conc. (ng/mL) 0 500 750	10 10 10 10 10 10 10 10 10 10	8 1 0 10 10 8 1 10 10 8 5 itte - 10 10 0 5 itte - 10 10 9 9	2 9 10 9 4 4 + 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 0 2 10 0 0 10 0 1	9 1 0 5itt - 10 10 9 1 0 5itt - 0 0 5itt - 10 10 0 0 5 10 0 0 0 10 0 0 8	1 9 10 9 8 4 9 10 1 9 10 0 1 9 10 0 1 9 9 10 0 1 9 9 10 0 2	9 1 0 10 10 9 1 10 10 10 10 9 1 10 0 5 itt - 0 0 5 itt 0 8	1 9 10 e C + 0 0 10 9 10 0 10 0 1 9 10 0 0 1 9 10 0 0 2
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Nortriptyline conc. (ng/mL) 0 500 750 1,250	10 10 10 10 10 10 10 10 10 10	8 1 0 Sitte - - 10 8 1 0 0 Sitte - - 10 10 0 8 8 1 0 0 Sitte - - 10 0 9 9 1	2 9 10 0 2 9 9 10 0 2 9 9 10 0 2 9 9 10 0 2 9 9 10 0 2 9 10 0 0 2 9 10 0 10 10 10 10 10 10 10 10 10 10 10 1	9 1 0 5itb - 10 9 1 0 0 5itb - 10 10 9 1 0 0 5itb - 10 0 0 8 5itb - 10 10 0 8 8 1	1 9 0 10 9 10 9 10 0 0 1 9 10 0 1 9 10 0 0 1 9 10 0 0 2 9	9 1 0 5itb - 10 9 1 0 5itb - 10 10 9 1 0 0 5itb - 10 0 0 5itb - 10 0 10 0 8 1 10 0 10 0 10 0 10 0 10	1 9 10 e C + 0 0 1 9 10 e C + 0 0 0 1 9 10 e C + 0 0 0 1 9 10 e C 2 9
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Nortriptyline conc. (ng/mL) 0 500 750 1,250 1,500	10 10 10 10 10 10 10 10 10 10	8 1 0 10 10 8 1 10 10 8 5 itte - 10 10 0 5 itte - 10 10 9 9	2 9 10 9 4 4 + 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 2 9 10 0 0 2 10 0 0 10 0 1	9 1 0 5itt - 10 10 9 1 0 5itt - 0 0 5itt - 10 10 0 0 5 10 0 0 0 10 0 0 8	1 9 10 9 8 4 9 10 10 9 10 10 10 9 10 10 10 9 9 10 0 1 9 9 2	9 1 0 10 10 9 1 10 10 10 10 9 1 10 0 5 itt - 0 0 5 itt 0 8	1 9 10 e C + 0 0 10 9 10 0 10 0 1 9 10 0 0 1 9 10 0 0 2
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Notriptyline conc. (ng/mL) 0 500 750 1,250 1,500 TRICYCLIC ANTIDEPRESSANTS (TCA50	10 10 10 10 10 10 10 10 10 10	8 1 0 Sitté - - 10 8 1 0 Sitté - 10 8 1 0 Sitté - - - - - - - - - - - - -	2 9 10 2 9 10 2 9 9 10 2 9 10 2 9 10 2 9 10 2 9 10 10 2 9 10 10 10 10 10 10 10 10 10 10 10 10 10	9 1 0 Sitt - 10 9 1 0 Sitt - 10 9 1 0 Sitt - 10 9 1 0 Sitt - - - - - - - - - - - - -	1 9 10 9 8 8 4 9 0 0 1 9 10 9 10 9 10 9 10 9 10 0 2 9 9 10	9 1 0 Sitt - 10 9 1 0 Sitt - 10 9 1 0 Sitt - 10 9 1 0 5 10 9 1 0 5 10 9 1 0 9 1 0 9 1 0 9 1 0 9 1 0 9 1 0 9 1 0 0 9 1 0 0 9 1 0 0 9 1 0 0 9 1 0 0 9 1 0 0 9 1 0 0 9 1 0 0 9 1 0 0 9 1 0 0 9 1 0 0 9 1 0 0 0 0 0 0 0 0 0 0 0 0 0	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 10 e C 9 10 0 1 9 10
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Nortriptyline conc. (ng/mL) 0 500 750 1,250 1,500 TRICYCLIC ANTIDEPRESSANTS (TCA50 Notrriptyline	10 10 10 10 10 10 10 10 10 10	8 1 0 Sitte - - 10 8 1 0 0 Sitte - - 10 10 0 8 8 1 0 0 Sitte - - 10 0 9 9 1	2 9 10 0 2 9 9 0 0 2 9 9 10 0 2 9 9 10 0 2 9 9 10 0 2 9 9 10 0 2 9 9 10	9 1 0 10 10 9 1 10 9 1 10 9 1 10 9 1 10 0 10 10 9 1 10 0 11 0 0 5 11 0 0 5 11 0 10 9 9 1 10 0 10 10 10 10 10 10 10 10 10 10 10	1 9 10 9 10 9 10 9 10 0 1 9 10 0 1 9 10 0 1 9 10 0 2 9 10 0 2 9 10	9 1 0 sitt - 10 9 1 0 10 9 1 0 10 9 1 0 10 9 1 0 10 9 10 0 10 8 1 0 Sitt	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 9 10 e C + 0 0 2 9 10 e C + 0 0 0 1 1 9 9 10 0 0 0 1 1 9 10 0 0 0 0
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Notrriptyline conc. (ng/mL) 0 1,250 1,250 1,250 1,250 1,250 1,250 Nortriptyline conc. (ng/mL)	10 10 10 10 10 10 10 10 10 10	8 1 0 5itt 10 10 8 1 0 5itt 10 10 10 8 5itt 10 10 9 9 1 0 5 5 1 0	2 9 10 2 9 10 2 9 10 2 9 10 0 2 9 10 0 0 2 9 10 0 0 2 9 10 0 0 2 9 10 0 0 2 9 9 10 0 0 2 9 9 10 0 0 2 9 9 10 0 0 0 10 10 10 10 10 10 10 10 10 10	9 1 0 Sitt - - 0 10 9 10 10 9 10 10 9 10 5 10 0 Sitt - - 10 0 Sitt - - - - - - - - - - - - -	1 9 9 8 8 4 10 0 1 10 9 9 10 0 10 10 9 9 10 0 0 10 9 9 10 0 0 10 9 9 10 0 10 10 10 10 10 10 10 10 10 10 10 1	9 1 0 Sitt - - 0 10 10 9 1 0 Sitt - 10 10 8 Sitt - - 10 0 Sitt - - - - - - - - - - - - -	1 9 10 e C + 0 10 9 10 e C + 0 0 11 9 10 0 0 11 9 0 0 10 0 0 1 1 9 9 10 0 0 10 0 10 0 10 10 10 10 10 10 10 1
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Nortriptyline conc. (ng/mL) 0 500 750 1,500 TRICYCLIC ANTIDEPRESSANTS (TCA50 Nortriptyline conc. (ng/mL) 0 500 750 1,500 1,500 TRICYCLIC ANTIDEPRESSANTS (TCA50 Nortriptyline conc. (ng/mL) 0	10 10 10 10 10 10 10 10 10 10	8 1 0 Sitti - - 10 8 1 0 Sitti - 10 10 10 8 1 0 Sitti - - 10 Sitti - - - - - - - - - - - - -	2 9 10 2 9 10 2 9 10 2 9 10 0 2 9 10 0 0 2 9 10 0 0 2 9 10 0 0 0 2 9 10 0 0 0 2 9 10 0 0 0 0 0 2 9 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	9 1 0 5itt - 10 9 1 0 5itt - 10 10 10 9 1 0 5itt - 10 10 10 5 5 10 0 5 10 10	1 9 9 10 1 9 10 1 9 10 10 10 9 10 10 9 9 10 0 0 1 10 0 0 2 9 9 10 0 0 1 10 0 10 10 10 10 10 10 10 10 1	9 1 0 Sitt - 10 9 1 0 Sitt - 10 0 Sitt - 10 0 Sitt - 10 10 9 1 0 Sitt - - - - - - - - - - - - -	1 9 10 e C + 0 1 9 10 e C + 0 0 1 1 9 9 10 0 0 2 9 9 10 0 0 2 9 9 10 0 0 1 9 10 0 0 1 9 10 0 0 10 10 10 10 10 10 10 10 10 10 10
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Nortriptyline conc. (ng/mL) 0 500 750 1.500 TRICYCLIC ANTIDEPRESSANTS (TCA50 Nortriptyline conc. (ng/mL) 0 500 750 1.500 TRICYCLIC ANTIDEPRESSANTS (TCA50 Nortriptyline conc. (ng/mL) 0 250	10 10 10 10 10 10 10 10 10 10	8 1 0 Sitté 10 10 8 1 0 Sitté 10 10 8 1 0 Sitté 10 10 8 1 0 Sitté 10 10 8 1 0 Sitté 10 10 10 10 10 10 10 10 10 10	2 9 10 0 2 9 10 2 9 10 0 2 9 10 0 2 9 10 0 0 2 9 10 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0	9 1 0 Sitt - 10 9 1 0 - 10 0 - 5 - 10 0 - 5 - - - - - - - - - - - - -	1 9 9 10 9 8 8 + 0 0 1 9 10 10 9 10 10 9 10 0 0 2 9 9 10 0 0 2 9 9 10 0 0 0 0 0 0 0 1 9 10	9 1 0 Sitt - 10 9 1 0 - 10 9 1 0 - 5 - 10 9 9 1 0 - 5 - - - - - - - - - - - - -	1 9 10 e C + 0 0 1 9 10 e C + 0 0 1 1 9 10 e C + 0 0 0 1 1 9 10 e C + 0 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 1 1 9 10 0 0 0
37.5 62.5 75 PHENCYCLIDINE (PCP 25) Phencyclidine conc. (ng/mL) 0 12.5 18.75 31.25 37.5 PROPOXYPHENE (PPX) Propoxyphene conc. (ng/mL) 0 150 225 375 450 TRICYCLIC ANTIDEPRESSANTS (TCA10 Nortriptyline conc. (ng/mL) 0 500 750 1,500 TRICYCLIC ANTIDEPRESSANTS (TCA50 Nortriptyline conc. (ng/mL) 0 500 750 1,500 1,500 TRICYCLIC ANTIDEPRESSANTS (TCA50 Nortriptyline conc. (ng/mL) 0	10 10 10 10 10 10 10 10 10 10	8 1 0 Sitti - - 10 8 1 0 Sitti - 10 10 10 8 1 0 Sitti - - 10 Sitti - - - - - - - - - - - - -	2 9 10 2 9 10 2 9 10 2 9 10 0 2 9 10 0 0 2 9 10 0 0 2 9 10 0 0 0 2 9 10 0 0 0 2 9 10 0 0 0 0 0 2 9 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	9 1 0 5itt - 10 9 1 0 5itt - 10 10 10 9 1 0 5itt - 10 10 10 5 5 10 0 5 10 10	1 9 9 10 1 9 10 1 9 10 10 10 9 10 10 9 9 10 0 0 1 10 0 0 2 9 9 10 0 0 1 10 0 0 1 10 0 0 1 1 9 9 10 10 10 10 10 10 10 10 10 10 10 10 10	9 1 0 Sitt - 10 9 1 0 Sitt - 10 0 Sitt - 10 0 Sitt - 10 10 9 1 0 Sitt - - - - - - - - - - - - -	1 9 10 e C + 0 1 9 10 e C + 0 0 1 1 9 9 10 0 0 2 9 9 10 0 0 2 9 9 10 0 0 1 9 10 0 0 1 9 10 0 0 10 10 10 10 10 10 10 10 10 10 10

RICYCLIC ANTIDEPRESSANTS (TCA3) Nortriptyline	n per	Sit	e A	Sit	eВ	Sit	еC
conc. (ng/mL)	site	-	+		+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	8	2	9	1	8	2
375	10	2	8	1	9	1	9
450	10	0	10	0	10	0	1(
RAMADOL (TML 100)	1	C:4	e A	0.14	eВ	Cit	еC
Tramadol conc. (ng/mL)	n per site	-	е А +	-	е Б +	- 510	9 C
0	10	10	+ 0	10		10	
50	10	10	0	10	0	10	0
75	10	7	3	9	1	8	2
125	10	2	8	9 1	9	1	9
150	10	0	10	0	10	0	10
RAMADOL (TML 200)	10	Ŭ	10	v	10	Ū	
	n per	Sit	еA	Sit	eВ	Sit	еC
Tramadol conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	C
100	10	10	0	10	0	10	C
150	10	9	1	9	1	8	2
250	10	1	9	9	9	2	2
300	10	0	10	0	10	0	1
RAMADOL (TML 300)	10	5	10	0	10	5	
	n per	Sit	e A	Sit	e B	Sit	еC
Tramadol conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	C
150	10	10	0	10	0	10	0
225	10	9	1	9	1	8	2
375	10	1	9	1	9	2	8
450	10	0	10	0	10	0	1
ETAMINE (KET1, 000)		Ţ				Ţ	<u> </u>
	n per	Sit	еA	Sit	eВ	Sit	еC
Ketamine conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	C
500	10	10	0	10	0	10	C
750	10	9	1	8	2	9	1
1,250	10	1	9	1	9	2	8
1,500	10	0	10	0	10	0	1
ETAMINE (KET500)							
Ketamine conc. (ng/mL)	n per	Sit	e A	Sit	eВ	Sit	еC
	site	-	+	-	+	-	+
0	10	10	0	10	0	10	C
250	10	10	0	10	0	10	C
375	10	9	1	9	1	8	2
625	10	1	9	1	9	2	8
750	10	0	10	0	10	0	1
ETAMINE (KET300)							
	n per	Sit	e A	Sit	e B	Sit	еC
Ketamine conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	(
150	10	10	0	10	0	10	C
225	10	9	1	9	1	9	1
375	10	9	9	9	9	9	g
	-		-		-		
450 ETAMINE (KET100)	10	0	10	0	10	0	1
	n	Sit	e A	Sit	eВ	Sit	e C
Ketamine conc. (ng/mL)	n per site			- 01			
0		10	- T	10	+	10	
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	C
75	10	9	1	9	1	9	1
	10	1	9	1	9	2	8
125	-	0	10	0	10	0	1
150	10					-	ē
150		-				Sit	еC
150 xycodone (OXY300)	n per	Sit	e A	Sit	еь		+
150 xycodone (OXY300) Oxycodone conc. (ng/mL)	n per site	-	+	-	+	-	
150 xycodone (OXY300) Oxycodone conc. (ng/mL) 0	n per site 10	- 10	+ 0	- 10	+ 0	- 10	C
150 xycodone (OXY300) Oxycodone conc. (ng/mL)	n per site	-	+	- 10 10	+	- 10 10	
150 xycodone (OXY300) Oxycodone conc. (ng/mL) 0	n per site 10	- 10	+ 0	- 10	+ 0	- 10	C
150 xycodone (OXY300) Oxycodone conc. (ng/mL) 0 150	n per site 10 10	- 10 10	+ 0 0	- 10 10	+ 0 0	- 10 10	0
150 xycodone (OXY300) Oxycodone conc. (ng/mL) 0 150 225	n per site 10 10 10	- 10 10 9	+ 0 0 1	- 10 10 9	+ 0 0 1	- 10 10 9	0 1 9
150 xycodone (OXY300) Oxycodone conc. (ng/mL) 0 150 225 375 350	n per site 10 10 10 10 10	- 10 10 9 1	+ 0 0 1 9	- 10 10 9 1	+ 0 0 1 9	- 10 10 9 1	0 1 9
150 xycodone (OXY300) Oxycodone conc. (ng/mL) 0 150 225 375 350 XYCODONE (OXY100)	n per site 10 10 10 10 10	- 10 10 9 1 0	+ 0 0 1 9	- 10 10 9 1 0	+ 0 0 1 9	- 10 10 9 1 0	0 1 9
150 xycodone (OXY300) Oxycodone conc. (ng/mL) 0 150 225 375 350	n per site 10 10 10 10 10	- 10 10 9 1 0	+ 0 1 9 10	- 10 10 9 1 0	+ 0 1 9 10	- 10 10 9 1 0	0 1 9 1(
150 xycodone (OXY300) Oxycodone conc. (ng/mL) 0 150 225 375 350 XYCODONE (OXY100)	n per site 10 10 10 10 10 10 n per	- 10 10 9 1 0	+ 0 1 9 10	- 10 10 9 1 0	+ 0 1 9 10	- 10 10 9 1 0	0 1 9 1(e C +
150 xycodone (OXY300) Oxycodone conc. (ng/mL) 0 150 225 375 350 XYCODONE (OXY100) Oxycodone conc. (ng/mL)	n per site 10 10 10 10 10 10 10	- 10 10 9 1 0 Sit	+ 0 1 9 10 e A +	- 10 10 9 1 0 Sit	+ 0 1 9 10 e B +	- 10 10 9 1 0 Situ	0 0 1 9 10 e C +

125	10	1	9	1	9	1	9
150	10	0	10	0	10	0	10
COTININE (COT 300)							
Cotinine conc. (ng/mL)	n per	Sit	e A	Sit	eВ	Site	еC
	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10 9	0
225	10	9 1	1	9	1	9	1
<u> </u>	10 10	0	10	0	10	0	10
COTININE (COT 200)	10	0	10	0	10	0	10
	n per	Sit	еA	Sit	еB	Site	e C
Cotinine conc. (ng/mL)	n per site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	9	1	9	1	9	1
250	10	1	9	1	9	2	8
300	10	0	10	0	10	0	10
COTININE (COT 100)							
Cotinine conc. (ng/mL)	n per	Sit	еA	Sit	eВ	Site	е С
Cottinine conc. (fig/file)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	9	1	9	1	9	1
125	10	1	9	1	9	1	9
150	10	0	10	0	10	0	10
2-Ethylidene-1,5-dimethyl-3,3-diphenylp	1			0.14	o P	Site	
EDDP conc. (ng/mL)	n per site	Sit		SIL	e B	Site	
0		- 10	+	- 10	+	-	+
150	10 10	10 10	0	10 10	0	10 10	0
		9	1		1		1
225 375	10 10	9	9	9	8	9	9
450	10	0	10	0	10	0	10
2-Ethylidene-1,5-dimethyl-3,3-diphenylp				Ū	10	Ū	10
	n per	Sit		Sit	eВ	Site	еC
EDDP conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	9	1	9	1	9	1
125	10	1	9	1	9	1	9
150	10	0	10	0	10	0	10
FENTANYL (FYL300)							
	n per	Sit	e A	Sit	e B	Site	e C
FYL conc. (ng/mL)	n per site	Site	e A +	Sit	e B +		e C +
		Site - 10		Site - 10	1		
FYL conc. (ng/mL)	site	-	+	-	+	Site -	+
FYL conc. (ng/mL)	site 10	- 10	+	- 10	+	Site - 10	+
FYL conc. (ng/mL) 0 150	site 10 10	- 10 10	+ 0 0	- 10 10	+ 0 0	Site - 10 10	+ 0 0
FYL conc. (ng/mL) 0 150 225	site 10 10 10	- 10 10 7	+ 0 0 3	- 10 10 9	+ 0 0	Site - 10 10 9	+ 0 0 1 9
FYL conc. (ng/mL) 0 150 225 375 450	site 10 10 10 10	- 10 10 7 1 0	+ 0 3 9 10	- 10 10 9 1 0	+ 0 1 9 10	Site - 10 10 9 1 0	+ 0 1 9 10
FYL conc. (ng/mL) 0 150 225 375 450 FENTANYL (FYL100)	site 10 10 10 10 10 10	- 10 10 7 1	+ 0 3 9 10	- 10 10 9 1	+ 0 1 9 10	Site - 10 10 9 1	+ 0 1 9 10
FYL conc. (ng/mL) 0 150 225 375 450 FENTANYL (FYL100) FYL conc. (ng/mL)	site 10 10 10 10 10 10 n per site	- 10 10 7 1 0 Situ	+ 0 3 9 10 e A +	- 10 10 9 1 0 Situ	+ 0 1 9 10 e B +	Site - 10 10 9 1 0 Site -	+ 0 1 9 10 e C +
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0	site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 7 1 0 Site - 10	+ 0 3 9 10 e A + 0	- 10 9 1 0 Sitt - 10	+ 0 1 9 10 e B + 0	Site - 10 10 9 1 0 Site - 10	+ 0 1 9 10 e C +
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL 100) FYL conc. (ng/mL) 0 50	site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 7 1 0 Situ - 10 10	+ 0 3 9 10 e A + 0 0	- 10 9 1 0 Situ - 10 10	+ 0 1 9 10 e B + 0 0	Site - 10 9 1 0 Site - 10 10	+ 0 1 9 10 e C + 0 0
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 50 75	site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 7 1 0 Situ - 10 10 8	+ 0 3 9 10 e A + 0 0 2	- 10 9 1 0 Situ - 10 10 9	+ 0 1 9 10 e B + 0 0 1	Site - 10 9 1 0 Site - 10 10 9	+ 0 1 9 1(e C + 0 0
FYL conc. (ng/mL) 0 150 225 375 450 FENTANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125	site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 7 1 0 Site - 10 10 8 1	+ 0 3 9 10 e A + 0 0 2 9	- 10 9 1 0 Sitt - 10 10 9 2	+ 0 1 9 10 • B + 0 0 1 8	Site - 10 9 1 0 5 5 5 6 - 10 10 9 1	+ 0 1 9 10 + 0 0 0 1 9
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL 100) FYL conc. (ng/mL) 0 50 75 125 150	site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 7 1 0 Situ - 10 10 8	+ 0 3 9 10 e A + 0 0 2	- 10 9 1 0 Situ - 10 10 9	+ 0 1 9 10 e B + 0 0 1	Site - 10 9 1 0 Site - 10 10 9	+ 0 1 9 10 + 0 0 0 1 9
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL 100) FYL conc. (ng/mL) 0 50 75 125 150	site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 7 1 0 Site - 10 10 10 8 8 1 0	+ 0 3 9 10 e A + 0 0 2 9 10	- 10 9 1 0 Site - 10 10 9 9 2 0	+ 0 1 9 10 e B + 0 0 1 1 8 10	Site - 10 10 9 1 0 Site - 10 10 9 9 1 0	+ 0 1 9 1(e C + 0 0 1 9 1(
FYL conc. (ng/mL) 0 150 225 375 450 FENTANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 150	site 10	- 10 10 7 1 0 Site - 10 10 10 8 8 1 0	+ 0 3 9 10 e A + 0 2 9 10 2 9 10	- 10 9 1 0	+ 0 1 9 10 e B + 0 0 1 8 10 e B	Site - 10 10 9 1 0 Site - 10 10 9 1 0 Site	+ 0 0 9 9 10 e C - + 0 0 0 0 1 1 9 9 9 10 e C
FYL conc. (ng/mL) 0 150 225 375 450 FENTANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 150 FENTANYL (FYL20) FYL conc. (ng/mL)	site 10	- 10 10 7 1 0 Site - 10 10 10 8 1 0 Site - - - - - - - - - - - - -	+ 0 3 9 10 • A + 0 0 2 9 10 • A +	- 10 9 1 0 Site - 10 10 10 9 2 0 Site -	+ 0 1 9 10 • B + 0 0 1 8 10 • B +	Site - 10 10 9 1 0 Site - 10 10 9 1 0 Site - Site - - - - - - - - - - - - -	+ 0 0 1 9 10 0 0 0 0 0 0 0 0 1 1 9 9 10 0 0 0
FYL conc. (ng/mL) 0 150 225 375 450 FENTANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 150 FENTANYL (FYL20) FYL conc. (ng/mL) 0 0 0 0 0 0 0 0 0	site 10	- 10 10 7 1 0 Situ - 10 10 8 1 0 Situ - 10 10 8 1 0 Situ - 10 10 - 10 - 10 - 10 - 10 - - - - - - - - - - - - -	+ 0 3 9 10 • A + 0 0 2 9 10 • A + 0 0 • A + 0	- 10 9 1 0 5 it 9 9 2 0 0 5 it 10	+ 0 1 9 10 • B + 0 0 10 • B • B • B • B • 0 0 • 0 • 0 • 0 • 0 • 0 • 0 • 0 • 0 •	Site - 10 9 1 0 Site - 10 9 1 0 Site - 10 10 9 1 0 10 10 9 1 10 10 10 10 10 10 10 10 10	+ 0 0 1 9 10 0 0 0 0 0 0 0 0 0 1 1 9 9 10 0 0 0
FYL conc. (ng/mL) 0 150 225 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 75 125 150 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 0 10	site 10	- 10 10 7 1 0 Situ - 10 10 8 1 0 Situ - 10 10 8 1 0 10 10 10 10 10 10 10 10	+ 0 3 9 10 e A + 0 0 2 9 10 2 9 10 e A + 0 0 0 0	- 10 10 9 1 0 Sitt - - 0 0 Sitt - 10 10 10	+ 0 1 9 10 e B + 0 0 1 8 10 e B + 0 0 0	Site - 10 10 9 1 0 Site - 10 10 - 10 10 10 10 10 10	++ 0 0 1 9 9 10
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 150 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 15	site 10	- 10 10 7 1 0 Situ - 10 10 8 1 0 Situ - 10 10 9 9	+ 0 3 9 10 • A + 0 0 2 9 10 • A + 0 0 0 1	- 10 10 9 1 0 Site - 10 9 2 0 Site - 10 10 9 2 0 Site - - 10 10 9 9 2 0 - - - 10 9 - - - - - - - - - - - - -	+ 0 1 9 10 e B + 0 0 1 8 10 e B + 0 0 1	Site - 10 9 1 0 Site - 10 10 9 1 0 Site - 10 10 9 1 0 9 1 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 10 10 10 10 10 10 10 10 10 10	++ 0 0 1 9 9 10
FYL conc. (ng/mL)	site 10	- 10 10 7 1 0 Sitt - 10 10 8 10 - 10 - 10 9 1 1	+ 0 3 9 10 e A + 0 2 9 10 e A + 0 0 10 9 10 9 10 9	- 10 10 9 1 0 Sitt - 10 10 9 2 0 Sitt - 10 10 9 2 0 10 - 10 9 1 10 9 1 10 9 1 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 e B + 0 0 1 8 10 e B + 0 0 1 9	Sitter - 10 10 9 1 0 Sitter - - 10 10 9 1 - - - - - - - - - - - - -	++ 0 0 9 9 10 + + 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
FYL conc. (ng/mL) 0 150 225 450 FENTANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 150 FENTANYL (FYL20) FYL conc. (ng/mL) 0 10 15 25 30	site 10	- 10 10 7 1 0 Situ - 10 10 8 1 0 Situ - 10 10 9 9	+ 0 3 9 10 • A + 0 0 2 9 10 • A + 0 0 0 1	- 10 10 9 1 0 Site - 10 9 2 0 Site - 10 10 9 2 0 Site - - 10 10 9 9 2 0 - - - 10 9 - - - - - - - - - - - - -	+ 0 1 9 10 e B + 0 0 1 8 10 e B + 0 0 1	Site - 10 9 1 0 Site - 10 10 9 1 0 Site - 10 10 9 1 0 9 1 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 1 10 10 9 9 10 10 10 10 10 10 10 10 10 10	++ 0 0 9 9 10 ++ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
FYL conc. (ng/mL)	site 10	- 10 10 7 - 0 Sitt - 10 10 8 1 0 Sitt - 10 10 9 1 0 0 - - - - - - - - - - - - -	+ 0 3 9 9 10 e A + 0 0 2 9 10 e A + 0 0 0 2 9 10 0 0 10	- 10 10 9 1 0 - 10 10 9 2 0 - - 10 10 9 2 0 - - 10 10 9 1 - - - - - - - - - - - - -	+ 0 1 9 10 e B + 0 0 1 8 10 e B + 0 0 0 1 1 9 0 0 1 1 9 9 10	Sitti - 10 10 9 1 1 0 5 5 10 0 9 1 1 0 0 9 1 1 0 0 9 1 1 0 0 9 1 0 0 0 9 1 0 0 10 0 9 10 0 9 10 0 9 10 10 0 9 9 10 0 10 0 9 9 10 0 10 0 10 0 9 9 10 10 0 10 0 9 9 10 10 0 9 9 10 10 0 9 9 10 0 9 9 10 0 9 9 10 0 9 9 10 0 9 9 10 0 9 9 10 0 9 9 10 0 9 9 10 0 9 9 10 0 9 9 10 0 9 9 10 10 0 9 9 10 10 0 9 9 10 10 10 0 9 10 10 10 10 10 10 10 10 10 10 10 10 10	+ 0 0 0 9 1 0
FYL conc. (ng/mL)	site 10	- 10 10 7 1 0 Sitt - 10 10 8 10 - 10 - 10 9 1 1	+ 0 3 9 9 10 + 0 0 2 9 9 10 0 0 1 1 9 10 0 0 0 1 1 9 9 0 0 0 0	- 10 10 9 1 0 Sitt - 10 10 9 2 0 Sitt - 10 10 9 2 0 10 - 10 9 1 10 9 1 10 9 1 10 10 10 10 10 10 10 10 10	+ 0 0 1 9 9 10 0 8 8 + 0 0 1 1 8 0 0 1 1 9 9 0 0 1 1 8 8 8 8 8	Sitter - 10 10 9 1 0 Sitter - - 10 10 9 1 - - - - - - - - - - - - -	++ 0 0 9 1 0 0 1 1 9 9 9 1 0 0 0 0 1 1 1 9 9 1 0 0 0 0
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 125 50 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 15 25 30 FENT ANYL (FYL10)	site 10	- 10 10 7 1 0 Sittu - 10 10 10 8 1 0 Sittu - 10 10 10 10 10 10 10 10 10 10	+ 0 3 9 10 - - - - - - - - - - - - - - - - - -	- 10 10 9 1 - 10 10 10 9 2 0 - 10 10 9 9 1 0 - 5 itth - - - - - - - - - - - - -	+ 0 1 9 9 10 • 8 + 0 0 1 8 10 • 8 + 0 0 1 8 • 10 • 9 10 • • 9 • 10 • • • • • • • • • • • • • • • • •	Sitti - - - - - - - - - - - - -	+ 0 0 1 9 10 + 0 0 0 1 1 9 9 0 10 0 0 0 0 0 0 0 0 0 0
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 75 125 150 FYL conc. (ng/mL) 0 75 125 150 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0	site 10	- 10 10 7 1 0 Sitth - 10 10 8 1 0 Sitth - 10 10 9 1 0 Sitth - 10 10 10 10 10 10 10 10 10 10	+ 0 3 9 10 e A + 0 0 2 9 10 e A + 0 0 0 0 10 e A + + 0 0 0 2 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0	- 10 10 9 1 0 - 10 10 9 2 0 - 10 10 9 2 0 - - 10 - - - - - - - - - - - - -	+ 0 1 9 10 e B + 0 0 0 0 1 1 8 8 10 e B + 0 0 0 1 9 9 10 e B + + 0 0 0 0 0 1 10 e B + + 0 0 0 0 0 0 0 10 0 10 0 10 0 0 0 0	Sitter - - - - - - - - - - - - -	+ 0 0 9 9 10 • C + + 0 0 0 0 11 9 9 10 • C • C • C • C • C • C • C • C • C • C
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 150 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 5 7 15 15 7 15 7 15 7 15 7 15 7 15 7 15 7 15 7 15 7 15 7 15 7 15 7 15 FYL conc. (ng/mL) 0 15 7 5 30 FYL conc. (ng/mL) 7 5 30 5 7 5 5 7 1 1 7 1 1 1 5 5 5 5 5 5 5	site 10	- 10 10 7 1 0 5 itti - 10 10 10 8 1 0 Sitti - 10 10 10 10 10 10 10 10 10 10	+ 0 0 3 3 9 10 + 0 0 2 9 10 0 8 A + 0 0 0 10 8 9 10 0 8 4 + 0 0 0 0 9 10 0 8 9 9 10 0 8 9 9 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 - 10 10 10 10 9 2 0 5 itt - 10 10 9 9 2 0 5 itt - - - - - - - - - - - - -	+ 0 0 1 9 10 e B + 0 0 1 1 8 10 e B + 0 0 0 1 1 9 9 10 e B + + 0 0 0 1 9 9 10 0 10 9 9 10 0 10 9 9 10 10 10 9 9 10 10 10 10 10 10 10 10 10 10 10 10 10	Sittu - - - - - - - - - - - - -	+ 00 00 11 99 10 e C 00 00 11 99 10 00 11 99 90 10 00 11 90 00 00 11 00 00 00 00 00 00 00 00 00 00
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 150 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 75 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 75 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 75 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 75 75 75 75 75 75 75	site 10	- 10 10 7 1 0 5 itti - 10 10 10 10 10 9 1 0 5 itti - - 10 10 10 10 10 10 10 10 10 10	+ 0 3 3 9 10 e A + 0 0 2 9 10 e A + 0 0 0 0 1 0 e A + + 0 0 0 0 10 e A + + 0 0 0 10 e A + + 0 0 0 10 e A 9 9 9 9 10 0 0 9 9 9 9 10 0 0 9 9 9 9 9	- 10 10 9 1 0 - 10 10 9 2 0 - 10 10 9 2 0 - - 10 - - - - - - - - - - - - -	+ 0 0 1 9 9 10 + 0 0 1 1 8 10 0 0 0 1 1 9 9 10 0 0 0 1 1	Sittl - - - - - - - - - - - - -	++ 00 99 10 00 00 11 10 00 00 00 11 99 90 00 00 00 00 00 00 00 00 00 00 00
FYL conc. (ng/mL) 0 150 225 375 450 FENTANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 150 FENTANYL (FYL20) FYL conc. (ng/mL) 0 15 25 30 FENTANYL (FYL10) FYL conc. (ng/mL) 0 5 7.5 12.5 12.5 12.5 FYL conc. (ng/mL) 0 15 7.5 12.5 12.5 FYL conc. (ng/mL) 0 15 7.5 12.5 FYL conc. (ng/mL) 0 15 7.5 12.5 FYL conc. (ng/mL) 15 7.5 12.5 FYL conc. (ng/mL) 15 7.5 12.5 FYL conc. (ng/mL) 15 7.5 12.5 FYL conc. (ng/mL) 15 7.5 12.5 FYL conc. (ng/mL) 7.5 7	site 10	- 10 10 7 7 1 0 5 10 10 10 8 1 0 5 10 10 10 9 1 0 5 10 10 9 1 0 10 10 10 10 10 10 10 10	+ 0 3 9 10 0 A + 0 0 2 9 9 10 0 0 0 1 10 0 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 10 10 9 9 1 - 10 10 9 2 0 - - 10 10 9 9 1 - 10 10 9 9 1 - - - - - - - - - - - - -	+ 0 0 1 9 10 • B + 0 0 0 1 1 8 0 0 0 1 1 9 10 • 0 0 0 1 9 10	Sitter - - 10 10 9 1 0 - - 10 10 9 1 0 - - - - - - - - - - - - -	+ 0 0 0 1 9 9 10 0 0 0 0 1 1 9 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 75 125 150 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 55 7.5 12.5 15	site 10	- 10 10 7 1 0 5 itti - 10 10 10 10 10 9 1 0 5 itti - - 10 10 10 10 10 10 10 10 10 10	+ 0 3 3 9 10 e A + 0 0 2 9 10 e A + 0 0 0 0 1 0 e A + + 0 0 0 0 10 e A + + 0 0 0 10 e A + + 0 0 0 10 e A 9 9 9 9 10 0 0 9 9 9 9 10 0 0 9 9 9 9 9	- 10 10 9 1 0 - 10 10 9 2 0 - 10 10 9 2 0 - - 10 - - - - - - - - - - - - -	+ 0 0 1 9 9 10 + 0 0 1 1 8 10 0 0 0 1 1 9 9 10 0 0 0 1 1	Sittl - - - - - - - - - - - - -	+ 0 0 0 1 9 9 0 0 0 0 1 1 9 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 75 125 150 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 15 25 10 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 5 7.5 12.5 15	site 10	- 10 10 7 1 0 7 1 0 10 10 8 1 0 5 10 10 10 0 9 1 0 5 10 10 9 1 0 0 10 10 10 10 10 10 10 1	+ 0 0 3 9 10 0 2 2 9 10 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 0 10 0 0 10 0 0 10 0 10 0 10 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 10 10 9 1 - 10 10 9 9 2 0 Sitt - 10 10 9 9 1 0 Sitt - 10 10 9 1 0 10 9 1 1 0 10 10 10 10 10 10 10 1	+ 0 0 1 9 10 0 1 1 8 0 0 1 1 9 10 0 0 1 9 10 0 0 1 1 9 10	Sitter - - - - - - - - - - - - -	++ 0 0 1 9 0 0 0 0 0 0 0 0 0 0 0 0 0
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 50 75 125 150 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 5 75 125 15 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 15 15 15 15 15 15 15 1	site 10	- 10 10 7 7 1 0 5 10 10 10 8 1 0 5 10 10 10 9 1 0 5 10 10 9 1 0 10 10 10 10 10 10 10 10	+ 0 0 3 9 10 0 0 4 + 0 0 0 2 9 9 10 0 0 0 10 0 0 10 0 9 10 0 0 0 10 0 0 0	- 10 10 9 1 - 10 10 9 9 2 0 Sitt - 10 10 9 9 1 0 Sitt - 10 10 9 1 0 10 9 1 1 0 10 10 10 10 10 10 10 1	+ 0 0 1 9 10 • 8 - - - - - - - - - - - - - - - - - -	Sitted 	+ 0 0 9 9 10 - - - - - - - - - - - - -
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL 100) FYL conc. (ng/mL) 0 75 125 125 15 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 K2 conc. (ng/mL)	site 10	- 10 10 7 7 1 0 5 10 10 10 10 10 10 10 10 10 10	+ 0 3 9 10 • A + 0 0 2 9 9 10 • A + 0 0 0 1 10 • A + 0 0 0 10 • • A + 0 0 0 2 9 9 10 • • • • • • • • • • • • • • • • • •	- 10 10 9 9 1 - 10 10 9 2 0 Sitt - 10 10 9 1 0 - 10 10 9 1 - 10 - - - - - - - - - - - - -	+ 0 0 1 9 10 • B + 0 0 1 8 8 10 • B + 0 0 0 1 1 9 10 • 0 0 1 1 9 10 • • 8 8 10 • • • • • • • • • • • • • • • • • •	Sittu - - 10 10 9 1 0 - 10 10 0 - - 10 0 - - 10 0 - - 10 - - - - - - - - - - - - -	+ 0 0 0 1 9 9 0 0 0 1 1 9 0 0 0 0 1 1 9 0 0 0 0 1 1 9 9 10 0 0 0 0 1 1 9 9 10 0 0 0 0 0 0 0 0 0 0 0 0 0
FYL conc. (ng/mL) 0 150 225 375 450 FENT ANYL (FYL100) FYL conc. (ng/mL) 0 75 125 150 FENT ANYL (FYL20) FYL conc. (ng/mL) 0 10 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 15 25 10 15 25 30 FENT ANYL (FYL10) FYL conc. (ng/mL) 0 5 7.5 12.5 15	site 10	- 10 10 7 1 0 7 1 0 10 10 8 1 0 5 10 10 10 0 9 1 0 5 10 10 9 1 0 0 10 10 10 10 10 10 10 1	+ 0 0 3 9 10 0 0 4 + 0 0 0 2 9 9 10 0 0 0 10 0 0 10 0 9 10 0 0 0 10 0 0 0	- 10 10 9 1 - 10 10 9 9 2 0 Sitt - 10 10 9 9 1 0 Sitt - 10 10 9 1 0 10 9 1 1 0 10 10 10 10 10 10 10 1	+ 0 0 1 9 10 • 8 - - - - - - - - - - - - - - - - - -	Sitted 	+ 0 0 9 9 10 - - - - - - - - - - - - -

37.5	10	8	2	8	2	9	1
62.5 75	10	1	9 10	2	8 10	2	8 10
K2 30					-		
K2 conc. (ng/mL)	n per site	Site		Site		Site	
0	10	- 10	+	- 10	+	- 10	+
15	10	10	0	10	0	10	0
22.5	10	8	2	9	1	9	1
37.5	10	1	9	1	9	1	9
45 K2 25	10	0	10	0	10	0	10
	n per	Site	eΑ	Site	Β	Site	еC
K2 conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
12.5	10	10	0	10	0	10	0
18.75 31.25	10 10	7	3	8	2	8	2
37.5	10	0	10	0	10	0	10
6-MAM							
6-MAM conc. (ng/mL)	n per site	Site		Site		Site	
0	site 10	- 10	+	- 10	+	- 10	+
5	10	10	0	10	0	10	0
7.5	10	9	1	9	1	9	1
12.5	10	1	9	1	9	1	9
15 MDA 500	10	0	10	0	10	0	10
	n per	Site	eΑ	Site	вВ	Site	эC
MDA conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250 375	10	10 9	0	10 9	0	10 9	0
625	10	1	9	1	9	1	9
750	10	0	10	0	10	0	10
ETG300 Ethyl Glucuronide	n por	Sit	еA	Sit	еB	Si	te C
Concentration (ng/mL)	n per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225 375	10 10	7	3	8	2	9 1	1
450	10	0	9 10	2	0 10	0	9 10
ETG500				-			
Ethyl Glucuronide	n per	Sit	e A	Sit	еB	Si	te C
Concentration (ng/mL)	Site	-	+	-	+	-	+
0 250	10 10	10 10	0	10 10	0	10 10	0
375	10	8	2	8	2	9	1
625	10	1	9	2	8	2	8
750 ETG1,000	10	0	10	0	10	0	10
Ethyl Glucuronide	n per	Sit	еA	Sit	еB	Si	te C
Concentration (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	8	2	8	2	9	1
1050		1	9	2	8	2	8 10
1250	10		10	0	10		
1250 1500 CLO 400	10	0	10	0	10	0	10
1500 CLO 400 Clonazepam	10 n per	0	10 e A		10 e B		te C
CLO 400 Clonazepam Concentration (ng/mL)	10 n per Site	0 Sit	e A +	Sit	e B +	Si -	te C +
CLO 400 Clonazepam Concentration (ng/mL) 0	10 n per Site 10	0 Sit - 10	e A + 0	Sit - 10	e B + 0	Si - 10	te C + 0
CLO 400 Clonazepam Concentration (ng/mL) 0 200	10 n per Site 10 10	0 Sit - 10 10	e A + 0 0	Sit - 10 10	e B + 0 0	Si - 10 10	te C + 0 0
CLO 400 Clonazepam Concentration (ng/mL) 0 200 300	10 n per Site 10 10 10	0 - 10 10 9	e A + 0 0 1	Sit - 10 10 8	e B + 0 2	Sir - 10 10 9	te C + 0 0 1
CLO 400 Clonazepam Concentration (ng/mL) 0 0 200 300 500	10 n per Site 10 10 10 10	0 - 10 10 9 1	e A + 0 0 1 9	Sit - 10 10 8 2	e B + 0 2 8	Sir - 10 10 9 1	te C + 0 0 1 9
CLO 400 Clonazepam Concentration (ng/mL) 0 200 300	10 n per Site 10 10 10	0 - 10 10 9	e A + 0 0 1	Sit - 10 10 8	e B + 0 2	Sir - 10 10 9	te C + 0 0 1
CLO 400 Clonazepam Concentration (ng/mL) 0 200 300 500 600 CLO 150 Clonazepam	10 n per Site 10 10 10 10 10 10	0 - 10 10 9 1 0 Site	e A + 0 1 9 10	Sit - 10 10 8 2 0 Site	e B + 0 2 8 10	Si - 10 10 9 1 0 Site	te C + 0 1 9 10 e C
CLO 400 Clonazepam Concentration (ng/mL) 0 200 300 500 600 CLO 150 Clonazepam Concentration (ng/mL)	10 n per Site 10 10 10 10 10 10 10	0 - 10 10 9 1 0 Site -	e A + 0 0 1 9 10 *	Site - 10 10 8 2 0 Site -	e B + 0 2 8 10 • B +	Si - 10 10 9 1 0 Site -	te C + 0 0 1 9 10 e C +
1500 400 Clonazepam Concentration (ng/mL) 0 200 300 500 600 150 Clonazepam Concentration (ng/mL) 0 0	10 n per Site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	0 Site - 10 10 9 1 0 Site - 10	e A + 0 1 9 10 2 8 A + 0	Site - 10 10 8 2 0 Site - 10	e B + 0 2 8 10 • 8 + 0	Si - 10 10 9 1 0 Site - 10	te C + 0 0 1 9 10 e C + 0
1500 Clonazepam Concentration (ng/mL) 0 200 300 500 600 Clonazepam Concentration (ng/mL) 0 75	10 n per Site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	0 Sit - 10 10 9 1 0 Site - 10 10	e A + 0 1 9 10 * A + 0 0	Site - 10 10 8 2 0 0 Site - 10 10	e B + 0 2 8 10 • 8 + 0 0	Sit - 10 10 9 1 0 Site - 10 10 10	te C + 0 0 1 9 10 e C + 0 0
CLO 400 Clonazepam Concentration (ng/mL) 0 0 200 300 500 600 600 Clonazepam Concentration (ng/mL) 0 0 75 112 12	10 n per Site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	0 Site - 10 10 9 1 0 Site - - 10 10 9	e A + 0 1 9 10 * A + 0 0 1	Site - 10 10 8 2 0 Site - 10 10 8	e B + 0 2 8 10 2 8 10 9 8 + 0 0 2	Sit - 10 9 1 0 5 5 5 10 10 9 9	te C + 0 1 9 10 0 0 + 0 0 1
1500 Clonazepam Concentration (ng/mL) 0 200 300 500 600 Clonazepam Concentration (ng/mL) 0 75	10 n per Site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	0 Sit - 10 10 9 1 0 Site - 10 10	e A + 0 1 9 10 * A + 0 0	Site - 10 10 8 2 0 0 Site - 10 10	e B + 0 2 8 10 • 8 + 0 0	Sit - 10 10 9 1 0 Site - 10 10 10	te C + 0 0 1 9 10 e C + 0 0

LSD 20									
Clonazepam Concentration (ng/mL)	n pe Site		S	Site A		Site	B	Si	te C +
0	10	-	10	0	10	,	0	10	0
10	10		10	0	10)	0	10	0
15	10		9	1	9		1	9	1
25	10		1	9	1		9	1	9
30 LSD 50	10		0	1(0 0		10	0	10
Clonazepam	n pe	r	S	Site A		Site	В	Si	te C
Concentration (ng/mL)	Site		-	+	-		+	-	+
0	10		10	0	10)	0	10	0
25	10		10	0	10)	0	10	0
37.5	10		9	1	9		1	9	1
62.5	10		1	9	1		9	1	9
75 LSD 10	10		0	1(0 0		10	0	10
	0.00	r	5	Site A		Site	в	Si	te C
Clonazepam Concentration (ng/mL)	n pe Site		-	+	-		+	-	+
0	10		10	0	10	,	0	10	0
5	10		10	0	10	_	0	10	0
7.5	10		9	1	9		1	9	1
12.5	10		1	9	1		9	1	9
15	10		0	10) 0		10	0	10
MPD300	<u> </u>			tito A	—	Site	D		to C
Methylphenidate (Ritalin) Concentration (ng/mL)	n pe Site		-	Site A		Site		- 51	te C
0	10	-	10	+	- 10		+	- 10	+
150	10		10	0	10	_	0	10	0
225	10		9	1	8		2	9	1
375	10		1	9	2		8	1	9
450 MPD150	10		0	10) 0		10	0	10
Methylphenidate (Ritalin)	0.00	r	5	Site A		Site	в	Si	te C
Concentration (ng/mL)	n pe Site	e		+	-		+	-	+
0	10		10	0	10)	0	10	0
75	10		10	0	10)	0	10	0
112.5	10		7	3	9		1	9	1
187.5	10		1	9	2		8	2	8
225	10		0	10) 0		10	0	10
ZOL			9	Site A		Site	B	Si	te C
Zolpidem Concentration (ng/mL)	n pe Site	er e	-	+	-	JILE	+	-	+
0	10		10	0	10	,	0	10	0
25	10		9	1	10)	0	10	0
75	10		0	10) 1		9	0	10
MEPHEDRONE (MEP 500)		- 1			1		-		
Mephedrone HCI Concentration. (ng/mL)	n pe site			Site A		Site		- 5	te C
0	10	_	10	+	10		+	10	+ 0
250	10		10	0	10		0	10	0
375	10		8	2	8		2	9	1
625	10		2	8	1	Ţ	9	2	8
750 MEPHEDRONE (MEP 100)	10		0	10	0 0		10	0	10
Mephedrone HCI	n pe	or .	5	Site A		Site	в	Si	te C
Concentration. (ng/mL)	site		-	+	-		+	-	+
0	10		10	0	10		0	10	0
50	10		10	0	10)	0	10	0
75	10		9	1	8		2	9 2	1 8
125 150	10		2	0			o 10	2	0 10
3, 4-METHYLENEDIOXYPYROVALERON					, 0			Ű	10
3, 4-	n		Site	A	Site	эB		Sit	e C
methylenedioxypyrovalerone Concentration (ng/mL)	per site	-	Т	+	-	4	۰T	- 1	+
0	10	10		0	10	(10	0
500	10	10		0	10	0		10	0
750	10	9	_	1 9	9	1		8	2
1250 1500	10 10	1	+	9 10	1	1		1	9 10
3, 4-METHYLENEDIOXYPYROVALERON			0)			_	~		
3, 4-methylenedioxypyrovalerone	n per		Site	А	S	ite B	3	Si	te C
4-methylenedloxypyrovalerone Concentration (ng/mL)	site	-	_[+	-	1	+	1	+
		-	-	-					

						r	
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	9	1 9	8	2
625 750	10 10	2	8 10	1	10	1	9 10
DIAZEPAM (DIA 300)	10	0	10	0	10	0	10
Diazepam Concentration (ng/mL)	n per	Site		Site		Site	еC
	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150 225	10 10	10 9	0	10 9	0	10 9	0
375	10	9	9	9	9	9	9
450	10	0	10	0	10	0	10
DIAZEPAM (DIA 200)		÷		÷		÷	
Diazepam Concentration (ng/mL)	n per	Site	eΑ	Site	B	Site	θC
	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	9	1	9	1	9	1
250	10	1	9	1	9	1	9
300 ZOPICLONE (ZOP 50)	10	0	10	0	10	0	10
ZOPICLONE (ZOP 50) Zopiclone	n per	Site	A	Site	в	Site	ЭC
Concentration (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
25	10	10	0	10	0	10	0
37.5	10	9	1	8	2	9	1
62.5	10	2	8	2	8	2	8
75	10	0	10	0	10	0	10
METHCATHINONE (MCAT 500)							
Methcathinone	n per	Site	eΑ	Site	в	Site	эC
Concentration (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	8	2	9	1
625	10	2	8	2	8	2	8
750	10	0	10	0	10	0	10
7 4 01 (000)							
7-ACL(300)	n per	Si	te A	Sit	еB	Sit	еC
7-ACL(300) 7- Aminoclonazepam Concentration (ng/mL)	n per Site	Si -	te A +	Sit	e B +	Sit	e C +
7- Aminoclonazepam	n per Site 10	-			e B + 0		e C + 0
7- Aminoclonazepam Concentration (ng/mL)	Site	-	+	-	+	-	+
7- Aminoclonazepam Concentration (ng/mL) 0	Site 10	- 10	+ 0	- 10	+ 0	- 10	+ 0
7- Aminoclonazepam Concentration (ng/mL) 0 150	Site 10 10	- 10 10	+ 0 0	- 10 10	+ 0 0	- 10 10	+ 0 0
7- Aminoclonazepam Concentration (ng/mL) 0 150 225	Site 10 10 10	- 10 10 8	+ 0 0 2	- 10 10 9	+ 0 0 1	- 10 10 9	+ 0 0 1
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375	Site 10 10 10 10 10	- 10 10 8 2	+ 0 0 2 8	- 10 10 9 2 0	+ 0 1 8 10	- 10 10 9 3	+ 0 0 1 7
7- Aminoclonazepam Concentration (ng/mL) 150 225 375 450 7-ACL(200) 7- Aminoclonazepam	Site 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0	+ 0 2 8 10	- 10 10 9 2 0	+ 0 1 8 10 e B	- 10 10 9 3 0	+ 0 1 7 10 e C
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL)	Site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 Si -	+ 0 2 8 10 te A +	- 10 10 9 2 0 Sit	+ 0 1 8 10 e B +	- 10 10 9 3 0 Sit	+ 0 1 7 10 e C +
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-AC(200) 7- Aminoclonazepam Concentration (ng/mL) 0	Site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 Si - 10	+ 0 2 8 10 te A + 0	- 10 10 9 2 0 Sit - 10	+ 0 1 8 10 e B + 0	- 10 10 9 3 0 5 it - 10	+ 0 1 7 10 e C + 0
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 100	Site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 Si - 10 10	+ 0 2 8 10 te A + 0 0	- 10 10 9 2 0 Situ - 10 10	+ 0 1 8 10 e B + 0 0	- 10 9 3 0 Sit 10 10	+ 0 1 7 10 e C + 0 0
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-AC[200] 7- Aminoclonazepam Concentration (ng/mL) 0 100 150	Site 10	- 10 10 8 2 0 5 i - 10 10 8	+ 0 2 8 10 te A + 0 0 2	- 10 10 9 2 0 0 5it - 10 10 9	+ 0 1 8 10 e B + 0 0 1	- 10 9 3 0 5 it - 10 10 8	+ 0 1 7 10 e C + 0 0 2
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 100 150 250	Site 10	- 10 10 8 2 0 5 i 0 5 i 0 5 i 0 10 10 8 2	+ 0 2 8 10 te A + 0 0 2 8	- 10 10 9 2 0 Sit - 0 5 10 10 9 2	+ 0 1 8 10 e B + 0 0 1 8	- 10 9 3 0 Sit - 10 10 8 2	+ 0 1 7 10 e C + 0 0 2 8
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 100 150 250 300	Site 10	- 10 10 8 2 0 5 i - 10 10 8	+ 0 2 8 10 te A + 0 0 2	- 10 10 9 2 0 0 5it 10 10 10 9	+ 0 1 8 10 e B + 0 0 1	- 10 9 3 0 5 it - 10 10 8	+ 0 1 7 10 e C + 0 0 2
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-AC(200) 7- Aminoclonazepam Concentration (ng/mL) 0 100 150 250 300 7-AC(100)	Site 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 Si - 10 10 8 2 0	+ 0 2 8 10 te A + 0 0 2 8	- 10 9 2 0 5it - 10 10 9 2 0	+ 0 1 8 10 e B + 0 0 1 8	- 10 9 3 0 Sit - 10 10 8 2 0	+ 0 1 7 10 e C + 0 0 2 8
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 100 150 250 300	Site 10	- 10 10 8 2 0 Si - 10 10 8 2 0	+ 0 2 8 10 te A + 0 0 2 8 10	- 10 9 2 0 5it - 10 10 9 2 0	+ 0 1 8 10 e B + 0 0 1 8 10	- 10 9 3 0 Sit - 10 10 8 2 0	+ 0 1 7 10 e C + 0 0 2 8 10
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 150 250 300 7- ACL(100) 7- Aminoclonazepam	Site 10	- 10 10 8 2 0 Si - 10 10 8 2 0 Si Si Si Si Si Si Si Si Si Si	+ 0 2 8 10 te A - + 0 0 2 8 10 te A	- 10 10 9 2 0 Sit - 10 10 9 2 0 Sit	+ 0 1 8 10 e B + 0 0 1 8 10 te B	- 10 9 3 0 Sit - 10 10 8 2 0 5	+ 0 1 7 10 • • • • 0 2 8 10 • •
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL)	Site 10	- 10 10 8 2 0 - 10 10 8 2 0 - - - - - - - - - - - - -	+ 0 2 8 10 te A + 0 0 2 8 10 te A + +	- 10 10 9 2 0 Sit - 10 10 9 2 0 Sit - - - - - - - - - - - - -	+ 0 1 8 10 • B + 0 0 1 8 10 • te B +	- 10 10 9 3 0 Sit - 10 10 8 2 0 - - - - - - - - - - - - -	+ 0 1 7 10 • • • • 0 0 2 8 10 • • •
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 255 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7- Aminoclonazepam Concentration (ng/mL) 0	Site 10	- 10 10 8 2 0 5i - 10 10 8 2 0 - 10 8 - 10 - 10 10 - 10 - 10 - 10 - - - - - - - - - - - - -	+ 0 2 8 10 te A + 0 0 2 8 10 te A + 0 0 2 8 10	- 10 10 9 2 0 Sit 10 10 9 2 0 Sit 10 10 9 2 0 10 10 10 10 10 10 10 10 10	+ 0 1 8 10 • B + 0 0 1 8 10 • B • + 0 • 0 • 1 • • • • • • • • • • • • • • • • • •	- 10 10 9 3 0 Sit - 10 10 8 2 0 - 10 8 2 0 - 10 10 10 10 10 10 10 10 10 10	+ 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 2 8 10
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 255 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 300 7- Aminoclonazepam Concentration (ng/mL) 0 50	Site 10		+ 0 2 8 10 te A + 0 0 2 8 10 10 te A + 0 0 0 2 8 10	- 10 10 9 2 0 Sin 10 10 9 2 0 Sin 10 10 10 10 10 10 10 10 10 10	+ 0 1 8 10 • B + 0 0 1 1 8 10 10 • E • F • • • • • • • • • • • • • • • • • •	- 10 10 9 3 0 Sit - 10 10 8 2 0 S - 10 10 10 10 10 10 10 10 10 10	+ 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 2 8 10
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-AMinoclonazepam Concentration (ng/mL) 0 50 75	Site 10		+ 0 2 8 10 te A + 0 2 8 10 2 8 10 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 9 2 0 - 10 10 9 2 0 - 10 10 7 1 10 7 1	+ 0 1 8 10 e B + 0 0 1 8 10 1 8 10 0 1 8 10 0 0 1 8 10 0 0 1 8 10 0 0 1 8 10 0 0 1 9	- 10 10 9 3 0 Sit - 10 10 8 2 0 - 10 10 9 2 2	+ 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 2 8 10 ite C 1 8 10
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 255 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 50 75 125 150	Site 10		+ 0 2 8 10 te A + 0 0 2 8 10 2 8 10 10 te A - 4 0 0 3	- 10 10 9 2 0 Sit - 10 10 9 2 0 - 10 10 - 10 - 10 7	+ 0 1 8 10 • B + 0 0 1 1 8 10 • B + 0 0 1 0 1 0 0 3	- 10 10 9 3 0 Sit - 10 10 8 2 0 S - 10 10 9 9 9 9 10 10 9 9 9 10 10 9 9 10 10 9 10 9 10 10 9 10 10 9 10 10 9 10 10 10 10 10 10 10 10 10 10	+ 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 2 8 10 ite C 1
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-AMinoclonazepam Concentration (ng/mL) 0 150 250 300 7-AMinoclonazepam Concentration (ng/mL) 0 50 75 125	Site 10	- 10 10 8 2 0 - 10 10 8 2 0 - - 10 10 8 2 0 - - - - - - - - - - - - -	+ 0 2 8 10 te A + 0 2 8 10 2 8 10 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 9 2 0 Sit - 10 10 9 2 0 - 10 10 - 10 10 - 10 10 - 10 - 10 - - - - - - - - - - - - -	+ 0 1 8 10 e B + 0 0 1 8 10 1 8 10 0 1 8 10 0 0 1 8 10 0 0 1 8 10 0 0 1 8 10 0 0 1 9	- 10 10 9 3 0 Siti 10 10 10 8 2 0 - 10 10 10 9 - - 10 10 9 2 0 0 - - - - - - - - - - - - -	+ 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 2 8 10 ite C 1 8 10
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 100 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 300 7-ACL(100) 75 125 150 CARFENTANYL(CFYL500)	Site 10	- 10 10 8 2 0 - 10 10 8 2 0 - - 10 10 8 2 0 - - - - - - - - - - - - -	+ 0 2 8 10 10 10 2 8 10 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 0 3 8 10	- 10 10 9 2 0 Sit - 10 10 9 2 0 - 10 10 - 10 10 - 10 10 - 10 - 10 - - - - - - - - - - - - -	+ 0 1 8 10 e B + 0 0 1 8 10 0 1 8 10 0 1 8 10 0 1 8 10 0 0 3 3 9 9 10	- 10 10 9 3 0 Siti 10 10 10 8 2 0 - 10 10 10 9 - - 10 10 9 2 0 0 - - - - - - - - - - - - -	+ 0 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 2 8 10 ite C + 1 0 0 1 1 7 10 0 0 2 8 10 0 0 1 2 8 10 0 0 0 0 1 1 7 10 0 0 0 0 0 0 0 0 0 0
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 255 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 50 75 125 150 CARFENTANYL(CFYL500) Carfentanyl	Site 10	- 10 10 8 2 0 - 10 10 8 2 0 - - 10 10 8 - - - 10 10 - - - - - - - - - - - - -	+ 0 2 8 10 10 2 8 10 2 8 10 2 8 10 0 3 8 10 0 3 8 10 0 8 10 0 8 10 0 8 10 0 8 10	- 10 10 9 2 0 - 10 10 10 9 2 0 - 10 10 10 - 10 10 - 10 - 10 - 5 if - - 10 - 10 - 5 if - - - - - - - - - - - - -	+ 0 1 8 10 0 1 8 0 0 1 8 0 0 1 1 8 10 0 1 1 8 10 0 0 1 1 8 10 0 0 1 1 8 10 0 0 0	- 10 10 9 3 0 - 10 10 10 8 2 0 - 10 10 9 - - 10 10 9 - - - - - - - - - - - - -	+ 0 0 1 7 10 e C + 0 0 0 2 2 8 10 ite C + 0 0 0 1 1 8 10 ite C + 10 0 0 0 1 1 7 7 10 0 0 1 1 7 7 10 0 0 0
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 50 75 125 150 CARFENTANYL(CFYL500) Carfentanyl Concentration (ng/mL) 0 250	Site 10	- 10 10 8 2 0 - 10 10 8 2 0 - - 10 10 10 7 2 0 - - - - - - - - - - - - -	+ 0 2 8 10 10 2 8 10 2 8 10 2 8 10 10 2 8 10 0 3 8 10 0 3 8 10 0 9 6 4 + 0 0 0 2 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 9 2 0 - 10 10 9 2 0 - 10 10 10 - - 10 10 - - - - - - - - - - - - -	+ 0 0 1 8 10 + 0 0 0 1 8 10 1 8 10 0 0 3 9 9 10 0 0 8 8 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 10 10 9 3 0 - 10 10 8 2 0 - 10 10 10 9 - - 10 10 - - - - - - - - - - - - -	+ 0 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 1 + 0 0 0 1 + 0 0 0 1 + 0 0 0 0 0 1 + 0 0 0 0 0 0 0 0 0 0 0 0 0
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 50 75 125 150 CARFENTANYL(CFYLS00) Carfentanyl Concentration (ng/mL) 0 250 375	Site 10	- 10 10 8 2 0 10 10 10 10 8 2 0 - 10 10 10 7 2 0 - - 10 - - - - - - - - - - - - -	+ 0 2 8 10 + 0 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 8 10 - 2 8 8 8 8 9 8 9 8 8 9 8 9 8 8 9 9 8 8 9 9 8 8 9 9 9 8 9 9 9 9 9 8 9	- 10 10 9 2 0 - 10 10 10 9 2 0 - 10 10 10 - - 10 10 - - - 10 - - - - - - - - - - - - -	+ 0 0 1 8 10 • B + 0 0 1 8 10 1 8 10 1 8 10 0 0 3 9 9 10 0 0 3 9 9 10	- 10 10 9 3 0 - 10 10 10 8 2 0 - 10 10 8 - - 10 10 8 - - - - - - - - - - - - -	+ 0 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 1 8 10 ite C + 0 0 2 8 10 ite C + 0 0 2 8 10 1 - - - - - - - - - - - - -
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 376 450 7-ACC(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 50 75 125 150 CARFENTANYL(CFYLS00) Carfentanyl Concentration (ng/mL) 0 250 375 625	Site 10	- 10 10 8 2 0 - 10 10 10 8 2 0 - 10 10 10 7 2 0 - 10 10 - 10 - - - - - - - - - - - - -	+ 0 2 8 10 10 + 0 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 0 3 8 10 - 0 0 3 8 8 10	. 10 10 10 2 0 . . . <	+ 0 0 1 8 10 • e B + 0 0 1 8 10 1 8 10 0 0 1 8 10 0 0 3 9 10 0 0 3 9 10 0 0 1 9 10	- 10 10 9 3 0 - 10 10 10 8 2 0 - 10 10 9 - - 10 10 9 - - 10 10 8 - - - 10 10 8 - - - - - - - - - - - - -	+ 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 1 8 10 ite C + 0 0 2 8 10 ite C + 0 0 2 8 10 10 10 10 10 10 10 10 10 10
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 150 7-ACL(100) 75 125 150 CARFENTANYL(CFYL500) Carfentanyl Concentration (ng/mL) 0 250 375 625 750	Site 10	- 10 10 8 2 0 10 10 10 10 8 2 0 - 10 10 10 7 2 0 - - 10 - - - - - - - - - - - - -	+ 0 2 8 10 + 0 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 8 10 - 2 8 8 8 8 9 8 9 8 8 9 8 9 8 8 9 9 8 8 9 9 9 8 8 9	- 10 10 9 2 0 - 10 10 10 9 2 0 - 10 10 10 - - 10 10 - - - 10 - - - - - - - - - - - - -	+ 0 0 1 8 10 • B + 0 0 1 8 10 1 8 10 1 8 10 0 0 3 9 9 10 0 0 3 9 9 10	- 10 10 9 3 0 - 10 10 10 8 2 0 - 10 10 8 - - 10 10 8 - - - - - - - - - - - - -	+ 0 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 1 8 10 ite C + 0 0 2 8 10 ite C + 0 0 2 8 10 1 - - - - - - - - - - - - -
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 50 75 125 150 CARFENTANYL(CFYL500) Carfentanyl Concentration (ng/mL) 0 250 375 625 750 CAFFEINE (CAF 1000)	Site 10	- 10 10 8 2 0 - 10 10 10 8 2 0 - 10 10 7 2 0 - - 10 - - - - - - - - - - - - -	+ 0 2 8 10 + 0 2 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 10 - 2 8 8 8 - 8 8 9 - 10 - 2 8 8 8 - 10 - 10 - 2 8 8 8 - 8 - 10 - 8 - 8 - 8 - 8 - 8 - 8 - 8 - 8 - 8 -	. 10 10 9 2 0	+ 0 0 1 8 10 e B + 0 0 1 8 10 1 8 10 0 3 9 9 10 0 3 9 10 0 1 9 10 0 1 1 9 10	- 10 10 9 3 0 - 10 10 10 8 2 0 - 10 10 8 2 0 - 10 10 8 2 0 - 5 10 - 10 - 10 8 2 0 - 5 - - - - - - - - - - - - -	+ 0 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 2 8 10 ite C + 0 0 2 8 10 ite C + 0 0 2 8 10 1 2 8 10 1 1 10 1 1 1 10 1 1 10 1 1 10 1 10 1 10 1 10 1 10 1 10 10
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 150 7-ACL(100) 75 125 150 CARFENTANYL(CFYL500) Carfentanyl Concentration (ng/mL) 0 250 375 625 750	Site 10	- 10 10 8 2 0 - 10 10 10 8 2 0 - 10 10 7 2 0 - - 10 - - - - - - - - - - - - -	+ 0 2 8 10 10 + 0 2 8 10 - 2 8 10 - 2 8 10 - 2 8 10 - 0 3 8 10 - 0 0 3 8 8 10	. 10 10 10 2 0 . . . <	+ 0 0 1 8 10 e B + 0 0 1 8 10 1 8 10 0 3 9 9 10 0 3 9 10 0 1 9 10 0 1 1 9 10	- 10 10 9 3 0 - 10 10 10 8 2 0 - 10 10 8 2 0 - 10 10 8 2 0 - 5 10 - 10 - 10 8 2 0 - 5 - - - - - - - - - - - - -	+ 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 1 8 10 ite C + 0 0 2 8 10 ite C + 0 0 2 8 10 10 10 10 10 10 10 10 10 10
7- Aminoclonazepam Concentration (ng/mL) 0 150 225 375 450 7-ACL(200) 7- Aminoclonazepam Concentration (ng/mL) 0 150 250 300 7-ACL(100) 7- Aminoclonazepam Concentration (ng/mL) 0 150 Concentration (ng/mL) 0 50 75 125 150 CARFENTANYL(CFYL500) Cartentanyl Concentration (ng/mL) 0 250 375 625 750 CAFEINE (CAF 1000) Cafferine	Site 10	- 10 10 8 2 0 10 10 10 8 2 0 10 10 10 7 2 0 Sili - 10 10 10 10 10 5 Sili - - - - - - - - - - - - -	+ 0 0 2 8 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	. 10 10 9 2 0 10 10 2 0 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 9 1 0 Silt	+ 0 0 1 8 10 € B + 0 0 1 8 10 1 8 10 1 8 10 0 0 1 8 10 0 0 3 9 9 10 0 0 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 8 8 10 1 1 1 8 8 10 1 1 1 1	- 10 10 9 3 0 - 10 10 10 8 2 0 - 10 10 10 8 - 10 10 10 8 - - 10 10 10 8 - - - - - - - - - - - - -	+ 0 0 1 7 10 e C + 0 0 2 8 10 ite C + 0 0 1 8 10 ite C + 0 0 2 8 10 ite C + 0 0 2 8 10 10 10 10 10 10 10 10 10 10

0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	9	1	8	2	9	1
1250	10	2	8	2	8	2	8
1500	10	0	10	0	10	0	10
CATHINE (CAT 150)							
(+)-Norpseudoephedrine HCI	n per	Site	A	Site	B	Site	C
Concentration(ng/mL)	site		+	-	+	-	+
0	10	10	0	10	0	10	0
75	10	10	0	10	0	10	0
112.5	10	9	1	8	2	9	1
187.5	10	2	8	2	8	2	8
225	10	0	10	0	10	0	10
TROPICAMIDE (TRO 350)		Site	Δ	Site	в	Site	
Tropicamide Concentration (ng/ml)	n per site	-	+	-	+	-	+
0	10	10	0	10	0	10	+ 0
175	10	10	0	10	0	10	0
262.5	10	8	2	8	2	8	2
437.5	10	2	8	2	8	2	8
525	10	0	10	0	10	0	10
TRAZODONE(TZD200)		0.44		0:44	D	0.44	
Trazodone (ng/ml)	n per	Site		Site		Site	
	site	-	+	-	+	-	+
0 100	10 10	10	0	10	0	10	0
100	10 10	10 8	0	10 8	0	10 8	0
250	10	8	9	8	2 8	8	9
300	10	2	8	2	8	2	8
ALPRAZOLAM(ALP)	10	-	0	-	Ű	-	Ű
Alprozolom Concentration (ng/ml)	n per	Site	Α	Site	вB	Site	θC
Alprazolam Concentration (ng/ml)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	9	1	8	2	9	1
125	10	2	8	2	8	2	8
150	10	0	10	0	10	0	10
PREGABALIN (PGB 50,000) Pregabalin	n	9	ite A	Si	te B	Site	
Concentration (ng/ml)	per Site		+	-	+	-	+
Concentration (ng/ml) 0	per Site 10	- 10	+	- 10	0	- 10	0
Concentration (ng/ml) 0 25,000	per Site 10 10	- 10 10	+ 0 0	- 10 10	0	- 10 10	0
Concentration (ng/ml) 0 25,000 37,500	per Site 10 10 10	- 10 10 8	+ 0 0 2	- 10 10 8	0 0 2	- 10 10 8	0 0 2
Concentration (ng/ml) 0 25,000 37,500 62,500	per Site 10 10	- 10 10	+ 0 0	- 10 10	0	- 10 10	0
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 150,000	per Site 10 10 10 10	- 10 10 8 2	+ 0 2 8	- 10 10 8 2	0 0 2 8	- 10 10 8 2	0 0 2 8
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 150,000 PREGABALIN (PGB 500)	per Site 10 10 10 10 10 10	- 10 10 8 2 0 0	+ 0 2 8 10	- 10 10 8 2 0 0	0 0 2 8 10 10	- 10 10 8 2 0 0	0 0 2 8 10 10
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 150,000 PREGABALIN (PGB 500) Pregabalin	per Site 10 10 10 10 10	- 10 10 8 2 0 0 0 S	+ 0 2 8 10	- 10 10 8 2 0 0	0 0 2 8 10	- 10 10 8 2 0	0 0 2 8 10 10
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 0	+ 0 2 8 10 10 ite A + 0	- 10 10 8 2 0 0 0 Si - 10	0 0 2 8 10 10 10 10 10	- 10 10 8 2 0 0 0 0 Site - 10	0 0 2 8 10 10 € C + 0
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 150,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250	per Site 10 10 10 10 10 10 10 n per Site 10 10	- 10 10 8 2 0 0 0 0 0 - - 10 10	+ 0 2 8 10 10 10 ite A + 0 0	- 10 10 8 2 0 0 0 5 i - 10 10	0 0 2 8 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 5 ite - 10 10	0 0 2 8 10 10 0 € C + 0 0
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 150,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 0 - - 10 10 9	+ 0 2 8 10 10 10 ite A + 0 0	- 10 10 8 2 0 0 0 Si - 10 10 8	0 0 2 8 10 10 10 te B + 0 0 2	- 10 10 8 2 0 0 0 5 ite - 10 10 8	0 0 2 8 10 10 0 0 2
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 150,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250	per Site 10 10 10 10 10 10 10 n per Site 10 10	- 10 10 8 2 0 0 0 0 0 - - 10 10	+ 0 2 8 10 10 10 ite A + 0 0	- 10 10 8 2 0 0 0 5 i - 10 10	0 0 2 8 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 5 ite - 10 10	0 0 2 8 10 10 0 € C + 0 0
Concentration (ng/ml) 0 0 25,000 37,500 62,500 150,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 1500	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 - 10 10 9 2	+ 0 2 8 10 10 10 ite A - - - - - - - - - - - - - - - - - - -	- 10 10 8 2 0 0 0 5 i - 10 10 10 8 2	0 0 2 8 10 10 10 te B + 0 0 2 8	- 10 10 8 2 0 0 5 5 5 5 5 5 5 5 5 5 5 5 5	0 0 2 8 10 10 0 2 + 0 0 2 8
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 0 375 625 750 1500 Codeine (COD200)	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 - - - - - - - - - - - - -	+ 0 2 8 10 10 ite A - 0 0 1 10 10 10 10 10	- 10 10 8 2 0 0 0 5 i - - 10 10 10 10 8 2 0 0	0 0 2 8 10 10 10 10 10 10 2 8 10 10	- 10 10 8 2 0 0 0 Site - 10 10 8 2 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 2 8 10 10 0 0 2 + 0 0 0 2 8 10 10
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 150,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 1500 Codeine (COD200) Codeine	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 - - - - - - - - - - - - -	+ 0 2 8 10 10 ite A - - - - - - - - - - - - -	- 10 10 8 2 0 0 0 5 i - - 10 10 10 10 8 2 0 0	0 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 - 5 Site - 10 10 10 8 2 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 2 8 10 10 10 10 0 2 + 0 0 2 8 10 10 10 10 10 2 C C
Concentration (ng/ml) 0 0 25,000 37,500 62,500 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 Codeine (COD200) Codeine Concentration (ng/mL)	per Site 10	- 10 10 8 2 0 0 0 - 10 10 9 2 0 0 - Sitter - - - - - - - - - - - - - -	+ 0 2 8 10 10 10 ite A + 0 0 1 1 8 10 10 10	- 10 10 8 2 0 0 0 Si - 10 10 8 2 0 0 0 Si - - - - - - - - - - - - -	0 0 2 8 10 10 10 10 10 10 2 8 10 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 5 5 10 10 10 8 2 0 0 5 5 5 5 5 5 5 5 5 5 5 5 5	0 0 2 8 10 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 4
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 150,000 Pregabalin Concentration (ng/ml) 0 250 375 625 750 625 750 625 750 625 750 1500 Concentration (ng/mL) 0	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 8 2 0 0 0 10 10 10 9 2 0 0 Sitt - 10 10 10 10 10 10 10 10 10 10	+ 0 2 8 10 10 10 ite A - + 0 0 1 1 10 10 10 e A + 0 0 0 0 0 0 10 0 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 10 10 8 2 0 0 5 - 10 10 10 8 2 0 0 5 - - 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 10 10 10 10 2 8 10 10 2 8 10 10 2 8 10 10 0 2 8 10 10 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 5 ite - 10 10 10 10 8 2 0 0 5 ite - 10 10 10 10 10 5 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 0 2 8 10 10 0 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml) 0 0 25,000 37,500 62,500 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 Codeine (COD200) Codeine Concentration (ng/mL)	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 - 10 10 9 2 0 0 - Sitter - - - - - - - - - - - - - -	+ 0 0 2 8 10 10 10 ite A + 0 0 0 10 10 e A + 0 0 0	- 10 10 8 2 0 0 - 10 10 10 8 2 0 0 0 Sit - 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 10 10 10 10 10 2 8 10 10 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 5 5 10 10 8 2 0 0 0 0 5 5 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 0 2 8 10 10 0 2 8 10 10 0 2 8 10 10 0 0 2 + 0 0 0 2 + 0 0 0 0 0 - - - - - - - - - - - - -
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 625 750 1500 Codeline (COD200) Codeline Concentration (ng/mL) 0 100	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 - 10 10 10 - 0 - - 10 10 - - - - - - - - - - - - -	+ 0 2 8 10 10 10 ite A - + 0 0 1 1 10 10 10 e A + 0 0 0 0 0 0 10 0 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 10 10 8 2 0 0 5 - 10 10 10 8 2 0 0 5 - - 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 10 10 10 10 2 8 10 10 2 8 10 10 2 8 10 10 0 2 8 10 10 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 5 ite - 10 10 10 10 8 2 0 0 5 ite - 10 10 10 10 10 5 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 0 2 8 10 10 0 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 625 750 Codeine Concentration (ng/mL) 0 100 150 250 300	per Site 10	- 10 10 8 2 0 0 0 0 0 10 9 2 0 0 0 0 0 0 0 0 0 0 0 0 0	+ 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 5i - 10 10 8 2 0 0 0 5i - 10 10 9	0 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 - 10 10 8 2 0 0 - 10 8 2 0 0 - - 10 5 - - - - - - - - - - - - -	0 0 2 8 10 10 9 C + 0 0 2 8 10 10 9 C + 0 0 2 8 10 10 9 C + 0 0 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml) 0 0 25,000 37,500 62,500 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 Codeline (COD200) Codeline (COD200) Codeline (Colored) 1500 Codeline (250 300 Zaleplon(ZAL)	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 - 10 10 9 2 2 0 0 0 5 - 10 10 10 10 10 10 10 10 10 0 10 0 10 1	+ 0 0 2 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 - 10 10 8 2 0 0 Sit - - 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 - 10 10 10 8 2 0 0 - - 10 10 9 2 0 0 - - 10 0 0 - - - - - - - - - - - - -	0 0 2 8 10 10 0 C + 0 0 2 8 10 0 2 8 10 0 2 8 10 0 2 8 10 0 0 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml)	per Site 10	- - - - - - - - - - - - - -	+ 0 2 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 - 10 10 8 2 0 0 Sit - - 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 - 10 10 10 8 2 0 0 - - 10 10 9 2 0 0 - - 10 0 0 - - - - - - - - - - - - -	0 0 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml)	per Site 10	- 10 10 8 2 0 0 - 10 9 9 2 0 0 - - 10 - - 10 - - - - - - - - - - - - -	+ 0 2 8 8 10 10 10 10 10 10 10 8 8 10 0 0 10 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 10 10 10 10 10 10 10 1	0 0 2 8 10 10 10 10 10 10 0 0 10 10	- 10 10 8 2 0 0 - 10 10 10 8 2 0 0 - 10 10 9 2 0 0 - 10 10 - 5 ite - - - - - - - - - - - - -	0 0 2 8 10 10 0 2 8 10 0 0 2 + 0 0 2 + 0 0 2 + 0 0 0 - - - - - - - - - - - - -
Concentration (ng/ml) 0 0 25,000 37,500 62,500 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 Codeine (COD200) Codeine (COD200) Codeine (COD200) Codeine (Concentration (ng/mL) 0 100 150 250 300 Zaleplon(ZAL) Concentration (ng/mL) 0 0 0	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 - - - - - - - - - - - - -	++ 0 2 2 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 10 10 8 2 0 0 10 10 8 2 0 0 0 10 10 8 2 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 0 10 10 10 10 10 10 10	0 0 2 8 10 10 0 2 8 10 10 0 2 8 10 10 0 2 8 10 10 0 2 8 10 10 0 2 8 10 10 0 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml)	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 10 10 9 2 0 0 10 10 9 2 0 0 10 10 10 9 2 0 0 10 10 10 10 10 10 10 10	+ + 0 0 2 2 8 10 10 10 10	- 10 10 8 2 0 0 5 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 10 10 2 8 10 10 2 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 10 8 2 0 0 5 10 10 10 10 8 8 2 2 0 0 5 10 10 10 10 10 10 5 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 9 C + 0 2 8 10 10 9 C + 0 2 8 10 10 9 C + 0 2 8 10 10 9 C + 0 0 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml)	per Site 10 10 10 10 10 10 10 10 10 10	- - - - - - - - - - - - - -	++ 0 2 2 8 10 10 10 10 10 10 10 10 10 10 8 10 0 1 1 8 10 0 1 1 8 10 0 0 1 1 10 10 10 10 10 10 10 10 10 1	- 10 10 8 2 0 0 0 10 10 10 8 2 0 0 5 10 10 10 9 1 0 9 9	0 0 2 8 10 10 10 10 10 10 10 10 10 10	. . 10 10 8 2 0 0 . .	0 0 0 2 8 10 10 10 10 2 8 10 10 10 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 1500 Codeine Codeine Concentration (ng/mL) 0 150 24 250 300 24 0 50 75 125	per Site 10	- - - - - - - - - - - - - -	++ 0 2 2 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 10 10 10 10 10 10 9 1 0 Siti - 10 10 10 10 8 - - 10 10 8 - - - - - - - - - - - - -	0 0 2 8 10 10 10 10 10 2 8 10 0 2 8 10 10 10 10 10 10 10 10 10 10	- - - - - - - - - - - - - -	0 0 2 8 10 10 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 10 2 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml)	per Site 10 10 10 10 10 10 10 10 10 10	- - - - - - - - - - - - - -	++ 0 2 2 8 10 10 10 10 10 10 10 10 10 10 8 10 0 1 1 8 10 0 1 1 8 10 0 0 1 1 10 10 10 10 10 10 10 10 10 1	- 10 10 8 2 0 0 0 10 10 10 8 2 0 0 5 10 10 10 9 1 0 9 9	0 0 2 8 10 10 10 10 10 10 10 10 10 10	. . 10 10 8 2 0 0 . .	0 0 0 2 8 10 10 10 10 2 8 10 10 10 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml) 0 25,000 37,500 62,500 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 Codeline (COD200) COdeline (COD2	per Site 10		++ 0 2 2 8 10 10 10 10 10 10 10 10 10 10 10 8 4 0 0 1 8 10 0 1 8 10 0 1 8 10 0 10 10 10 10 10 10 10 10 10 10 10 1	- 10 10 8 2 0 0 10 10 10 8 2 0 0 5 5 10 10 10 9 1 0 10 10 9 2 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 2 8 10 10 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10	- - - - - - - - - - - - - -	0 0 2 8 10 10 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 10 2 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml)	per Site 10 10 10 10 10 10 10 10 10 10	- - - - - - - - - - - - - -	+ + 0 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 10 8 2 0 0 5 5 - 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 10 10 2 8 10 10 10 2 2 8 10 10 10 10 10 10 10 10 10 10	- - - - - - - - - - - - - -	0 0 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml)	per Site 10	. 10 10 8 0 0 . .	++ 0 2 2 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 5 10 10 10 10 8 2 0 0 5 5 10 10 10 10 10 10 10 10 10 10	0 0 2 8 10 10 10 10 10 10 10 10 10 10	. 10 10 10 8 2 0 0 Site 10 10 10 8 2 0 0 Site - 10 10 10 0 10 - 10 10 9 2 0 0 Site - 10 10 9 1 0 - 10 0 10 - 10 -	0 0 0 2 8 10 10 10 2 8 10 10 10 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml)	per Site 10	. . 100 10 8 . 0 0 	++ 0 2 2 8 10 10 10 10 10 10 10 10 10 10 8 10 0 1 8 10 0 0 0	- 10 10 8 2 0 0 0 10 10 10 10 10 10 10 1	0 0 2 8 10 10 10 10 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 10 10 10 10 8 8 2 0 0 10 10 10 10 10 10 10 10	0 0 0 2 8 10 10 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml) 0 0 25,000 37,500 62,500 75,000 PREGABALIN (PGB 500) Pregabalin Concentration (ng/ml) 0 250 375 625 750 Codeline (COD200) Codeline (COD200 Codeline (COD200) Codeline (COD200) Codeline (COD200 Codeline (COD200) Codeline (COD200) Codeline (COD200 Codeline (COD200) Codeline (COD200 Codeline (COD200) Codeline (COD200 Codeline (COD200) Codeline (COD200 Codeline (COD200) Codeline (COD200) Codeline (COD200 Codeline (COD200) Codeline (COD200 Codeline (COD200) Codeline (COD200 Cod	per Site 10	- - 100 10 8 2 0 0 0 0 - 10 10 9 2 0 0 0 - 10 - 10 - 10 - 10 0 - - 10 10 9 10 0 5 - - 10 10 9 10 10 9 10 10 9	++ 0 2 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 10 10 10 10 10 10 10 10	0 0 2 8 10 10 10 10 10 10 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10	. . 10 10 8 . . .	0 0 2 8 10 10 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 10 2 2 8 10 10 10 10 10 10 10 10 10 10
Concentration (ng/ml)	per Site 10	. . 100 10 8 . 0 0 	++ 0 2 2 8 10 10 10 10 10 10 10 10 10 10 8 10 0 1 8 10 0 0 0	- 10 10 8 2 0 0 0 10 10 10 10 10 10 10 1	0 0 2 8 10 10 10 10 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10	- 10 10 8 2 0 0 0 10 10 10 10 8 8 2 0 0 10 10 10 10 10 10 10 10	0 0 0 2 8 10 10 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 2 2 8 10 10 10 2 8 10 10 10 10 10 10 10 10 10 10

Gabapentin (GAB) GAB	n	Sit	еA	Sit	e B	Sit	te C
Concentration (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
1,000	10	10	0	10	0	10	0
1,500	10	9	1	9	1	8	2
							_
2,500	10	2	8	2	8	2	8
3,000	10	0	10	0	10	0	10
Carisoprodol (CAR)							
CAR	n	Sit		Sit	еB		te C
Concentration (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
1,000	10	10	0	10	0	10	0
1,500	10	9	1	9	1	8	2
2,500	10	2	8	2	8	2	8
3,000	10	0	10	0	10	0	1(
AB-PINACA(ABP)							
	n	Sit	e A	Si	te B	Sit	te C
AB-PINACA Concentration (ng/mL)	per		+		+	_	
Concentration (ng/mE)	Site	-	Ŧ	-	-	-	+
0	10	10	0	10	0	10	0
5	10	10	0	10	0	10	0
7.5	10	8	2	8	2	9	1
12.5	10	2	8	3	7	1	9
	-						
15	10	0	10	0	10	0	10
	T	<u> </u>		<u>.</u>	- P	<u> </u>	
QUETIAPINE Concentration (ng/mL)	n ner Site	Site		Site		Site	1
Concentration (ng/mL)	per Site	- 10	+	- 10	+	- 10	+
0	10		0	10	0	-	0
500	10	10	0	10	0	10	0
750	10	9	1	9	1	9	1
1250	10	1	9	1	9	1	9
1500	10	0	10	0	10	0	10
Fluoxetine(FLX)							
Fluoxetine	n	Site	эA	Site	e B	Site	еC
Concentration (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	9	1	9	1
625	10	2	8	2	8	2	8
750 JR-144	10	0	10	0	10	0	10
	n	Site	- A	Site	e B	Site	<u> </u>
UR-144 5-Pentanoic acid	per			310			
Concentration (ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
12.5	10	10	0	10	0	10	0
18.75	10	9	1	8	2	9	1
31.25	10	1	9	2	8	2	8
37.5	10	0	10	0	10	0	10
Kratom(KRA)							
					۵R	-	~ ^
Mitragynine	n	Sit	e A	Sit	eв	Site	ec
	n per Site	Sit	e A +	Sit	+	Site	+
Mitragynine			1		1	-	1
Mitragynine Concentration (ng/mL) 0	per Site 10	- 10	+ 0	- 10	+	- 10	+
Mitragynine Concentration (ng/mL) 0 150	per Site 10 10	- 10 10	+ 0 0	- 10 10	+ 0 0	- 10 10	+ 0 0
Mitragynine Concentration (ng/mL) 0 150 225	per Site 10 10 10	- 10 10 9	+ 0 0 1	- 10 10 9	+ 0 0 1	- 10 10 9	+ 0 0
Mitragynine Concentration (ng/mL) 0 150 225 375	per Site 10 10 10 10	- 10 10 9 1	+ 0 0 1 9	- 10 10 9 1	+ 0 0 1 9	- 10 10 9 2	+ 0 0 1 8
Mitragynine Concentration (ng/mL) 0 150 225 375 450	per Site 10 10 10	- 10 10 9	+ 0 0 1	- 10 10 9	+ 0 0 1	- 10 10 9	+ 0 0 1 8
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Tilidine(TLD)	per Site 10 10 10 10 10	- 10 10 9 1 0	+ 0 1 9 10	- 10 10 9 1 0	+ 0 1 9 10	- 10 10 9 2 0	+ 0 1 8 10
Mitragynine Concentration (ng/mL) 0 150 225 375 450 filldine(TLD) Nortilidine	per Site 10 10 10 10 10 n	- 10 10 9 1 0	+ 0 0 1 9	- 10 10 9 1 0	+ 0 0 1 9	- 10 10 9 2 0	+ 0 0 1 8
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Tilidine(TLD) Nortilidine Concentration (ng/mL)	per Site 10 10 10 10 10 10 n per Site	- 10 10 9 1 0 Sit	+ 0 1 9 10 e A +	- 10 10 9 1 0 Sit	+ 0 1 9 10 e B +	- 10 10 9 2 0 Site	+ 0 1 8 10 e C +
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Tilldine(TLD) Nortilidine	per Site 10 10 10 10 10 10 n per Site 10	- 10 10 9 1 0	+ 0 1 9 10 e A	- 10 10 9 1 0	+ 0 1 9 10 e B	- 10 10 9 2 0	+ 0 1 8 10 e C
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Filidine(TLD) Nortilidine Concentration (ng/mL)	per Site 10 10 10 10 10 10 n per Site	- 10 10 9 1 0 Sit	+ 0 1 9 10 e A +	- 10 10 9 1 0 Sit	+ 0 1 9 10 e B +	- 10 10 9 2 0 Site	+ 0 1 8 10 e C +
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Tilidine Concentration (ng/mL) 0	per Site 10 10 10 10 10 10 n per Site 10	- 10 10 9 1 0 Sitt - 10 10	+ 0 1 9 10 e A + 0	- 10 10 9 1 0 Sit - 10	+ 0 1 9 10 e B + 0	- 10 10 9 2 0 5 ite - 10	+ 0 1 8 10 e C + 0
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Filidine(TLD) Nortilidine Concentration (ng/mL) 0 25	per Site 10 10 10 10 10 10 n per Site 10 10 10	- 10 9 1 0 Sitt - 10 10	+ 0 1 9 10 e A + 0 0	- 10 9 1 0 Sit - 10 10	+ 0 1 9 10 e B + 0 0	- 10 10 9 2 0 Site - 10 10	+ 0 1 8 10 e C + 0 0
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Filidine(TLD) 0 25 37.5	per Site 10 10 10 10 10 10 n per Site 10 10 10 10 10	- 10 9 1 0 Sit - 10 10 8	+ 0 1 9 10 e A + 0 0 2	- 10 9 1 0 Sit - 10 10 9	+ 0 0 1 9 10 e B + 0 0 1	- 10 9 2 0 Site - 10 10 9	+ 0 0 1 8 10 e C + 0 0 1 8
Mitragynine Concentration (ng/mL) 0 150 225 375 450 rilidine(TLD) 0 25 375 375 62.5 75	per Site 10 10 10 10 10 10 10 10 10 10	- 10 9 1 0 Sitt - 10 10 8 2	+ 0 1 9 10 e A + 0 0 2 8	- 10 9 1 0 Sitt - 10 10 9 2	+ 0 1 9 10 • B + 0 0 1 8	- 10 9 2 0 Site - 10 10 9 2	+ 0 0 1 8 10 e C + 0 0 1 8
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Tilidine(TLD) 0 25 37.5 62.5 75 150	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 Sitt - 10 10 8 2 0	+ 0 1 9 10 e A + 0 0 2 8 10	- 10 9 1 0 5 it 10 10 9 2 0	+ 0 1 9 10 e B + 0 0 1 8 10	- 10 9 2 0	+ 0 1 8 10 e C + 0 0 1 8 8 10
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Trilldine(TLD) 0 25 375 37.5 62.5 75	per Site 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 Sitt - 10 10 8 2 0	+ 0 1 9 10 e A + 0 0 2 8 10 ite A	- 10 9 1 0 5 it 10 10 9 2 0	+ 0 1 9 10 e B + 0 0 1 8 10 e B	- 10 9 2 0 Site - 10 10 9 2	+ 0 0 1 8 10 e C + 0 0 1 1 8 8 10 0 0 1 1 8 8 0 0 0 0 0 0
Mitragynine Concentration (ng/mL) 0 150 225 375 450 filidine(TLD) 0 25 37.5 62.5 75 450	per Site 10 Site	- 10 10 9 1 0 Sitt - 10 10 10 8 2 0 - Sitt - - - - - - - - - - - - -	+ 0 1 9 10 e A + 0 0 2 8 10 tte A +	- 10 9 1 0 Sitt - 10 10 9 2 0 5 itt - -	+ 0 1 9 10 • B + 0 0 1 8 10 • B +	- 10 9 2 0 Site - Site - Site -	++ 0 0 1 8 10 e C ++ 0 0 0 1 1 8 10 0 0 1 1 8 0 0 1 1 8 10 0 1 1 8 10 0 1 1 8 10 10 10 10 10 10 10 10 10 10 10 10 10
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Trilidine(TLD) 0 25 375 450 Trilidine(TLD) 0 25 37.5 62.5 75 62.5 75 α-PVP Concentration (ng/mL) 0	per Site 10	- 10 10 9 1 0 Sitt - 10 10 8 2 0 Sitt - 10 10 8 2 0 - 10 10 10 - 10 - 10 - - - - - - - - - - - - -	+ 0 1 9 10 e A + 0 0 2 8 10 ite A	- 10 10 9 1 0 Sit - 10 10 9 2 0 Sit - 10 10 9 2 0 Sit - 10 10 9 2 0 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 e B + 0 0 1 8 10 e B	- 10 9 2 0 Site - 10 10 9 2 0 Site - 10 10 10 9 2 10 10 10 10 10 10 10 10 10 10	+ 0 0 1 8 10 e C + 0 0 1 1 8 8 10 0 0 1 1 8 8 0 0 0 0 0 0
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Tilidine(TLD) Concentration (ng/mL) 0 25 37.5 62.5 75 10 25 37.5 62.5 75 10 25 37.5 62.5 75 10 27	per Site 10 Site	- 10 10 9 1 0 Sitt - 10 10 10 8 2 0 - Sitt - - - - - - - - - - - - -	+ 0 1 9 10 e A + 0 0 2 8 10 tte A +	- 10 9 1 0 Sitt - 10 10 9 2 0 5 itt - -	+ 0 1 9 10 • B + 0 0 1 8 10 • B +	- 10 9 2 0 Site - Site - Site -	++ 0 0 1 8 10 e C ++ 0 0 0 1 1 8 10 0 0 1 1 8 0 0 1 1 8 10 0 1 1 8 10 0 1 1 8 10 10 10 10 10 10 10 10 10 10 10 10 10
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Trilidine(TLD) 0 25 375 450 Trilidine(TLD) 0 25 37.5 62.5 75 62.5 75 α-PVP Concentration (ng/mL) 0	per Site 10	- 10 10 9 1 0 Sitt - 10 10 8 2 0 Sitt - 10 10 8 2 0 - 10 10 10 - 10 - 10 - - - - - - - - - - - - -	+ 0 1 9 10 e A + 0 0 2 8 10 10 tte A + 0 0 2 8	- 10 10 9 1 0 Sit - 10 10 9 2 0 Sit - 10 10 9 2 0 Sit - 10 10 9 2 0 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 • B + 0 0 1 8 10 • B + 10	- 10 9 2 0 Site - 10 10 9 2 0 Site - 10 10 10 9 2 10 10 10 10 10 10 10 10 10 10	++ 0 0 1 1 8 10 0 0 0 1 1 8 10 0 0 1 1 8 0 0 0 1 1 8 0 0 0 0
Mitragynine Concentration (ng/mL) 0 150 225 375 450 filidine(TLD) Nortilidine Concentration (ng/mL) 0 25 37.5 62.5 75 alpha-Pyrrolidinovalerophenone (α-PV α-PVP Concentration (ng/mL) 0 1000 1500	per Site 10	- 10 10 9 1 0 Sitt - 10 10 8 2 0 - 10 10 8 - - 10 10 8 2 0 - - - - - - - - - - - - -	+ 0 1 9 10 e A + 0 0 2 8 10 tte A + 0 0 2 2 8 10 0 2 2	- 10 10 9 1 0 Sitt - 10 10 9 2 0 Sitt - 10 10 8	+ 0 1 9 10 e B + 0 0 1 8 10 e B + 0 0 2	- 10 9 2 0 - 10 10 9 2 0 Site - 10 10 9 2 0 - - 10 10 9 2 0 - - - - - - - - - - - - -	++ 0 0 1 8 10 + 0 0 0 1 8 10 0 0 1 0 0 0 1 0 0 0 1 1 8 0 0 0 0
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Tilidine(TLD) 0 25 37.5 62.5 75 1000 1000 1500	per Site 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 Sitt - 10 10 8 2 0 - 10 10 8 2 0 - 10 10 8 2 0 - - - - - - - - - - - - -	+ 0 1 9 10 e A + 0 0 2 8 10 tte A + 0 0 2 8 10 tte A 8 10 tte A 8 10 tte A 8 10 tte A 8 10 tte A 10 tte A 10 A 10 A A A A A A A A A A A A A A A	- 10 10 9 1 0 Sitt - 10 9 2 0 Sitt - 10 10 8 3	+ 0 0 1 9 9 10 e B + 0 0 1 8 10 e B + 0 0 2 7	- 10 10 9 2 0 - 10 10 9 2 0 Site - 10 10 9 2 0 - 10 10 9 2 10 10 10 9 2 10 10 10 9 10 10 10 10 10 10 10 10 10 10	++ 0 0 1 8 10 e C + + 0 0 0 1 1 8 10 - - - - - - - - - - - - -
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Trilidine(TLD) 0 25 37.5 62.5 75 62.5 75 62.5 1000 1000 1500 2,500 3,000	per Site 10	- 10 10 9 1 0 Sitt - 10 10 8 2 0 - 10 10 8 - - 10 10 8 2 0 - - - - - - - - - - - - -	+ 0 1 9 10 e A + 0 0 2 8 10 tte A + 0 0 2 2 8 10 0 2 2	- 10 10 9 1 0 Sitt - 10 10 9 2 0 Sitt - 10 10 8	+ 0 1 9 10 e B + 0 0 1 8 10 e B + 0 0 2	- 10 9 2 0 - 10 10 9 2 0 Site - 10 10 9 2 0 - - 10 10 9 2 0 - - - - - - - - - - - - -	++ 0 0 1 8 10 0 0 1 1 8 0 0 0 1 1 0 0 0 1 0 0 0 1 1 8 8 10 0 0 0
Mitragynine Concentration (ng/mL) 0 150 225 375 450 rilidine(TLD) 0 25 37.5 62.5 75 450 100 0 25 37.5 62.5 75 1000 1500 2,500 3,000 Alpha-Pyrrolidinovalerophenone (α-PV	per Site 10	- 10 10 9 1 0 5 5 10 10 10 10 8 2 0 5 5 10 10 10 8 2 0 5 5 1 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 • • • • • • • • • • • • • • • • • •	- 10 10 9 1 0 5it - 10 10 9 2 0 5it - 10 10 10 9 2 0 5it - - 10 10 9 2 0 0 - - - - - - - - - - - - -	+ 0 1 9 10 e B + 0 0 0 1 8 8 10 e B + 0 0 0 2 2 7 7	- 10 10 9 2 0 Site - 10 10 10 9 2 0 Site - 10 10 9 1 0	++ 0 0 1 8 10 0 0 0 1 1 8 0 0 0 1 1 8 0 0 0 1 1 9 9 10
Mitragynine Concentration (ng/mL) 0 150 225 375 450 filidine(TLD) 0 25 37.5 62.5 75 1pha-Pyrrolidinovalerophenone (α-PV 0 1500 2,500 3,000 4,500	per Site 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 5 5 10 10 10 10 8 2 0 5 5 10 10 10 8 2 0 5 5 1 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 e A + 0 0 2 8 10 tte A + 0 0 2 8 10 tte A 8 10 tte A 8 10 tte A 8 10 tte A 8 10 tte A 10 tte A 10 A 10 A A A A A A A A A A A A A A A	- 10 10 9 1 0 5it - 10 10 9 2 0 5it - 10 10 10 9 2 0 5it - - 10 10 9 2 0 0 - - - - - - - - - - - - -	+ 0 0 1 9 9 10 e B + 0 0 1 8 10 e B + 0 0 2 7	- 10 10 9 2 0 Site - 10 10 10 9 2 0 Site - 10 10 9 1 0	++ 0 0 1 8 10 0 0 0 1 1 8 0 0 0 0 1 9
Mitragynine Concentration (ng/mL) 0 150 225 375 450 Trilidine(TLD) 0 25 37.5 62.5 75 450 100 0 25 37.5 62.5 75 alpha-Pyrrolidinovalerophenone (α-PV 0 1000 1500 2,500 3,000	per Site 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 5 5 10 10 10 10 8 2 0 5 5 10 10 10 8 2 0 5 5 10 10 10 10 10 10 10 10 10 10	+ 0 1 9 10 • • • • • • • • • • • • • • • • • •	- 10 10 9 1 0 5it - 10 10 9 2 0 5it - 10 10 10 9 2 0 5it - - 10 10 9 2 0 0 - - - - - - - - - - - - -	+ 0 1 9 10 e B + 0 0 0 1 8 8 10 e B + 0 0 0 2 2 7 7	- 10 10 9 2 0 Site - 10 10 10 9 2 0 Site - 10 10 9 1 0	++ 0 0 1 8 10 0 0 0 1 1 8 0 0 0 1 1 8 0 0 0 1 1 9 9 10
Mitragynine Concentration (ng/mL) 0 150 225 375 450 filidine(TLD) 0 25 37.5 62.5 75 1pha-Pyrrolidinovalerophenone (α-PV 0 1500 2,500 3,000 4,500	per Site 10 10 10 10 10 10 10 10 10 10 10 10 10	- 10 10 9 1 0 Sitt 10 10 10 8 2 0 - 10 10 10 8 2 0 - 5 10 10 10 10 10 10 - 5 10 10 - 5 10 - 10 - - - - - - - - - - - - -	+ 0 1 9 10 e A + 0 0 2 8 10 te A + 0 0 2 8 10 te A + 10 te A 10 te A + 10 te A + 10 te A + 10 te A + 10 te A + 10 te A + 10 te A + 10 te A + 10 A + 10 A + 10 A A + 10 A + 10 A A + 10 A + A + 10 A + 10 A + 10 A A + 10 A A + 10 A A A A A A A A A A A A A A A A A A	- 10 10 9 1 0 Sitt - 10 10 9 2 0 Sitt - 10 10 8 3 0 Sitt S	+ 0 1 9 10 e B + 0 0 0 1 8 10 e B + 0 0 0 2 2 7 10 e B + + 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 10 10 9 2 0 Site - 10 10 9 2 0 Site - 10 10 9 1 0 10 9 1 0 Site Site - 10 5 10 9 1 0 Site - 10 5 10 9 1 0 Site - 10 5 1 0 9 1 0 Site - 10 5 1 0 9 1 0 Site - 1 0 Si	++ 0 0 1 8 10 0 0 1 1 8 0 0 1 1 8 0 0 0 1 1 8 0 0 0 1 1 8 0 0 0 1 1 8 8 0 0 0 0

	50				10		8		2	9		1	-	9	1	
	50 00			-+	10		2		8 10	3		7	_	1)	9 10	_
pha-Pyrrolidinovale		enor	ne (α-	PVP)	0		10		,	10		J	10	_
alpha-Pyrrolidin	ovale	rophe	enone		n			Site	A		Site			Site	С	
Concentrat		.g/mL	.)		per S		-	<u> </u>	+	-		+		-	+	_
	0 50				10		10		0	1	-	0	_	0	0	-
	75			-	10		8		2	8	-	2		9	1	-
	25				10		2	_	8	2		8	-	1	9	-
	50				10)	0		10	C)	10	()	10	
pha-Pyrrolidinovale	roph	enon	e (α-	PVP	1		1	Site		r –	0.1	_	1	0.1	_	1
a-PVP Cond	entra	ition (ng/m	L)		per Site	-	-	+ +	-	Site	в +	-	Site	+	
	0					10		10	+		0	+ 0	- 1	0	+	
	150					10	-	10	0	-	0	0	_	0	0	1
	225					10		7	3	1	8	2	ę	9	1	1
	375					10	_	2	8		1	9	1		9	
	450					10		0	10		0	10	()	10	1
					nalyt											
drug-free urine pool elow.	was	spike	ed wi	th dr	ugs a	t the	liste	d cor	ncentr	ation	s. Th	e res	sults	are s	umma	ari
	A	CE	A	MP	A	MP	A	MP	BA	٨R	BA	٨R	BZ	20	BZ	0
Drug Concentration Cut-off Range		000		000		00	3	00	30		20	00	50		30	-
	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+
0% Cut-off -50% Cut-off	30	0	30	0	30	0	30	0	30 30	0	30 30	0	30 30	0	30 30	(
-25% Cut-off	26	4	26	4	25	5	27	3	27	3	26	4	27	3	27	3
Cut-off	14	16	15	15	15	15	15	15	16	14	15	15	15	15	15	1
+25% Cut-off	3	27	3	27	3	27	4	26	4	26	3	27	4	26	3	2
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	3
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	3
		ZO		ZO		JP	Bl	JP	CC			C		C	CC	
Drug Concentration Cut-off Range	- 2	00 +	- 1	00 +	- 1	0	-	5 +	- 30)0 +	- 20	00 +	- 1	50 +	- 10	00
0% Cut-off	- 30	+	- 30	+	30	+	- 30	+	- 30	+	30	+	- 30	+	30	(
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	(
-25% Cut-off	27	3	27	3	26	4	26	4	26	4	26	4	27	3	27	••
Cut-off	16	14	14	16	14	16	14	16	13	17	14	16	16	14	16	1
+25% Cut-off	3	27	3	27	3	27	3	27	3	27	3	27	4	26	4	2
+50% Cut-off +300% Cut-off	0	30 30	0	30 30	0	30 30	0	30 30	0	30 30	0	30 30	0	30 30	0	3
100070 Out-On	0	50	0	50		50		50		00	5	00	5	00	5	
Drug Concentration		HC 50		HC 50		HC 25		TD	M 20		M	ET 000	M	ET 00	ME 30	T
Cut-off Range	-	50 +	-	+	-	5 +	-	+	- 20	+	-	+	-)0 +	- 3	
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	(
-25% Cut-off	27	3	26	4	27	3	26	4	25	5	27	3	27	3	27	:
Cut-off +25% Cut-off	15 4	15	14 3	16	15 4	15	14	16	15 4	15	16 3	14	16 4	14	15	1
+25% Cut-off +50% Cut-off	4	26 30	3	27 30	4	26 30	3 0	27 30	4	26 30	3	27 30	4	26 30	3	2
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	3
•	-	·		•												<u> </u>
Drug Concentration	MDI		MD		MC OI		MC O		0			CP		CP	Р	P
Cut-off Range	1,0		50	JU	30	00		0	20	υU	5	0	2	25		-
00/ 014 -#	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	L
0% Cut-off -50% Cut-off	30 30	0	30 30	0	30 30	0	30 30	0	30 30	0	30 30	0	30 30	0	30 30	╀
-25% Cut-off	26	4	25	5	27	3	26	4	27	3	26	4	25	5	26	t
Cut-off	15	15	14	16	15	15	15	15	14	16	15	15	15	15	15	
+25% Cut-off	5	25	4	26	5	25	3	27	4	26	3	27	3	27	3	
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	
		ML		ML		ИL		ET	K		K			T	M	יר
Drug Concentration Cut-off Range		00	_	00		00		000	50		30			00	IVIC	
0% Cut-off	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+	- 30	•
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	
-25% Cut-off	27	3	27	3	27	3	27	3	27	3	26	4	27	3	26	
	15	15	15	15	15	15	15	15	15	15	16	14	15	15	15	1
Cut-off											r .		~	07		2
+25% Cut-off	4	26	4	26	3	27	3	27	4	26	4	26	3	27	4	_
		26 30 30	4 0 0	26 30 30	3 0 0	27 30 30	3 0 0	27 30 30	4 0 0	26 30 30	4 0 0	26 30 30	3 0 0	30 30	4 0 0	3

Drug Concentrat Cut-off Range			00		OX 30())		OT 00		COT 100	E	EDD 300		EDD 10			FYL 20		FYI 10	
0% Cut-off	, 	- 30	+	3	-	+	- 30	+	- 30	+	·) :	30	+	- 30	+	- 3	_	+	- 30	+
-50% Cut-off		30	0	_	0	0	30	0	30	_	_	30	0	30	0	3	_	0	30	0
-25% Cut-off		27	3	_	7	3	27	3	2	_	_	27	3	26	4	2	_	3	27	3
Cut-off +25% Cut-off		15 4	15	_	5 4	15 26	15 4	15 26	14	_	6 [·]	15 4	15 26	15 3	15 27		_	16 26	15 3	15 27
+50% Cut-off		4	30	_	_	20 30	4	30	4	_	0	4 0	30	0	30	_	_	20 30	0	30
+300% Cut-of	f	0	30) (5	30	0	30	0	3	0	0	30	0	30	0	5	30	0	30
Drug	К	2	К	2	6-1	1AM	M	DA	E.	TF	ET	G	ET	G	CI	LO		LO	1 13	SD
Drug Concentration	5		3			0		00		00	50		100			00		50		20
Cut-off Range	- 30	+	- 30	+	- 30	+	-	+	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+	- 30	+
	30 30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	-	30	0
	27	3	27	3	27	3	26	4	25	5	26	4	26	4	26	4	26	-	27	3
	15	15	16	14	15	15	15	15	16	14	15	15	15	15	14	16	14		14	16
	3	27	4	26	4	26	3	27	4	26	3	27		27	5	25	5	25	3	27
	0 0	30 30	0	30 30	0	30 30	-	30 30	0	30 30	0	30 30	0	30 30	0	30 30	0	30	_	30 30
100070 Out on	0	00	U	00	Ū	00	Ū	00	Ŭ	00	v						Ŭ	00	Ŭ	00
Drug Concentratio Cut-off Range	on	LSE 50)	MP	D	z	OL		DMA 300		THC 200		VOP/ OPI 200		ME 500			EP 00		DPV 000
00/ 0-+#			+	-	+	-	+	-	+	-	+					+	-	+	-	+
0% Cut-off -50% Cut-off	_	_	_	30 29	0	30 30	0	30		30	-	3		-	_	0	30 30	0	30 30	0
-25% Cut-off	_	_	3	*	*	26	4	25		26	_	2	_	-	_	3	24	6	26	4
Cut-off				15	15	14	16	15		_	-		-		-	15	17	13	14	16
+25% Cut-off	_	-	27	*	*	5	25	3	27	4	26	_		_	_	26	4	26	3	27
+50% Cut-off +300% Cut-off	_		30 30	1 0	29 30	0	30 30	_	30 30	-	30			_		30 30	0	30 30	0	30 30
+300 % Cut-on			0	0	50	0	50	0	50	0	50	, 0	, 00		, ,	50	0	50	U	50
Drug Concentratio Cut-off Range	n	MDF 500			00		DI/ 200		T⊦ 30		1	THC 30		K2 25		-	ZOF 50		/CA1	
0% Cut-off	_	- 30	+	- 30	+	-	- 30	+	- 30	+	- 30	_	+	- 30	+	- 3	0	+	- 30	+
-50% Cut-off		30	0	30	0		29	1	30	0	30	_	•	30	0	3		0	30	0
-25% Cut-off	_	25	5	27	3	_	27	3	27	3	20	_		25	5	2	_	3	28	2
Cut-off		15	15	15	15	_	5	15	14	16	14	_		14	16	1	_	13	17	13
+25% Cut-off +50% Cut-off	_	3 0	27 30	3	27	_		27 29	4	26 30	4			3 0	27 30	4		26 30	3	27 30
+300% Cut-off	+	0	30	0	30			29 30	0	30	0			0	30	0		30	0	30
							<u> </u>					_								
Drug Concentration		ACL		ACL 200	-	7-A 10			=YL 00		CAF 000		CAT 150			RO 50	A	٨LP		PVP 100
Cut-off Range	-	+	-	+		-	+	•	+	-	+			F	-	+	-	+	-	+
	30	0	30	0		30	0	30	_	30	_	_		_	30	0	30	_	30	0
	30 26	0	30 27	0		29 27	1	30 25	0	30	0				30 27	0	30		30 26	0
	14	16	14	10	_	13	17	14	_	-	13	_		_	27 15	15	17	_	_	15
+25% Cut-off	5	25	3	2	_	4	26	6	24	-	25	_		_	3	27	3	-	-	17
+50% Cut-off	0	30	0	30	_	1	29	0	30	-	30	_		0	0	30	0	-	-	30
+300% Cut-off	0	30	0	30	J	0	30	0	30	0	30) (3	0	0	30	0	30	0	30
Drug		-YL 300		FYL 100		CC 30		TC 10			CA 00		CA 600		DPI 000		TH 20		C/ 20	
Concentration Cut-off Range	-	+	-	100	+	-	+	-	+	-	+	-	+	-	1	+	-	+	-	+
0% Cut-off	30		30			30	0	30	0	30	0	30	0	30	_	0	30	0	30	0
-50% Cut-off	30		30			30	0	30	0	30	0	30	0	30		0	30	0	30	0
-25% Cut-off Cut-off	27 17	_	26	_		25 15	5 15	25 15	5 15	26 14	4 16	27 14	3 16	2	_	3 16	27 14	3 16	28 16	2 14
+25% Cut-off	4	26	_	2	_	4	26	4	26	3	27	3	27	4	_	26	2	28	3	27
+50% Cut-off	0	30	_	3	_	0	30	0	30	0	30	0	30	0) (30	0	30	0	30
+300% Cut-off	0	30	0	3	0	0	30	0	30	0	30	0	30	0)	30	0	30	0	30
Drug Concentration Cut-off Range		1PD 150		PGB 0,00		PG 50		G/ 20	00		ZD 00		NB 500		200 200		Z/ 10	00		RD 00
-	- 30	+	- 30		+	- 30	+	- 30	+	- 30	+	- 30	+	-	_	+	-	+	- 30	+
0% Cut-off -50% Cut-off	30	-	30	_		30 30	0	30	0	30	0	30			-	0	30 30	0	30	0
-25% Cut-off	26	_	25			25	5	28	2	28	2	27		-		3	27	3	27	3
Cut-off	15	15	15	i 1	5	15	15	16	14	14	16	14	1 16	5 1-	4	16	15	15	15	15
+25% Cut-off	5	25	5	2	_	6	24	3	27	3	27	4	-		_	25	3	27	3	27
+50% Cut-off +300% Cut-off	0	30 30	_	3	_	0	30 30	0	30 30	0	30 30	_	_	_	_	30 30	0	30 30	0	30 30
			1 0		~	-	~~	v	- 55	, v			00	1			2	55	, v	00

_			0.7	-	-	~								5						
Drug Concentration Cut-off Range	AE	10	Q1 10	Р 100	FL 50			-144 25	KF 30	00	TL 5	0	LS 1	0		9VP 100		VP 00	α-F 3(00
-	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	25	5	29	1	29	1	28	2	28	2	29	1	27	3	26	4	27	3	27	3
Cut-off	15	15	15	15	15	15	15	15	14	16	15	15	14	16	15	15	15	15	15	15
+25% Cut-off	4	26	1	29	2	28	3	27	1	29	1	29	3	27	3	27	3	27	4	26
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
The following table the Multi-Drug Rapi	lists id Te	s the est C	conc	entratte a	ation It 5 r	s of	con		Spec inds			hat a	are d	etec	ted a	as po	ositiv	e in	urine	e by
Analytes					cor (ng	/mL	.) 'AM		naly PHE									onc. g/ml	_)	
Acetaminophen					5,0	00			E (AN		í	0								_
D,L-Amphetamine	sulfa	ate			300		-17		hente			<u> </u>					1.0	000		
L-Amphetamine					25,	000			apro									,000		
(±) 3,4-Methylenedi	ioxy				500	1			etho									000		
amphetamine									-Amp			е					1,1	000		
	21.12						ETA		IE (A								150	0		
D,L-Amphetamine : L-Amphetamine	sulfa	1e			150) 500			hente apro								50 25	00 5,000		
L-Ampnetamine (±) 3,4-Methylenedi	ίοχν								apro etho:			mine					20	000 000		
amphetamine	y				250)			-Amp								50			
		_	_	_	AN	/PH	ETA	MIN	IE (Å	MP	300)			_						
D,L-Amphetamine	sulfa	ate			75			Ρ	hente	ermir	ne						30			
L-Amphetamine	_				10,	000			apro								15	,000)	
(±) 3,4-Methylenedi	юху				150)			etho:									000		
amphetamine					BA	PR	THE		-Amp ES (E								30	U		
Amobarbital					5,0		101		pher		500	/					60	0		_
5,5-Diphenylhydant	toin				8,0				proba		al						50			
Allobarbital					600				utaba								20			
Barbital					8,0				utalb									000		
Talbutal					200				uteth								50			
Cyclopentobarbital Pentobarbital					30,	000			heno ecob								30			
rentobarbitai							TUF		ES (E)					00	0		_
Amobarbital					3,0				pher			·					40	0		
5,5-Diphenylhydant	toin				5,0	00		A	proba	arbita	al						30			
Allobarbital					400				utaba		al						15			
Barbital Talbutal					5,0 150				utalb								5,	000		
Cyclopentobarbital						, 000			uteth heno		ital						20			
Pentobarbital					5,0				ecob								20			
					BEN	zor	DIAZ		NES			0)								
Alprazolam					200				roma									500		
a-hydroxyalprazola	m				2,5				hlord			de						500		
Clobazam					300 800				itraze orchl			ovid					30 20			
Clonazepam Clorazepatedipotas	siur	n			800				ordia			UXIU	,					500		_
Delorazepam					1,5				xaze								50			
Desalkylflurazeparr	۱				300)		Te	emaz	zepa							30	0		
Flunitrazepam					300				iazep								50			
(±) Lorazepam		aid-			5,0				stazo									,000		
RS-Lorazepamgluc Midazolam	uror	nde			300) 000		-11	riazo	dII)							р,	000		_
							DIAZ	EPI	NES	(BZ	0 30	0)					-1			
Alprazolam		_	_		100		_		roma			.,		_			90	0		
a-hydroxyalprazola	m				1,5	00		С	hlord	iaze	poxi	de					90	0		
Clobazam					200				itraze								20			
Clonazepam		2			500				orchl			oxid	Э				10			
Clorazepatedipotas Delorazepam	SIU	11			500 900			0	ordia xaze		a111						90 30			
Delorazeparn Desalkylflurazeparr	ı				200				xaze emaz		m						10			
Flunitrazepam			_		200)			iazep			_				_	30		_	
(±) Lorazepam					3,0				stazo									000		
RS-Lorazepamgluc	uror	nide			200			Ti	riazo	lam							3,	000		
Midazolam					6,0		2010	'ED''	NES	(P7)	0.20	0)					1			
Alprazolam					70	201	JIAZ		roma			5)					60	0		
a-hydroxyalprazola	m				1,0	00			hlord			de					60			
Clobazam					120)		N	itraze	epan	ì						12	20		
Clonazepam		_		_	300			N	orchl	ordia	azep	oxid	•				70			
Clorazepatedipotas	siur	n			300				ordia								60			
Delorazepam					600				xaze								20			
Desalkylflurazeparr Flunitrazepam					120				emaz iazep		111						70 20			_
(±) Lorazepam					2,0				staze									000		_
RS-Lorazepamgluc	uror	nide			120				riazo									000		
Midazolam				_	4,0	00					_									
		_		_	BEN	zor	DIAZ		NES			0)		_						
Alprazolam					40	,			roma			-					30			
a-hydroxyalprazola	111				500	,		U	hlord	iazê	μυχι	ue					30	U		

Clobazam	60	Nitrazepam	60
Clonazepam	150	Norchlordiazepoxide	40
Clorazepatedipotassium	150	Nordiazepam	300
Delorazepam	300	Oxazepam	100
Desalkylflurazepam	60	Temazepam	40
Flunitrazepam	60	Diazepam	100
±) Lorazepam	1,000	Estazolam	2,000
RS-Lorazepamglucuronide	60	Triazolam	1,000
Vidazolam	2,000		
		PHINE (BUP 10)	
Buprenorphine	10	Norbuprenorphine	50
Buprenorphine 3-D-Glucuronide	50	Norbuprenorphine 3-D-Glucuronide	100
	BUPRENOR	PHINE (BUP 5)	
Buprenorphine	5	Norbuprenorphine	25
Buprenorphine 3-D-Glucuronide	25	Norbuprenorphine 3-D-Glucuronide	50
	COCAIN	E (COC 300)	
Benzoylecgonine	300	Cocaethylene	20,000
Cocaine HCI	200	Ecgonine	30,000
		E (COC 200)	
Benzoylecgonine	200	Cocaethylene	13,500
Cocaine HCI	135	Ecgonine	20,000
	COCAIN	É (COC 150)	
Benzoylecgonine	150	Cocaethylene	1,0000
Cocaine HCI	120	Ecgonine	15,000
		E (COC 100)	
Benzoylecgonine	100	Cocaethylene	7,000
Cocaine HCI	80	Ecgonine	10,000
		NA (THC300)	
Cannabinol	200,000	∆8-THC	100,000
11-nor-∆8-THC-9 COOH	200	∆9-THC	100,000
11-nor-∆9-THC-9 COOH	300		
		NA (THC200)	
Connahinal		<u> </u>	69.000
Cannabinol	140,000	∆8-THC	68,000
11-nor-∆8-THC-9 COOH	120	∆9-THC	68,000
11-nor-∆9-THC-9 COOH	200		
		NA (THC150)	
Cannabinol	100,000	∆8-THC	50,000
11-nor-∆8-THC-9 COOH	100	∆9-THC	50,000
11-nor-∆9-THC-9 COOH	150		
	MARIJUA	NA (THC50)	
Cannabinol	35,000	∆8-THC	17,000
11-nor-∆8-THC-9 COOH	30	∆9-THC	17,000
11-nor-∆9-THC-9 COOH	50		
	MARIJUA	NA (THC30)	
Cannabinol	20,000	∆8-THC	10,000
11-nor-∆8-THC-9 COOH	20	∆9-THC	10,000
11-nor-∆9-THC-9 COOH	30		
		NA (THC25)	
Cannabinol	17,500	∆8-THC	8,500
11-nor-∆8-THC-9 COOH	15	∆9-THC	8,500
11-nor-∆9-THC-9 COOH	25	20 1110	0,000
		NA (THC20)	
Cannabinol	14,000	∆8-THC	6,800
	14,000	∆9-THC	6,800
11-nor-∆8-THC-9 COOH		A9-THC	0,000
11-nor-∆9-THC-9 COOH	20		
		ONE (MTD300)	
Methadone	300	Doxylamine	100,000
		DNE (MTD200)	05.000
Methadone	200	Doxylamine	65,000
		AMINE (MET1, 000)	
p-Hydroxymethamphetamine	25,000	(±)-3,4-Methylenedioxy-	12,500
D-Methamphetamine	1,000	methamphetamine	
L-Methamphetamine	20,000	Mephentermine	50,000
	METHAMPHE	TAMINE (MET500)	
p-Hydroxymethamphetamine	12,500	(±)-3,4-Methylenedioxy-	6,250
D-Methamphetamine	500	methamphetamine	1
-Methamphetamine	10,000	Mephentermine	25,000
		TAMINE (MET300)	
-Hydroxymethamphetamine	7,500	(±)-3,4-Methylenedioxy-	3,750
D-Methamphetamine	300	methamphetamine	5,
L-Methamphetamine	6,000	Mephentermine	15,000
		HETAMINE (MDMA1, 000) Ecstasy	.0,000
(±) 3,4-Methylenedioxy			1
		3,4-Methylenedioxyethyl-amphetamine	e600
methamphetamine HCI	1,000		1
±) 3,4-Methylenedioxyampheta	1,000 6,000		
±) 3,4-Methylenedioxyampheta mine HCl	6,000		
±) 3,4-Methylenedioxyampheta nine HCl METHYLENEDI	6,000	PHETAMINE (MDMA500) Ecstasy	
±) 3,4-Methylenedioxyampheta nine HCl METHYLENEDI ±) 3,4-Methylenedioxy	6,000		e 300
±) 3,4-Methylenedioxyampheta nine HCl METHYLENEDI ±) 3,4-Methylenedioxy nethamphetamine HCl	6,000 ОХҮМЕТНАМ І	HETAMINE (MDMA500) Ecstasy 3,4-Methylenedioxyethyl-amphetamine	e 300
t) 3,4-Methylenedioxyampheta mine HCl <u>METHYLENEDI</u> t) 3,4-Methylenedioxy methamphetamine HCl t) 3,4-Methylenedioxyampheta	6,000 OXYMETHAMI 500		∍300
(±) 3,4-Methylenedioxyampheta mine HCl (±) 3,4-Methylenedioxy methamphetamine HCl (±) 3,4-Methylenedioxyampheta mine HCl	6,000 OXYMETHAMI 500 3,000	3,4-Methylenedioxyethyl-amphetamine	∍300
	6,000 OXYMETHAMI 500 3,000		9300
	6,000 DXYMETHAMI 500 3,000 DXYMETHAMI	3,4-Methylenedioxyethyl-amphetamine HETAMINE (MDMA300) Ecstasy	
 2) 3.4-Methylenedioxyampheta mine HCI METHYLENEDI 2) 3.4-Methylenedioxy enthamphetamine HCI 2) 3.4-Methylenedioxyampheta mine HCI METHYLENEDI 2) 3.4-Methylenedioxy nethamphetamine HCI 	6,000 OXYMETHAMI 500 3,000	3,4-Methylenedioxyethyl-amphetamine	
 2) 3.4-Methylenedioxyampheta mine HCI METHYLENEDI 2) 3.4-Methylenedioxy enthamphetamine HCI 2) 3.4-Methylenedioxyampheta mine HCI METHYLENEDI 2) 3.4-Methylenedioxy nethamphetamine HCI 	6,000 DXYMETHAMI 500 3,000 DXYMETHAMI 300	3,4-Methylenedioxyethyl-amphetamine HETAMINE (MDMA300) Ecstasy	
	6,000 DXYMETHAMI 500 3,000 DXYMETHAMI 300 1,800	3,4-Methylenedioxyethyl-amphetamine HETAMINE (MDMA300) Ecstasy 3,4-Methylenedioxyethyl-amphetamine	
t) 3.4-Methylenedioxyampheta mine HCl METHYLENEDI t) 3.4-Methylenedioxy methamphetamine HCl ±) 3.4-Methylenedioxyampheta mine HCl METHYLENEDI t) 3.4-Methylenedioxy methamphetamine HCl ±) 3.4-Methylenedioxyampheta mine HCl	6,000 DXYMETHAMI 500 3,000 DXYMETHAMI 300 1,800	3,4-Methylenedioxyethyl-amphetamine HETAMINE (MDMA300) Ecstasy 3,4-Methylenedioxyethyl-amphetamine (MOP/OPI 300)	
	6,000 DXYMETHAMI 500 3,000 DXYMETHAMI 300 1,800 MORPHINE 200	3,4-Methylenedioxyethyl-amphetamine HETAMINE (MDMA300) Ecstasy 3,4-Methylenedioxyethyl-amphetamine	
(±) 3,4-Methylenedioxy methamphetamine HCI (±) 3,4-Methylenedioxyampheta mine HCI	6,000 DXYMETHAMI 500 3,000 DXYMETHAMI 300 1,800 MORPHINE	3,4-Methylenedioxyethyl-amphetamine HETAMINE (MDMA300) Ecstasy 3,4-Methylenedioxyethyl-amphetamine (MOP/OPI 300)	ə 180

Ethylmorphine	6,000	Oxymorphone	50,000
lydrocodone	50,000	Procaine	15,000
lydromorphone	3,000	Thebaine	6,000 300
-Monoacethylmorphine		Morphine (MOP/OPI 200)	300
Codeine	160	Norcodeine	4,000
evorphanol	1,000	Normorphone	40,000
Morphine-3-β-D-Glucuronide	600	Oxycodone	20.000
Ethylmorphine	4,000	Oxymorphone	40,000
Hydrocodone	40,000	Procaine	10,000
lydromorphone	2,000	Thebaine	4,000
5-Monoacethylmorphine	200	Morphine	200
		(MOP/OPI 100)	
Codeine	80	Norcodeine	2,000
_evorphanol	500	Normorphone	20,000
Morphine-3-β-D-Glucuronide Ethylmorphine	300 2,000	Oxycodone Oxymorphone	10,000 20,000
Hydrocodone	20,000	Procaine	5,000
Hydromorphone	1,000	Thebaine	2,000
6-Monoacethylmorphine	200	Morphine	100
		ONE (MQL 300)	
Vlethaqualone	300		
•	MORPHINE/OF	PIATE (OPI 2,000)	
Codeine	2,000	Morphine	2,000
Ethylmorphine	3,000	Norcodeine	25,000
Hydrocodone	50,000	Normorphone	50,000
Hydromorphone	15,000	Oxycodone	25,000
_evorphanol	25,000	Oxymorphone	25,000
6-Monoacetylmorphine Morphine 3-β-D-glucuronide	3,000 2,000	Procaine	50,000 25,000
viorphine 3-p-o-glucuroniae		Thebaine PIATE (OPI 1,000)	20,000
Codeine	1,000	Morphine	1,000
Ethylmorphine	1,500	Norcodeine	12,500
Hydrocodone	25,000	Normorphone	25,000
Hydromorphone	7,500	Oxycodone	12,500
Levorphanol	12,500	Oxymorphone	12,500
6-Monoacetylmorphine	1,500	Procaine	25,000
Morphine 3-β-D-glucuronide	1,000	Thebaine	12,500
		NE(MPRD100)	
Normeperidine		Meperidine	100
	PHENCYCI	IDINE (PCP 50)	
Dhanavalidina			0E 000
Phencyclidine	50	4-Hydroxyphencyclidine	25,000
Phencyclidine	50 PHENCYCLI 25 PROPOXY	4-Hydroxyphencyclidine DINE (PCP 25) 4-Hydroxyphencyclidine PHENE (PPX)	12,500
Phencyclidine D-Propoxyphene TRIC	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDER	4-Hydroxyphencyclidine DINE (PCP 25) 4-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene PRESSANTS (TCA1000)	12,500 300
Phencyclidine D-Propoxyphene TRIC Nortriptyline	50 PHENCYCLI 25 PROPOXY 300	4-Hydroxyphencyclidine DINE (PCP 25) 4-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene	12,500
Phencyclidine D-Propoxyphene TRIC Nortriptyline Nordoxepine	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000	4-Hydroxyphencyclidine DINE (PCP 25) 4-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene PRESSANTS (TCA1000) [mipramine	12,500 300 400
Phencyclidine Phencyclidine D-Propoxyphene TRIC Nordoxxepine Trimipramine Amitriptyline	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500	4-Hydroxyphencyclidine DINE (PCP 25) 4-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene PRESSANTS (TCA1000) Imipramine Clomipramine	12,500 300 400 50,000
Phencyclidine D-Propoxyphene TRIC Nortriptyline Vordoxepine Trimipramine Amitriptyline Promazine Promazine	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 1,500 3,000	4-Hydroxyphencyclidine DINE (PCP 25) 4-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine	12,500 300 400 50,000 2,000 2,000 50,000
Phencyclidine D-Propoxyphene TRIC Nortriptyline Trinipramine Amitriptyline Promazine Designamine	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 1,500 3,000 200	4-Hydroxyphencyclidine DINE (PCP 25) 4-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene PRESSANTS (TCA100) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine	12,500 300 400 50,000 2,000 2,000 50,000 50,000
Phencyclidine Phencyclidine TRIC O-Propoxyphene TRIC Vordrxepine Trimipramine Amitriptyline Promazine Desipramine Dyclobenzaprine	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 1,500 3,000 200 2,000	4-Hydroxyphencyclidine DINE (PCP 25) H-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden	12,500 300 400 50,000 2,000 2,000 50,000
D-Propoxyphene D-Propoxyphene Nortriptyline Nordxepine Tmipramine Amitriptyline Promazine Desipramine Dyclobenzaprine TRIC	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 3,000 200 2,000 CYCLIC ANTIDE CYCLIC ANTIDE	4-Hydroxyphencyclidine DINE (PCP 25) OINE (PCP 25) PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PESSANTS (TCA500)	12,500 300 400 50,000 2,000 2,000 50,000 50,000 10,000
Phencyclidine D-Propoxyphene TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Promazine Desipramine Cyclobenzaprine TRIC Vortriptyline TRIC	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 1,500 2,000 2,000 2,000 CYCLIC ANTIDE 500	4-Hydroxyphencyclidine DINE (PCP 25) 4-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene PRESSANTS (TCA100) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine	12,500 300 400 50,000 2,000 2,000 50,000 50,000 10,000 200
Phencyclidine Phencyclidine TRIC O-Propoxyphene TRIC Vordriptyline Trimipramine Trimipramine Promazine Desipramine Dyclobenzaprine TRIC Vortriptyline Vordrxepine Vordsxepine	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 200 2,000 CYCLIC ANTIDE 500 250	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine	12,500 300 50,000 2,000 2,000 50,000 50,000 10,000 10,000 200 25,000
D-Propoxyphene D-Propoxyphene TRIC Nortriptyline Nordoxepine Amitriptyline Promazine Desipramine Cyclobenzaprine Dyclobenzaprine TRIC Nortriptyline Nordoxepine Trimipramine	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) PHENE (PPX) D-Norpropoxyphene PRESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Clomipramine Doxepine	12,500 300 400 50,000 2,000 2,000 50,000 50,000 10,000 200 250,000 1,000
Phencyclidine Phencyclidine TRIC Orbopoxyphene TRIC Nordriptyline Arnitriptyline Promazine Desipramine Cyclobenzaprine TRIC Nordriptyline Nordoxepine Trimipramine Arnitriptyline Nordixepine Trimipramine Arnitriptyline	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 1,500 3,000 200 2,000 CYCLIC ANTIDE 500 250 1,500 750	4-Hydroxyphencyclidine DINE (PCP 25) H-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline	12,500 300 400 50,000 2,000 2,000 50,000 10,000 25,000 25,000 1,000 1,000
Phencyclidine Phencyclidine TRIC O-Propoxyphene TRIC Vordxepine Trimipramine Amitriptyline Promazine Desipramine Dyclobenzaprine TRIC Vortriptyline Vordoxepine Trimipramine Amitriptyline Promazine	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) PHENE (PPX) D-Norpropoxyphene PRESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Clomipramine Doxepine	12,500 300 400 50,000 2,000 2,000 50,000 50,000 10,000 200 250,000 1,000
Phencyclidine Phencyclidine TRIC O-Propoxyphene TRIC Vordriptyline Vordoxepine Trimipramine Amitriptyline Promazine Desipramine Vordoxepine Trimipramine Amitriptyline Promazine Promazine Promazine Promazine Pesipramine Syclobenzaprine Voclobenzaprine Promazine Pesipramine Voclobenzaprine	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 200 2,000 CYCLIC ANTIDE 500 250 1,500 750 1,500 1,00	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden Doxepine Maprotiline PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Pormethazine Pormethazine Pormethazine Doxepine Maprotiline	12,500 300 400 50,000 2,000 2,000 50,000 10,000 200 25,000 1,000 1,000 1,000 25,000
2-Propoxyphene 3-Propoxyphene TRIC Vortriptyline Vordoxepine Trimipramine Amitriptyline Promazine Desipramine TRIC Vordoxepine Trimipramine Amitriptyline Promazine Desipramine Desipramine Zyclobenzaprine Zyclobenzaprine TRIC	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500 7,50 1,500 1,500 1,500 2,50 1,500 2,50 1,500 2,50 1,500 2,50 1,500 2,50 1,500 2,50 1,500 2,50 1,500 2,50 1,500 2,50 2,50 1,500 2,50	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Ilmipramine Clomipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Ilmipramine Clomipramine Doxepine Maprotiline Poromethazine Perphenazine Perphenazine Perphenazine Perphenazine Perphenazine Perphenazine	12,500 300 400 50,000 2,000 2,000 50,000 50,000 10,000 25,000 1,000 1,000 1,000 1,000 25,000 5,000 5,000
Phencyclidine P-Propoxyphene TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Yromazine Designamine Cyclobenzaprine TRIK Vortriptyline Amitriptyline Promazine Designamine Amitriptyline Yromazine Designamine Cyclobenzaprine TRIK Vortriptyline TRIK Vortriptyline TRIK Vortriptyline	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 200 200 200 200 200 200 200	4-Hydroxyphencyclidine DINE (PCP 25) 4-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene PRESSANTS (TCA100) Ilmipramine Clomipramine Clomipramine Doxepine Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine	12,500 300 400 50,000 2,000 2,000 50,000 10,000 200 25,000 1,0
Phencyclidine Phencyclidine D-Propoxyphene TRIC Vortriptyline Vordoxepine Trimipramine Amitriptyline Promazine Desipramine Cyclobenzaprine TRIC Vortriptyline Vordoxepine Trimipramine Pomazine Desipramine Cyclobenzaprine TRIC Vortriptyline Vordoxepine TRIC Vortriptyline Vortriptyline Vordoxepine TRIC Vordoxepine TRIC	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500 750 1,500 1,500 1,500 1,500 250 1,50	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Comipramine Clomipramine Clomipramine Clomipramine	12,500 300 400 50,000 2,000 2,000 50,000 10,000 25,000 1,000 1,000 25,000 1,000 25,000 1,000 25,000 1,000 25,000 1,000 25,000 1,000 25,000 1,000 25,000 1
D-Propoxyphene TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Promazine Desipramine Vyclobenzaprine TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Vordxepine Trimipramine Amitriptyline Vyclobenzaprine Vyclobenzaprine TRIC Vortriptyline Vyclobenzaprine TRIC Vortriptyline Vordxepine TRIC Vortriptyline Vordxepine TRIC Vortriptyline Vordxepine TRIC Vortriptyline Vordxepine TRIC Vordxepine T	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Perphenazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Clomipramine Clomipramine Clomipramine Clomipramine Clomipramine Clomipramine Clomipramine	12,500 300 400 50,000 2,000 2,000 50,000 50,000 10,000 200 25,000 1,
Phencyclidine Phencyclidine Phencyclidine Phencyclidine Nordxepine TRIC Nordxepine Amitriptyline Promazine Desipramine Cyclobenzaprine TRIC Nordriptyline Nordxepine Primipramine Amitriptyline TRIC Nortriptyline TRIC Nordxepine TRIC Nordxe	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,00	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Dithiaden Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Clomipramine Doxepine Maprotiline	12,500 300 400 50,000 2,000 2,000 50,000 10,000 10,000 10,000 10,000 1,000 1,000 1,000 25,000 5,000 1,000
Phencyclidine Phencyclidine Phencyclidine Phencyclidine Nordxepine TRIC Nordxepine Amitriptyline Promazine Desipramine Cyclobenzaprine TRIC Nordriptyline Nordxepine Primipramine Amitriptyline TRIC Nortriptyline TRIC Nordxepine TRIC Nordxe	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Pormethazine Perphenazine Doxepine Maprotiline PRESSANTS (TCA300) Imipramine Clomi	12,500 300 400 50,000 2,000 2,000 50,000 50,000 10,000 200 25,000 1,
Phencyclidine Phencyclidine Poropoxyphene TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Promazine Desipramine Vyclobenzaprine TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Promazine Desipramine Vyclobenzaprine Vyclobenzaprine TRIC Vortriptyline Vyclobenzaprine TRIC Vortriptyline Vyclobenzaprine TRIC Vortriptyline Promazine	50 PHENCYCLI 25 PROPOXY 300 500 500 500 3,000 200 2,000 200 2,000 200 2,000 200 2	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphencyclidine PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Promethazine Promethazine Perphenazine	12,500 300 400 50,000 2,000 2,000 50,000 50,000 50,000 50,000 200 25,000 1,000 1,000 1,000 5,000 5,000 120 15,000 600 600 600 15,000
Phencyclidine Phencyclidine Poropoxyphene TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Promazine Desipramine Vyclobenzaprine TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Promazine Desipramine Vyclobenzaprine Vyclobenzaprine TRIC Vortriptyline Vyclobenzaprine TRIC Vortriptyline Vyclobenzaprine TRIC Vortriptyline Promazine	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500 750 1,500 2,000 2,	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Promethazine Promethazine Promethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Pormethazine Doxepine Maprotiline Promethazine Pormethazine Doxepine Maprotiline Promethazine Pormethazine Doxepine Maprotiline Pormethazine Doxepine Maprotiline Pormethazine Doxep	12,500 300 400 50,000 2,000 2,000 50,000 10,000 10,000 10,000 10,000 1,000 1,000 1,000 25,000 5,000 1,000
Phencyclidine Phencyclidine Phencyclidine TRIC Nortriptyline Nordoxepine Trimipramine Amitriptyline Promazine Desipramine TRIC Nortriptyline TRIC Syclobenzaprine TRIC Nortriptyline TRIC Syclobenzaprine TRIC Syclobenzaprine TRIC Syclobenzaprine Desipramine TRIC Syclobenzaprine Desipramine Desipramine Desipramine TRIC Syclobenzaprine Desipramine Desipramine Desipramine TRIC Syclobenzaprine Desipramine Syclobenzaprine Desipramine TRIC Syclobenzaprine TRIC Syclobenzaprine TRIC TRIC TRIC TRIC TRIC TRIC TRIC TRIC	50 PHENCYCLI 25 PROPOXY 300 CYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500 750 1,500 2,000 2,	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Dithiaden Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Dithiaden Promethazine Perphenazine Dithiaden Dithiaden Promethazine Pomethazine Pomptenazine Dithiaden Dithiaden Dithiaden Promethazine Pomptenazine Dithiaden Dithiaden Dithiaden Dithiaden	12,500 300 400 50,000 2,000 2,000 50,000 10,000 200 25,000 1,0
2-Propoxyphene 3-Propoxyphene TRIC Vortriptyline Vordoxepine Trimipramine Promazine Desipramine Vordoxepine Trimipramine Mnitriptyline Vordoxepine Trimipramine Oxorbiptyline Vordoxepine Trimipramine TRIC Vordoxepine Trimipramine Cyclobenzaprine Cyclobenzaprine Cyclobenzaprine Cyclobenzaprine Cyclobenzaprine Desipramine Cyclobenzaprine TRIC Vordoxepine Trimipramine Natriptyline Vordoxepine Trimipramine Desipramine Desitertamadol	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 2,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Doxepine Maprotiline Promethazine Porphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden Doxepine Maprotiline Promethazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline	12,500 300 400 50,000 2,000 2,000 2,000 50,000 50,000 10,000 25,000 25,000 25,000 25,000 1,000 15,000 50,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 10,000 10,000 10,000 10,000
Phencyclidine Phencyclidine Phencyclidine Phencyclidine TRIC Vordoxepine TRIC Vordoxepine Trimipramine Vordoxepine Trimipramine Vordoxepine Trimipramine Vordoxepine Trimipramine Vordoxepine Trimipramine TRIC Vordoxepine Trimipramine Vordoxepine Trimipramine Vordoxepine Trimipramine Vordoxepine Trimipramine Vordoxepine Trimipramine Vordoxepine Trimipramine Namitriptyline Vordoxepine Trimipramine Desipramine Desmethyl-cis-tramadol	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 3,000 200 200 2,000 250 500 1,500 250 1,500 100 1,500 250 500 200 100 1,500 1,500 450 900 60 600 600 600 200 100	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) F-Hydroxyphencyclidine PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imigramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Porphenazine Dithiaden Promethazine Porphenazine Doxepine Maprotiline Promethazine Porphenazine Dithiaden Doxepine Maprotiline Promethazine Perphenazine Dithiaden Clomipramine Clomipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden Oxepine Doxepine Dithiaden Promethazine Perphenazine Dithiaden Porphenazine Dithiaden Porphenazine Dithiaden O(TML 00) G-Desmethyl-cis-tramadol Phencyclidine	12,500 300 400 50,000 2,000 2,000 50,000 10,000 200 25,000 1,0
Phencyclidine D-Propoxyphene TRIC Vortriptyline Vordxepine Amitriptyline Promazine Desipramine Cyclobenzaprine TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Promazine Desipramine Cyclobenzaprine TRIC Vortriptyline TRIC Vortriptyline TRIC Vordxepine TRIC Vordxepine TRIC Vordxepine TRIC Vordxepine Desipramine Cyclobenzaprine TRIC Vordxepine TRIC Vordxepi	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 1,500 2,000 CYCLIC ANTIDE 500 2200 200 250 1,500 750 1,500 100 100 150 900 50 CYCLIC ANTIDE 300 CYCLIC ANTIDE 300 CYCLIC ANTIDE 300 150 150 900 50 CYCLIC ANTIDE 300 150 900 50 150 900 50 100 100 100 100 100 100 10	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Doxepine Maprotiline Promethazine Doxepine Maprotiline Promethazine Doxepine Maprotiline Promethazine Doxepine Doxepine Maprotiline Promethazine Doxepine Maprotiline Promethazine Doxepine Maprotiline Promethazine Doxepine Maprotiline Doxepine Mapr	12,500 300 400 50,000 2,000 2,000 50,000 10,000 25,000 1,000 1,000 1,000 1,000 1,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 10,
Phencyclidine Phencyclidine Phencyclidine Phencyclidine TRIC Vortriptyline Vordoxepine Trimipramine Promazine Poesipramine Trimipramine Trimipramine Trimipramine Promazine Desipramine Cyclobenzaprine Trimipramine	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden Doxepine Dithiaden Doxepine Dithiaden Doxepine Dithiaden Dith	12,500 300 400 50,000 2,000 2,000 50,000 10,000 200 25,000 1,000 1,000 1,000 1,000 15,000 10,00
Phencyclidine Phencyclidine D-Propoxyphene TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Promazine Desipramine Cyclobenzaprine TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Desipramine Dyclobenzaprine TRIC Vortriptyline Vordxepine TRIC Vortriptyline Vordxepine TRIC Desipramine Amitriptyline Vordxepine TRIC Vortriptyline Vordxepine TRIC Promazine Desipramine Amitriptyline Promazine Desipramine Promazine Desipramine Dyclobenzaprine TRIC Vortriptyline Vordxepine TRIC Dis-tramadol Dis-tramadol Dis-tramadol	50 PHENCYCLI 25 PROPOXY 300 5YCLIC ANTIDEF 1,000 500 3,000 3,000 2,00 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 1,500 1,500 1,500 1,500 2,000 1,500 3,000 1,500 1,500 2,000 1,50 900 60 500 750 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 <	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Promethazine Promethazine Promethazine Promethazine PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Dithiaden Promethazine Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden D (TML 100) o-Desmethyl-cis-tramadol Phencyclidine	12,500 300 400 50,000 2,000 2,000 2,000 50,000 50,000 200 25,000 1,000 1,000 1,000 1,000 1,000 1,000 15,000 50,000 120 15,000 15,000 10,000 10,000 10,000 10,000 20,000 20,000
Phencyclidine Phencyclidine D-Propoxyphene TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Promazine Desipramine Cyclobenzaprine TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Desipramine Dyclobenzaprine TRIC Vortriptyline Vordxepine TRIC Vortriptyline Vordxepine TRIC Desipramine Amitriptyline Vordxepine TRIC Vortriptyline Vordxepine TRIC Promazine Desipramine Amitriptyline Promazine Desipramine Promazine Desipramine Dyclobenzaprine TRIC Vortriptyline Vordxepine TRIC Dis-tramadol Dis-tramadol Dis-tramadol	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500 750 1,500 250 1,500 750 1,500 1,500 250 1,500 750 1,500 250 1,500 750 750 750 750 750 750 750	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Pomethazine Doxepine Maprotiline Promethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Perphenazine Doxepine Perphenazine Doxepine Perphenazine Doxepine Perphenazine Doxepine P	12,500 300 400 50,000 2,000 2,000 50,000 10,000 200 25,000 1,000 1,000 1,000 1,000 15,000 10,00
Phencyclidine Phencyclidine Phencyclidine Phencyclidine TRIC Nortriptyline Nordoxepine Trimipramine Amitriptyline Poromazine Posipramine TRIC Nortriptyline Nordoxepine TRIC Posipramine Promazine Posipramine TRIC Nortriptyline TRIC Nortriptyline TRIC Nortriptyline TRIC Nortriptyline TRIC Codenzaprine TRIC TRIC TRIC TRIC TRIC TRIC TRIC TRIC	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 200 200 200 200 200 200 200	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden RESSANTS (TCA300) Imipramine Clomipramine Dithiaden Promethazine Perphenazine Dithiaden Pormethazine Perphenazine Dithiaden Doxepine Maprotiline Promethazine Perphenazine Dithiaden Doxepine Maprotiline Promethazine Perphenazine Dithiaden D	12,500 300 400 50,000 2,000 2,000 50,000 10,000 200 25,000 1,000 25,000 1,000 1,000 1,000 15,000 10,00
Phencyclidine Phencyclidine Phencyclidine Phencyclidine SPropoxyphene TRIC Vortriptyline Vordxepine Trimipramine Amitriptyline Vordxepine TRIC Vortriptyline Vordxepine TRIC Vordxepine TRIC Vordxepine TRIC Cyclobenzaprine Designamine Amitriptyline Vordxepine TRIC Vordxepine TRIC Social S	50 PHENCYCLI 25 PROPOXY 300 5YCLIC ANTIDEF 1,000 500 3,000 1,500 3,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 900 60 600 600 600 100 100,000 TRAMADC 200 200 200 200 200 200 200 <td>4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Clomipramine Clomipramine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Dithiaden Dithiaden Dithiaden Dithiaden Doxepine Maprotiline Promethazine Doxepine Dithiaden Doxepine Dithiaden Dithiaden D (TML 100) o-Desmethyl-cis-tramadol Phencyclidine d.I-O-Desmethyl-cis-tramadol Phencyclidine</td> <td>12,500 300 400 50,000 2,000 2,000 2,000 50,000 10,000 25,000 1,000 1,000 1,000 1,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 10,</td>	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Clomipramine Clomipramine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Dithiaden Dithiaden Dithiaden Dithiaden Doxepine Maprotiline Promethazine Doxepine Dithiaden Doxepine Dithiaden Dithiaden D (TML 100) o-Desmethyl-cis-tramadol Phencyclidine d.I-O-Desmethyl-cis-tramadol Phencyclidine	12,500 300 400 50,000 2,000 2,000 2,000 50,000 10,000 25,000 1,000 1,000 1,000 1,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 10,
Phencyclidine Phencyclidine P-Propoxyphene TRIC Vortriptyline Vordoxepine Trimipramine Amitriptyline Poromazine Poesipramine Vordoxepine Trimipramine Mnitriptyline Vordoxepine Trimipramine Mnitriptyline Vordoxepine Trimipramine Desipremine Oycobenzaprine Opconcidine Poesmethyl-cis-tramadol Dis-tramadol Toroxclidine n-Desmethyl-cis-tramadol Dis-tramadol Toroxelidine	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500 750 1,500 750 1,500 750 1,500 1,500 750 1,500 1,500 1,500 1,500 750 1,500 1,000 1,7	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Coxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Compiramine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Dothiaden Dithiaden DL (TML 100) o-Desmethyl-cis-tramadol Phencyclidine QI-O-Desmethyl venlafaxine DL (TML 300) o-Desmethyl-cis-tramadol Phencyclidine	12,500 300 400 50,000 2,000 2,000 2,000 20,000 10,000 25,000 1,000 10,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 3,0
Phencyclidine Phencyclidine P-Propoxyphene TRIC Vortriptyline Vordoxepine Trimipramine Amitriptyline Poromazine Poesipramine Vordoxepine Trimipramine Mnitriptyline Vordoxepine Trimipramine Mnitriptyline Vordoxepine Trimipramine Desipremine Oycobenzaprine Opconcidine Poesmethyl-cis-tramadol Dis-tramadol Toroxclidine n-Desmethyl-cis-tramadol Dis-tramadol Toroxelidine	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 2,00	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene PHENE (PPX) D-Norpropoxyphene PESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden Dithiaden Doxepine Maprotiline Promethazine Perphenazine Dithiaden Dit 100 -Desmethyl-cis-tramadol Phencyclidine QI-O-Desmethyl venlafaxine D(TML 200) D-Desmethyl-cis-tramadol Phencyclidine QI-O-Desmethyl venlafaxine D(TML 200) D-Desmethyl-cis-tramadol Phencyclidine	12,500 300 400 50,000 2,000 2,000 2,000 50,000 10,000 25,000 1,000 1,000 1,000 1,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 15,000 10,
Phencyclidine Phencyclidine Phencyclidine Phencyclidine TRIC Vortriptyline Vordoxepine Trimipramine Pyclobenzaprine Vyclobenzaprine Pyclobenzaprine Desipramine Dyclobenzaprine TRIC Vortriptyline Vordoxepine Trimipramine Amitriptyline Vordoxepine Trimipramine Desipramine Dyclobenzaprine Dyclobenzaprine Dyclobenzaprine Dyclobenzaprine Desipramine Dyclobenzaprine TRIC Vordoxepine Trimipramine Amitriptyline Pyclobenzaprine Desipramine Dyclobenzaprine Dyclobenzaprine Dyclobenzaprine Desipramine Dyclobenzaprine Trimipramine Amitriptyline Promazine Desipramine Dyclobenzaprine Dyclobenzaprine Dyclobenzaprine Dyclobenzaprine Desipramine Dyclobenzaprine Dyclobenzaprine Dosmethyl-cis-tramadol Cis-tramadol Trocyclidine Tr	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Doxepine Maprotiline Promethazine Doxepine Maprotiline Promethazine Doxepine Maprotiline Promethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxepine Maprotiline Doxemethyl-cis-tramadol Phencyclidine d,I-O-Desmethyl ventafaxine C (KET1, 000)	12,500 300 400 50,000 2,000 2,000 50,000 50,000 50,000 50,000 10,000 200 25,000 1,000 25,000 50,000 50,000 50,000 12,000 15,000 600 600 600 600 15,000 15,000 15,000 15,000 10,000 10,000 100,000 20,000 20,000 20,000 20,000 20,000 20,000 30,000 30,000 300,000 150,000
Phencyclidine Phencyclidine Phencyclidine Phencyclidine TRIC Vortriptyline Vordoxepine Trimipramine Vortriptyline Vordoxepine Trimipramine Vortriptyline Vordoxepine Trimipramine Desipramine Vordoxepine Trimipramine Desipramine Vordoxepine Trimipramine Desipramine Desipramine Desipramine Desipramine Dosmethyl-cis-tramadol Derocyclidine Voesmethyl-cis-tramadol Vordoxepine Trocyclidine Vordoxepine Cetamine Vordoxepine Cetamine	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 200 200 200 200 200 200 200	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Coxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Dithiaden PRESSANTS (TCA300) Imipramine Coxepine Maprotiline Promethazine Perphenazine Dithiaden Doxepine Maprotiline Promethazine Perphenazine Dithiaden Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Pormethazine Doxepine Maprotiline Perphenazine Dithiaden DL (TML 100) c-Desmethyl-cis-tramadol Phencyclidine d.I-O-Desmethyl venlafaxine DL (TML 300) c-Desmethyl-cis-tramadol Phencyclidine d.I-O-Desmethyl venlafaxine DL (TML 300) Comethyl-cis-tramadol Phencyclidine d.I-O-Desmethyl venlafaxine DL (TML 300) Comethyl venlafaxine C (KET1, 000) Maprotiline	12,500 300 400 50,000 2,000 2,000 2,000 50,000 10,000 200 25,000 1,000 1,000 1,000 1,000 1,000 15,000 10,000
Phencyclidine Phencyclidine Phencyclidine Phencyclidine Nordrxepine TRIC Nordriptyline Amitriptyline Promazine Desipramine Cyclobenzaprine TRIC Nordriptyline Nordoxepine TRIC Desipramine Dyclobenzaprine Dyclobenzaprine Dyclobenzaprine Dyclobenzaprine TRIC Nordriptyline Nordoxepine TRIC Nordriptyline Nordoxepine TRIC Dyclobenzaprine	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 2,000 CYCLIC ANTIDE 500 2,000 CYCLIC ANTIDE 500 2,000 CYCLIC ANTIDE 500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 2,000 CYCLIC ANTIDE 500 1,000 1,000 1	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Promethazine Dithiaden Promethazine Promethazine Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Doxepine Maprotiline Promethazine Promethazine Dithiaden Dit	12,500 300 400 50,000 2,000 2,000 2,000 50,000 50,000 10,000 25,000 1,000 1,000 1,000 1,000 15,000 15,000 15,000 15,000 10,
2-Propoxyphene 2-Propoxyphene TRIC Vortriptyline Vordoxepine Trimipramine Amitriptyline 2-gromazine Desipramine 2-grobenzaprine Trimipramine Amitriptyline Vordoxepine Trimipramine Amitriptyline 2-grobenzaprine 2-grobenzaprine Trimipramine Amitriptyline 2-grobenzaprine Trimipramine Amitriptyline 2-grobenzaprine 2-grobenzaprine 2-gromazine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gipramine 2-gordine 1-Desmethyl-cis-tramadol 2-grocyclidine 1-Desmethyl-cis-tramadol 2-grocyclidine 1-Desmethyl-cis-tramadol 2-gocyclidine 1-Desmethyl-cis-tramadol 2-gocyclidine 4-dethoxyphenamine	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500 750 1,500 1,500 1,500 1,500 750 1,500 1,000 CYCLIC ANTIDE 300 1,000 CYCLIC ANTIDE 300 300 300 300 300 300 300 2,000 CYCLIC ANTIDE 300 1,000 CYCLIC ANTIDE 300 300 300 300 300 2,000	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Compiramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Compiramine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxesmethyl-cis-tramadol Phencyclidine d.I-O-Desmethyl veniafaxine D(ML 300) D-Desmethyl veniafaxine C(KET1 , 000) Benzphetamine (+) Chlorpheniramine	12,500 300 400 50,000 2,000 2,000 2,000 20,000 10,000 10,000 10,000 10,000 15,000 15,000 15,000 15,000 15,000 15,000 10,000 100,000 20,000
Phencyclidine Phencyclidine Phencyclidine TRIC Nortriptyline Nordoxepine Trimipramine Amitriptyline Promazine Pesipramine Zyclobenzaprine TRIC Nortriptyline Nordoxepine Trimipramine Amitriptyline Vordoxepine Trimipramine Amitriptyline Vordoxepine Trimipramine Zyclobenzaprine	50 PHENCYCLI 25 PROPOXY 300 5YCLIC ANTIDEF 1,000 500 3,000 3,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 1,500 200 100 100,000 100,000 7 1,000 2,000 200,000 200,000 2,000	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) PHENE (PPX) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden Dithiaden PRESSANTS (TCA500) Imipramine Clomipramine Doxepine Maprotiline Promethazine Perphenazine Dithiaden Dithiaden Dithiaden Dithiaden Dithiaden Ditfine Pormethazine Perphenazine Dithiaden Ditfine Doxepine Maprotiline Promethazine Perphenazine Dithiaden Ditfine Doxepine Maprotiline Promethazine Perphenazine Dithiaden Ditfine Doxepine Ditfine Pomethazine Perphenazine Ditfine Ditfine Ditfine Doxepine Ditfine Promethazine Perphenazine Ditfinaden Ditfine Ditfine Ditfine Pomethyl-cis-tramadol Phencyclidine d,I-O-Desmethyl-cis-tramadol Phencyclidine d,I-O-Desmethyl-cis-tramadol Phencyclidine d,I-O-Desmethyl-cis-tramadol Phencyclidine d,I-O-Desmethyl-cis-tramadol Phencyclidine Condine EDDP	12,500 300 400 50,000 2,000 2,000 2,000 10,000 50,000 10,000 25,000 1,000 1,000 1,000 1,000 1,000 15,000 10,0
Phencyclidine D-Propoxyphene TRIC Nordoxepine Trimipramine Amitriptyline Promazine Desipramine Cyclobenzaprine Trimipramine Nordoxepine Trimipramine Amitriptyline Promazine Promazine Desipramine Cyclobenzaprine Promazine Desipramine Cyclobenzaprine Promazine Desipramine Desipramine Cyclobenzaprine Desipramine Desipra	50 PHENCYCLI 25 PROPOXY 300 SYCLIC ANTIDEF 1,000 500 3,000 2,000 2,000 CYCLIC ANTIDE 500 250 1,500 750 1,500 1,500 1,500 1,500 750 1,500 1,000 CYCLIC ANTIDE 300 1,000 CYCLIC ANTIDE 300 300 300 300 300 300 300 2,000 CYCLIC ANTIDE 300 1,000 CYCLIC ANTIDE 300 300 300 300 300 2,000	4-Hydroxyphencyclidine DINE (PCP 25) DINE (PCP 25) D-Norpropoxyphene RESSANTS (TCA1000) Imipramine Compiramine Doxepine Maprotiline Perphenazine Perphenazine Dithiaden PRESSANTS (TCA500) Imipramine Compiramine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Promethazine Perphenazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Pomethazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxepine Maprotiline Perphenazine Doxesmethyl-cis-tramadol Phencyclidine d.I-O-Desmethyl veniafaxine D(ML 300) D-Desmethyl veniafaxine C(KET1 , 000) Benzphetamine (+) Chlorpheniramine	12,500 300 400 50,000 2,000 2,000 2,000 20,000 10,000 10,000 10,000 10,000 15,000 15,000 15,000 15,000 15,000 15,000 10,000 100,000 20,000

	Meperidine d-Methamphetamine I-Methamphetamine	25,000 50,000
100,000 25,000 KETAMIN	I-Methamphetamine	
25,000 KETAMIN		50,000
KETAMIN	3,4-Methylendioxymethamphetamine (MDMA)	100,000
KETAMIN	Thioridazine	50,000
500	IE (KET500)	
	Benzphetamine	12,500
1,000	(+) Chlorpheniramine Clonidine	12,500 50,000
12,500 12,500	EDDP	25,000
12,500	4-Hydroxyphencyclidine	25,000
12,500	Levorphanol	25,000
12,500	MDE	25,000
		12,500
		25,000 25,000
		25,000 50,000
50,000	(MDMA)	00,000
12,500	Thioridazine	25,000
		0.050
		6,250 6,250
		30,000
	EDDP	15,000
6,250	4-Hydroxyphencyclidine	15,000
6,250	Levorphanol	15,000
	MDE Menoridine	15,000
		6,250 15,000
		15,000 15,000
		30,000
	(MDMA)	
	Thioridazine	15,000
		2,000
		2,000
		10,000
2,000	EDDP	5,000
2,000	4-Hydroxyphencyclidine	5,000
2,000	Levorphanol	5,000
2,000		5,000
		2,000
		5,000
		5,000 5,000
		10,000
	(MDMA)	
		150,000
		75,000
	Nattexone	75,000
	NE (OXY100)	
		50,000
300	Naloxone	25,000
50,000	Naltrexone	25,000
25,000	(COT 300)	
		7,500
	E (COT 200)	7,000
200	(-)-Nicotine	5,000
Cotinine	(COT 100)	
		2,500
) 300
METHYL-3.3-		
		100
	/L (FYL300)	
	Buspirone	50,000
	Sufentanyl	150,000
	(L (EXI 100)	L
	RL (FYL100) Buspirone	15,000
>300,000 50,000	Fentanyl	100
	Sufentanyl	50,000
20	YL (FYL20)	
FENTAN	Buspirone	15,000
FENTAN 600,000		
FENTAN 600,000 50,000	Fentanyl	100
FENTAN 600,000 50,000 20	Fentanyl Sufentanyl	100 50,000
FENTAN 600,000 50,000 20 FENTAN	Fentanyl Sufentanyl YL (FYL10)	50,000
FENTAN 600,000 50,000 20 FENTAN 300,000	Fentanyl Sufentanyl YL (FYL10) Buspirone	50,000 8,000
FENTAN 600,000 50,000 20 FENTAN 300,000 25,000 10	Fentanyl Sufentanyl YL (FYL10) Buspirone Fentanyl Sufentanyl Sufentanyl	50,000
FENTAN 600,000 50,000 20 FENTAN 300,000 25,000 10 NTHETIC MA	Fentanyl Sufentanyl YL (FYL10) Buspirone Fentanyl Sufentanyl RIJUANA (K2-50)	50,000 8,000 50 25,000
FENTAN 600,000 50,000 20 FENTAN 300,000 25,000 10 NTHETIC MA 50	Fentanyl Sufentanyl YL (FYL10) Buspirone Fentanyl Sufentanyl RIJUANA (K2-50) JWH-073 4-butanoic acid	50,000 8,000 50 25,000 50
FENTAN 600,000 50,000 20 FENTAN 300,000 25,000 10 NTHETIC MA 50 400	Fentanyl Sufentanyl YL (FYL10) Buspirone Fentanyl Sufentanyl RIJUANA (K2-50)	50,000 8,000 50 25,000
FENTAN 600,000 50,000 20 FENTAN 300,000 25,000 10 NTHETIC MA 50 400 500	Fentanyl Sufentanyl YL (FYL10) Buspirone Fentanyl Sufentanyl RIJUANA (K2-50) JWH-073 4-butanoic acid	50,000 8,000 50 25,000 50
	12,500 12,500 12,500 12,500 KETAMIN 300 6,250 6,	12,500 MDE 12,500 Meperidine 250 d-Methamphetamine 12,500 I-Methamphetamine 50,000 3,4-Methylendioxymethamphetamine (MDMA) Itioridazine KETAMINE (KET300) 300 300 Benzphetamine 600 (+) Chlorpheniramine 6,250 Clonidine 6,250 EDDP 6,250 Levorphanol 6,250 Levorphanol 6,250 MDE 6,250 Meperidine 150 d-Methamphetamine 6,250 Moperidine 150 d-Methamphetamine 6,250 Inbiridazine KETAMINE (KET100) 100 100 Benzphetamine 2,000 Clonidine 2,000 Levorphanol 2,000 Levorphanol 2,000 Levorphanol 2,000 Heyeridine 10,000 Thioridazine 2,000 Levorphanol 2,0

JWH-018 4-Hydroxypentyl	250	JWH-018 5-Hydroxypentyl	300
JWH-073 4-Hydroxybuty	300		
JWH-018 5-Pentanoic acid	25	ARIJUANA (K2-25) JWH-073 4-butanoic acid	25
JWH-018 4-Hydroxypentyl	200	JWH-073 4-butanoic acid	250
JWH-073 4-Hydroxybuty	250		200
		norphine (6-MAM)	
6-Monoacethylmorphine	10	Morphine	100,000
	HYLENEDIOX	YAMPHETAMINE (MDA 500)	5 000
(±) 3,4-Methylenedioxy amphetamine	500	Methoxyphenamine D-Amphetamine	5,000 2,000
D,L-Amphetamine sulfate	400	Phentermine	2,000
L-Amphetamine	30,000	Maprotiline	100,000
		CURONIDE(ETG300)	
Ethyl- β -D-Glucuronide	300	Propyl β-D-glucuronide	30,000
Morphine 3β-glucuronide	60,000	Morphine 6β-glucuronide	60,000
Glucuronic Acid	60,000	Ethanol	>100,000
Methanol	>100,000		
		CURONIDE(ETG500)	50.000
Ethyl- β -D-Glucuronide	500 100.000	Propyl β-D-glucuronide	50,000 100,000
Morphine 3β-glucuronide Glucuronic Acid	100,000	Morphine 6β-glucuronide Ethanol	>100,000
Methanol	>100,000	Ethanoi	>100,000
		URONIDE(ETG1,000)	
Ethyl- β -D-Glucuronide	1,000	Propyl β-D-glucuronide	100,000
Morphine 3β-glucuronide	>100,000	Morphine 6β-glucuronide	>100,000
Glucuronic Acid	>100,000	Ethanol	>100,000
Methanol	>100,000		
Clonazonam		PAM(CLO 400)	200
Clonazepam Alprazolam	400 200	Flunitrazepam	300 1,250
a-hydroxyalprazolam	200 2,000	(±) Lorazepam RS-Lorazepamglucuronide	250
a-nydroxyalprazolam Bromazepam	2,000	Midazolam	5,000
Chlordiazepoxide	1,000	Nitrazepam	200
Clobazam	250	Norchlordiazepoxide	200
Clorazepatedipotassium	600	Nordiazepam	1,000
Delorazepam	1,000	Oxazepam	350
Desalkylflurazepam	250	Temazepam	150
Diazepam	300	Triazolam	5,000
Estazolam	1,250	PAM(CLO 150)	
Clonazepam	150	Flunitrazepam	120
Alprazolam	75	(±) Lorazepam	500
a-hydroxyalprazolam	750	RS-Lorazepamglucuronide	100
Bromazepam	400	Midazolam	2,000
Chlordiazepoxide	400	Nitrazepam	75
Clobazam	100	Norchlordiazepoxide	75
Clorazepatedipotassium	250	Nordiazepam	400
Delorazepam Desalkylflurazepam	400 100	Oxazepam Temazepam	130 60
Diazepam	120	Triazolam	2,000
Estazolam	500	Thazolam	2,000
		ETHYLAMIDE (LSD 10)	
Lysergic Acid Diethylamide	10		
		ETHYLAMIDE (LSD 20)	
Lysergic Acid Diethylamide	20		
		ETHYLAMIDE (LSD 50)	- I
Lysergic Acid Diethylamide	50 METHVI PH	ENIDATE (300)	
Methylphenidate (Ritalin)	300	Ritalinic Acid	1,000
metry promotion (retain)		ENIDATE (150)	.,
Methylphenidate (Ritalin)	150	Ritalinic Acid	500
		DEM(ZOL)	
Zolpidem	50		
		ONE(MEP500)	
Mephedrone HCI	500	R(+)-Methcathinone HCI	7500
S(-)-Methcathinone HCl	2500	3-Fluoromethcathinone HCl	7500
4-Fluoromethcathinone HCl	1500	Methoxyphenamine	100,000
		ONE(MEP100)	•
Mephedrone HCI	100	R(+)-Methcathinone HCI	1500
S(-)-Methcathinone HCI	500	3-Fluoromethcathinone HCI	1500
4-Fluoromethcathinone HCI	300	Methoxyphenamine	500,000
3, 4-METHYL	ENEDIOXYPY	(ROVALERONE (MDPV 1000)	
3, 4- methylenedioxypyrovalerone	1000		
	ENEDIOXYP	YROVALERONE (MDPV 500)	
3, 4- methylenedioxypyrovalerone	500		
		M (DIA 300)	
Diazepam	300	Midazolam	6,000
Clobazam	200	Nitrazepam	200
Clonazepam	500	Norchlordiazepoxide	100
Clorazepate dipotassium	500	Nordiazepam	900
Alprazolam	100	Flunitrazepam	200
a-hydroxyalprazolam	1,500	(±) Lorazepam	3,000
Bromazepam	900	RS-Lorazepam glucuronide	200
Chlordiazepoxide	900	Triazolam	3,000
Estazolam			
	6,000	Temazepam	100
Delorazepam	6,000 900	Temazepam Oxazepam	100 300

	M (DIA 200)	
200	Midazolam	4000
120		120
300	Norchlordiazepoxide	70
300		600
70		120
1000	(±) Lorazepam	2000
600	RS-Lorazepam glucuronide	120
600	Triazolam	2000
	Temazepam	70
600	Oxazepam	200
120		
		50
500		1500
		1500
		3,000
	RS-Lorazepam glucuronide	2,700
6,000		4,500
9,000	Nordiazepam	15,000
2,400	Temazepam	9,000
6,000	7-Aminoclonazepam	300
6,000		
4,000	Flunitrazepam	2,000
4,000	RS-Lorazepam glucuronide	1,800
4,000	Norchlordiazepoxide	3,000
6,000	Nordiazepam	10,000
1,600	Temazepam	6,000
4,000	7-Aminoclonazepam	200
4,000		
-AMINOCLONA	ZEPAM(7-ACL100)	
2,000	Flunitrazepam	1,000
2,000	RS-Lorazepam glucuronide	900
2,000	Norchlordiazepoxide	1,500
3,000		5,000
800	Temazepam	3,000
2,000	7-Aminoclonazepam	100
2,000		
CARFENTA	NYL(CFYL500)	
500	Fentanyl	100
CAFFEINE	E (CAF 1000)	
1000		
CATHINE	E (CAT 150)	
	(+)3,4-Methylenedioxyamphetamine	100
	(MDA)	
100	p-Hydroxyamphetamine	100
12,500	Methoxyphenamine	12,500
TROPICAM	IDE (TRO 350)	
350		
ALPRAZOL		
300	Flunitrazepam	200
1,500	(±) Lorazepam	3,000
900	RS-Lorazepamglucuronide	200
900	Midazolam	6,000
200	Nitrazepam	200
500	Norchlordiazepoxide	100
500	Nordiazepam	900
900	Oxazepam	300
200	Temazepam	100
300	Triazolam	3,000
6000		
	IN (PGB50,000)	
50,000		
PREGABA	LIN (PGB500)	
500		
CODEIN	E (COD 200)	
200	Morphine	300
6,000	Ethylmorphine	6,000
50,000	Hydrocodone	50,000
	Hydromorphone	3,000
30,000		
	Levorphanol	1,500
30,000 50,000 15,000	Levorphanol 6-Monoacethylmorphine	1,500 300
50,000		
50,000 15,000 6,000	6-Monoacethylmorphine Morphine 3-β-D-glucuronide	300
50,000 15,000 6,000	6-Monoacethylmorphine	300
50,000 15,000 6,000 ZALEPLC 100	6-Monoacethylmorphine Morphine 3-β-D-glucuronide DN (ZAL100)	300
50,000 15,000 6,000 ZALEPLC 100 CANNAE	6-Monoacethylmorphine Morphine 3-β-D-glucuronide DN (ZAL100) BINOL(CNB)	300 800
50,000 15,000 6,000 ZALEPLO 100 CANNAE 500	6-Monoacethylmorphine Morphine 3-β-D-glucuronide DN (ZAL100)	300
50,000 15,000 6,000 ZALEPLO 100 CANNAE 500 300	6-Monoacethylmorphine Morphine 3-β-D-glucuronide N (ZAL100) INOL(CNB) Δ9 -THC	300 800
50,000 15,000 6,000 2ALEPLC 100 CANNAE 500 300 GABAPE	6-Monoacethylmorphine Morphine 3-β-D-glucuronide DN (ZAL100) BINOL(CNB)	300 800
50,000 15,000 6,000 ZALEPLC 100 CANNAE 500 300 GABAPE 2,000	6-Monoacethylmorphine Morphine 3-β-D-glucuronide N (ZAL100) INOL(CNB) Δ9 -THC INTIN(GAB)	300 800
50,000 15,000 6,000 ZALEPLC 100 CANNAE 500 300 GABAPE 2,000 TRAZOE	6-Monoacethylmorphine Morphine 3-β-D-glucuronide N (ZAL100) INOL(CNB) Δ9 -THC	300 800
50,000 15,000 6,000 ZALEPLC 100 CANNAE 500 300 GABAPE 2,000 TRAZOE 200	6-Monoacethylmorphine Morphine 3-β-D-glucuronide N (ZAL100) INOL(CNB) Δ9 -THC NTIN(GAB) DONE(TZD)	300 800
50,000 15,000 6,000 ZALEPLC 100 CANNAE 500 300 GABAPE 2,000 TRAZOE 200 CARISOPE	6-Monoacethylmorphine Morphine 3-β-D-glucuronide N (ZAL100) INOL(CNB) Δ9 -THC INTIN(GAB)	300 800
50.000 15,000 6,000 ZALEPLC 100 CANNAE 500 300 GABAPE 2,000 TRAZOI 200 CARISOPF 2000	6-Monoacethylmorphine Morphine 3-β-D-glucuronide N (ZAL100) INOL(CNB) Δ9 -THC NTIN(GAB) DONE(TZD) RODD((CAR)	300 800
50.000 15,000 6,000 ZALEPLC 100 CANNAE 500 300 GABAPE 2,000 TRAZOE 200 CARISOPF 2000 CARISOPF 2000 AB-F	6-Monoacethylmorphine Morphine 3-β-D-glucuronide N (ZAL100) INOL(CNB) Δ9 -THC NTIN(GAB) DONE(TZD)	300 800
	200 200 200 200 200 200 200 200 200 200	DIAZEPAM (DIA 200) 200 Midazolarm 120 Nitrazeparm 300 Norchlordiazepoxide 300 Nordiazeparm 70 Flunitrazeparm 1000 (±) Lorazeparm 600 600 Triazolarm 4000 Temazeparm 800 Oxazeparm 120 EXECTORE (ZOP 50) 50 Zopiclone METHCATHINONE (MCAT 500) 500 500 R(+)-Methcathinone HCI 100000 3-Fluoromethcathinone HCI 1000000 R(+)-Methcathinone HCI 40000 Norchiordiazeparm 5.000 RS-Lorazeparm glucuronide 8.000 Norchiordiazeparm 6.000 Flunitrazeparm 6.000 RS-Lorazeparm glucuronide 4.000 RS-Lorazeparm glucuronide 8.000 Rorchiordiazepoxide 8.000 Rorchiordiazepoxide 8.000 Rorchiordiazepoxide 8.000 Fentaryl 4.000 RS-Lorazeparm glucuronide <tr< td=""></tr<>

	40		40	
AB-PINACA 5-hydroxypentyl	10	AB-FUBINACA 10		
AB-PINACA 4-hydroxypentyl	10,000	UR-144 5-Pentanoic 5,00		
UR-144 5-hydroxypentyl	10,000	UR-144 4-hydroxypentyl 1000		
APINACA 5-hydroxypentyl	10000	ADB-PINACA Pentanoic Acid 10		
ADB-PINACA N-(5-hydroxypentyl)	30	5-fluoro AB-PINACA	30	
())))		N-(4-hydroxypentyl)	00	
5-fluoro AB-PINACA	25			
		UR-144		
UR-144 5-Pentanoic acid	25	UR-144 4-hydroxypentyl	10,000	
UR-144 5-hydroxypentyl	5000	XLR-11 4-hydroxypentyl	2,000	
5-fluoro AB-Pina N-(4-hydroxypentyl)	^{ca} 10,000	ADB-PINAC N-(4-hydroxypentyl)	>10,000	
AB-PINACA 4-hydroxypentyl	>10.000			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	QUET	IAPINE(QTP)		
Quetiapine	1000	Norquetiapine	10.000	
	FLUO	XETINE(FLX)		
Fluoxetine	500			
	KRA	TOM(KRA)		
Mitragynine	300	7-hydroxymitragynine	>50.000	
	TILI	DINE(TLD)		
Nortilidine	50	Tilidine	100	
		phenone (α-PVP 1000)		
Alpha-Pyrrolidinovalerophenone	2000			
		lerophenone (α-PVP 1000)		
Alpha-Pyrrolidinovalerophenone	1000	· · · · · · · · · · · · · · · · · · ·		
	Pyrrolidinov	alerophenone (α-PVP 500)		
Alpha-Pyrrolidinovalerophenone	500			
	rolidinovaler	ophenone (α-PVP 300)		
Alpha-Pyrrolidinovalerophenone	300			

Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.005-1.045) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The Multi-Drug Rapid Test Cassette was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that

tested in duplicate using inteen orug-nee unne and spiked unne samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results. **Effect of Urinary pH** The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the Multi-Drug Rapid Test Cassette. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free uri ne or drug positive urine containing above related calibrator substances. The following compounds show no cross-reactivity when tested with the Multi-Drug Rapid Test Cassette at a concentration of 100 μg/mL.

	Non Cross-Rea	icting compounds	
Acetophenetidin	Cortisone	Zomepirac	d-Pseudoephedrine
N-Acetylprocainamide	Creatinine	Ketoprofen	Quinidine
Acetylsalicylic acid	Deoxycorticosterone	Labetalol	Quinine
Aminopyrine	Dextromethorphan	Loperamide	Salicylic acid
Amoxicillin	Diclofenac	Meprobamate	Serotonin
Ampicillin	Diflunisal	Isoxsuprine	Sulfamethazine
I-Ascorbic acid	Digoxin	d,I-Propanolol	Sulindac
Apomorphine	Diphenhydramine	Nalidixic acid	Tetracycline
Aspartame	Ethyl-p-aminobenzoate	Naproxen	Tetrahydrocortisone,
Atropine	β-Estradiol	Niacinamide	3-acetate
Benzilic acid	Estrone-3-sulfate	Nifedipine	Tetrahydrocortisone
Benzoic acid	Erythromycin	Norethindrone	Tetrahydrozoline
Bilirubin	Fenoprofen	Noscapine	Thiamine
d,I-Brompheniramine	Furosemide	d,I-Octopamine	Thioridazine
	Gentisic acid	Oxalic acid	d,I-Tyrosine
Cannabidiol	Hemoglobin	Oxolinic acid	Tolbutamide
Chloral hydrate	Hydralazine	Oxymetazoline	Triamterene
Chloramphenicol	Hydrochlorothiazide	Papaverine	Trifluoperazine
Chlorothiazide	Hydrocortisone	Penicillin-G	Trimethoprim
d,I-Chlorpheniramine	o-Hydroxyhippuric acid	Perphenazine	d,I-Tryptophan
Chlorpromazine	3-Hydroxytyramine	Phenelzine	Uric acid
Cholesterol	d,I-Isoproterenol	Prednisone	Verapamil
Clonidine			
	MANCE CHARACTERISTI		
blood alcohol level. The		cohol Rapid Test can v	.30% for approximate relative vary based on local regulations

and laws. Test results can be compared to reference levels with color chart on the foil package. [ALCOHOL ASSAY SPECIFICITY]

The Urine Alcohol Rapid Test will react with methyl, ethyl and allyl alcohols.

[ALCOHOL INTERFERING SUBSTANCES]

The following substances may interfere with the **Urine Alcohol Rapid Test** when using samples other than urine. The named substances do not normally appear in sufficient quantity in urine to interfere with the test.

A. Agents which enhance color development Peroxidases

- Strong oxidizers
- B. Agents which inhibit color development Reducing agents: Ascorbic acid, Tannic acid, Pyrogallol, Mercaptans and tosylates, Oxalic acid, Uric Acid
- Bilirubin
- L-dopa . L-methyldopa Methampyrone .

[BIBLIOGRAPHY]

- Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), 1. Research Monograph 73, 1986.
- 2 3
- Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735. Stewart DJ, Inaba T, Lucassen M, Kalow W. Clin. Pharmacol. Ther. April 1979; 25 ed: 464, 264-8.
- Ambre J. J. Anal. Toxicol.1985; 9:241. 4.

Winger, Gail, A Handbook of Drug and Alcohol Abuse, Third Edition, Oxford Press, 1992, page 146 Robert DeCresce. Drug Testing in the workplace. 1989 page 114. 5 6

- Glass, IB, The International Handbook of Addiction Behavior, Routledge Publishing, New York, NY, 7. 1991:216
- 8 B. Cody, J.T., "Specimen Adulteration in drug urinalysis. Forensic Sci. Rev., 1990, 2:63.
- Tsai, S.C. et.al., J. Anal. Toxicol. 1998; 22 (6): 474 C.
- Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ., Foster City, 10. CA 2002
- Hardman JG, Limbird LE. Goodman and Gilman's: The Pharmacological Basis for Therapeutics. 11. 10th Edition. McGraw Hill Medical Publishing, 2001; 208-209.
- 12. Cumming, E. (22 April 2010). "Mephedrone: Chemistry lessons". London: The Daily Telegraph. Retrieved 2010-09-14
- "Drugs crackdown hailed a success". BBC News. 8 March 2010. Retrieved2010-03-31.
- 14. Kihara, Rhiannon; Day, Edward (May 2014). "Transient psychotic episodes following recreational use of NRG-3". Progress in Neurology and Psychiatry 18 (3): 14-18. doi:10.1002/pnp.331. Retrieved 22 March2015
- Schifano, F.; Albanese, A.; Fergus, S.; Stair, J. L.; Deluca, P.; Corazza, O.; Davey, Z.; Corkery, J.; Siemann, H.; Scherbaum, N.; Farre', M.; Torrens, M.; Demetrovics, Z.; Ghodse, A. H.; Psychonaut 15 Web, M.; Rednet Research, G. (2010). "Mephedrone (4-methylmethcathione; 'meow neow'): chemical, pharmacological and clinical issues".Psychopharmacology 214 (3):593–602. doi:10.1007/s00213-010-2070-x.ISSN 0033-3158. PMID 21072502.
- 16. "Assessment of Zopiclone" (PDF). World Health Organization. Essential Medicines and Health Products World Health Organization. p.9 (Section 5. Pharmacokinetics). Retrieved5 December 2015.
- 17. Kratzsch C, Tenberken O, Peters FT et al. Screening, library-assisted identification, and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem, and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J. Mass Spec. 39: 856-872, 2004.
- 18. Gustavsen I, Al-Sammurraie M, Mørland J, Bramness JG. Impairment related to blood drug concentrations of zopiclone and zolpidem compared with alcohol in apprehended drivers. Accid. Anal. Prev. 41: 462-466, 2009.
- 19. R. Baselt, Disposition of Toxic Drugs and Chemicals i Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1677-1679.
- 20. Calkins RF, Aktan GB, Hussain KL (1995), "Methcathinone: the next illicit stimulant epidemic?", Journal of Psychoactive Drugs. 27 (3): 277-85. doi:10.1080/ 02791072.1995.10472472. PMID 8594170
- Methcathinone, <u>https://en.wikipedia.org/wiki/Methcathinone.</u>
 Bersani, F. S.; Corazza, O.; Simonato, P.; Mylokosta, A.; Levari, E.; Lovaste, R.; Schifano, F. (2013). "Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy".General Hospital Psychiatry 35 (5):571-3.Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd Ed. Biomedical Publ., Davis, CA. 1982; 488
- 23. Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.).NewYork:McGraw-Hill Medical. p. 375. ISBN 9780071481274.
- 24. American Psychiatric Association (2013). "Substance-Related and Addictive Disorders". American Psychiatric Publishing. pp. 1–2. Retrieved 10 July 2015. 25. Juliano LM, Griffiths RR (2004). "A critical review of caffeine withdrawal: empirical validation of
- symptoms and signs, incidence, severity, and associated features". Psychopharmacology (Berl.) 176 (1):1–29. doi:10.1007/s00213-004-2000-x. PMID 15448977. Archived from the original on 29 January 2012
- 26. Arnaud MJ. Pharmacokinetics and metabolism of natural methylxanthines in animal and man. Handb Exp Pharmacol 2011: 200:33-91
- 27. Jeukendrup AE, Randell R-Fat burners: nutrition supplements that increase fat metabolism. Obes Rev 2011; 193:1-24. 28. Curmming, E. (22 April 2010). "Mephedrone: Chemistry lessons". London: The Daily Telegraph.
- Retrieved 2010-09-14
- 29. "Drugs crackdown hailed a success". BBC News. 8 March 2010. Retrieved2010-03-31.
- 30. Kihara, Rhiannon; Day, Edward (May 2014). "Transient psychotic episodes following recreational use of NRG-3". Progress in Neurology and Psychiatry 18 (3): 14-18. doi:10.1002/pnp.331. Retrieved 22 March2015
- 31. Schifano, F.; Albanese, A.; Fergus, S.; Stair, J. L.; Deluca, P.; Corazza, O.; Davey, Z.; Corkery, J.; Siemann, H.; Scherbaum, N.; Farre', M.; Torrens, M.; Demetrovics, Z.; Ghodse, A. H.; Psychonaut Web, M.; Rednet Research, G. (2010). "Mephedrone (4-methylmethcathinone; 'meow meow'): pharmacological and clinical issues". Psychopharmacology 214 (3):593-602. chemical doi:10.1007/s00213-010-2070-x.ISSN 0033-3158. PMID 21072502.
- 32. Work Group on Panic Disorder (January 2009). APA Practice Guideline for the Treatment of Patients With Panic Disorder (2nd ed.).
- 33. "FDA approved labeling for Xanax revision 08/23/2011" (PDF). Federal Drug Administration. 2011-08-23. p. 4. Retrieved 2011-09-14. "Xanax XR (Alprazolam) Clinical Pharmacology – Prescription Drugs and Medications". RxList. First
- DataBank. July 2008. 34. Frampton, JE (September 2014). "Pregabalin: a review of its use in adults with generalized anxiety
- disorder. "CNS Drugs 28 (9): 835-54.
- "Pregabalin". The American Society of Health-System Pharmacists. Retrieved Oct 23,2015. 36. 3. D.R. Guay. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am. J.
- Geriatr. Pharmacother. 3: 274–287 (2005). 37. 4. "Summary of product characteristics" (PDF). European Medicines Agency. 6 March 2013. Retrieved
- 6 May 2013
- 38. 5. "Detection times of Pregabalin in urine after illicit use: when should a positive specimen be
- Detection infestion of regulation in onitic and infestion decision of pointer operation of pointer operation of the pointer operation oper
- 40. Andre, Christelle M.; Hausman, Jean-Francois; Guerriero, Gea (2016-02-04), "Cannabis sativa; The Plant of the Thousand and One Molecules". Frontiers in Plant Science. 7: 19
- 41. McCallum ND, Yagen B, Levy S, Mechoulam R (May 1975). "Cannabinol: a rapidly formed metabolite of delta-1- and delta-6-tetrahydrocannabinol". Experientia. 31 (5): 520-1
- 42. Mahadevan A, Siegel C, Martin BR, Abood ME, Beletskaya I, Razdan RK (October 2000). "Novel cannabinol probes for CB1 and CB2 cannabinoid receptors". Journal of Medicinal Chemistry, 43 (20): 3778-85
- 43. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998)
- 44. "Gabapentin". The American Society of Health-System Pharmacists. Archived from the original on 8 September 2017. Retrieved 23 Oct 2015 45. Wijemanne, S; Jankovic, J (June 2015). "Restless legs syndrome: clinical presentation diagnosis and
- treatment". Sleep medicine. 16 (6): 678-90. 46. "Suicidal Behavior and Ideation and Antiepileptic Drugs". U.S. Food and Drug Administration (FDA).
- Archived from the original on 1 August 2009.
- 47. "Neurontin packaging insert" U.S. Food and Drug Administration (FDA). 1 May 2009. Archived from the original on 14 December 2010. Retrieved 16 July 2010. 48. Agarwal P, Griffith A, Costantino HR, Vaish N (2010). "Gabapentin enacarbil - clinical efficacy in

restless legs syndrome". Neuropsychiatr Dis Treat. 6: 151-8.

- 49. Calandre EP, Rico-Villademoros F, Slim M (2016). "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Rev Neurother. 16 (11): 1263-1277
- 50. Calandre EP, Rico-Villademoros F, Slim M (2016). "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Rev Neurother. 16 (11): 1263-1277
- 51. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (2010)."A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin". Clin Pharmacokinet. 49(10): 661-9.
- 52. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM (2008). "Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin". J Clin Pharmacol. 48 (12): 1378–88.
 Schatzberg, AF; Nemeroff, CB, eds. (2009). Textbook of Psychopharmacology (4th ed.). Washington,
- D.C.: American Psychiatric Publishing. ISBN 978-1-58562-309-9.
- 54 . Amalia Scotto di Telia, Ciro di Nunzio, Pietrantonio Ric(1986). Determination of Trazodone and Its Metabolite, m-CPP, in Serum and Urine by HPLC 233-235.
- 55. Jauch R, Kopitar Z, Prox A, Zimmer Á; Kopitar; Prox; Zimmer (1976). "[Pharmacokinetics and metabolism of trazodone in man

Number: 145018207 Effective Date: 2019-10-22